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Abstract 
 
Autoantibodies are present in many patients with demyelinating diseases and 
have been shown to have pathogenic potential in the case of people with 
neuromyelitis optica (NMO). However, it is still debated whether antibodies that 
are present in people with multiple sclerosis (MS) are pathogenic. There are 
multiple different mechanisms by which autoantibodies could exert their effects in 
MS, and they could potentially target any cell/structure within the central nervous 
system (CNS), although the focus of antibody studies in MS has been almost 
solely on myelin antigens. Recently, however, some evidence has suggested that 
astrocytes could also be targeted in MS. Therefore, there is a need for a simple 
but robust in vitro model to allow the testing of antibodies against 
oligodendrocytes and astrocytes. The hypothesis tested in this thesis is that a cell 
culture model containing a mixture of mature glial cells could be a useful model 
by which to test the pathogenicity of the antibodies from people with MS, and the 
antigens that they are targeting. In order to test this hypothesis, this thesis set out 
to develop a mature mixed glial cell culture model, to test whether one cell type 
could be killed without impacting on the health of the other cells, and to then use 
this model to test antibodies from people with MS. 
 
Chapter 2 describes the development of a rat neonatal-derived mature mixed 
glial culture.  A method was developed that allowed cultures with a mixture of 
protoplasmic (type 1) and fibrous (type 2) astrocytes to grow alongside mature 
oligodendrocytes. This method did not rely on addition of extra growth factors, 
presumably due to the production of all factors required for growth of each cell 
type by the other cells in the mixed culture. Because of this co-dependence on 
the other cells in the mixed culture for growth and development, the next step 
was to test whether specific targeting (killing) of one cell would result in the death 
of the other cells in culture, as that could potentially interfere with the 
interpretation of results in later chapters investigating the effects of antibodies in 
patient sera. In Chapter 3, it was found that oligodendrocytes could be selectively 
targeted (using a commercially-available antibody against sulfatide) and the 
astrocytes remained unaffected. It proved to be more difficult to find a cell 
surface-expressed molecule that could target only astrocytes and not have 
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adverse effects on oligodendrocytes. In the literature, one molecule that is 
generally considered to be expressed on astrocytes, but not oligodendrocytes, is 
GLAST, a glutamate transporter. Initial studies using an antibody against the 
intracellular N-terminus of GLAST confirmed that only astrocytes in culture were 
stained by this antibody. An antibody was therefore generated that was specific 
for an epitope of GLAST (GLAST152-172) that is expressed on the extracellular 
side of the membrane. However, when this antibody was tested for its ability to 
kill astrocytes in culture, both oligodendrocytes and astrocytes were killed. 
Further investigation revealed that the GLAST152-172 antibody labelled both 
oligodendrocytes and astrocytes in vitro and in vivo.  
 
As there are several splice variants of GLAST known, their expression in 
oligodendrocytes in vivo and in vitro was tested in Chapter 4. Two of the splice 
variants, GLAST 1a and 1c, were found to be expressed in both oligodendrocytes 
and astrocytes, whereas 1b was specific for astrocytes. Because GLAST was 
also expressed on oligodendrocytes, it was not a useful target to try to specifically 
kill astrocytes. Therefore, in Chapter 5, the use of a chemical (DL-amino adipic 
acid or DL-AAA), which has been widely reported in the literature to specifically kill 
astrocytes, was investigated. Unexpectedly, however, DL-AAA killed the 
oligodendrocytes in the mixed cultures at a lower dose than was required to kill 
astrocytes. DL-AAA works through a cystine-glutamate antiporter (C/GAP), which 
had only been reported to be expressed on astrocytes. Immunocytochemistry 
using an antibody specific for C-GAP showed that this molecule was also 
expressed on oligodendrocytes in culture.  
 
Because it appeared that it might prove much more difficult than anticipated to 
specifically kill astrocytes in vitro, it was decided to return to testing MS patient 
sera. Patient sera were tested first for their ability to label cells in culture. 
Because it has been reported that sera can have some non-antibody-mediated 
cytotoxic effects, IgG samples were purified from patient and control sera and 
tested for their ability, in the presence of complement, to kill oligodendrocytes 
and/or astrocytes. Some sera were found to have this potential. In addition, given 
the earlier results showing expression of glutamate transports on oligodendro-
cytes and astrocytes, the IgG samples were also tested in ELISA to determine 
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their ability to bind to the glutamate transports; some sera showed reactivity to 
glutamate transporter proteins. Finally, to test whether MS patient antibodies 
might have some other functional effects, they were finally tested for their ability 
to opsonise human myelin, thereby increasing its uptake by macrophages. 
Almost all MS sera were found to opsonize myelin and enhance its uptake, 
compared to sera from healthy individuals or patients with other neurological 
diseases. 
 
This thesis therefore showed that a mature mixed glial cell culture could be 
generated and used to study some functional properties of antibodies from MS 
patient sera. In addition, it showed the novel finding of expression of a range of 
molecules involved in glutamate uptake and exchange on oligodendrocytes: 
these could potentially be targets of autoimmune attack in MS. 
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1.1. Introduction 
 
It has been postulated for years that many diseases affecting the central nervous 
system (CNS) might have an immunological basis. There has been a focus on 
cell-mediated immunity in disease pathogenesis, but recently it has become clear 
that autoantibodies directed against a variety of molecules are also likely to be 
pathogenic. For example, autoantibodies against the N-methyl D-aspartate 
(NMDA) receptor are now thought to be the cause of severe psychosis in patients 
with anti-NMDA receptor encephalitis (Wandinger et al., 2011) and possibly in a 
subset of patients with schizophrenia (Zandi et al., 2011). However, one group of 
diseases which are known to typically produce auto-reactive antibodies, but for 
which the role of these autoantibodies is still debated, is the putative autoimmune 
CNS demyelinating diseases, which include diseases such as multiple sclerosis 
(MS) and neuromyelitis optica (NMO). 
 
Determining whether autoantibodies present in CNS demyelinating diseases are 
functionally relevant autoantibodies that do indeed play a pathogenic role in these 
diseases is therefore an unmet area of research. If the antibodies can be shown 
to be pathogenic, then fairly simple therapeutic strategies, such as antigen-
specific immuno-apheresis, could be envisaged.  
 
There are several ways in which the potential pathogenicity of autoantibodies 
could be explored, and initially the intent of this thesis was to use an animal 
model utilising C3H/HeJ mice to explore the pathogenic role of antibodies, as 
work from the lab had previously suggested that these antibodies might play a 
pathogenic role (Greer and Pender, 2008; Muller et al., 2005). However, following 
the building of a new animal house shortly after this thesis was commenced, 
many issues arose with the development of disease in this animal model, and 
unfortunately the model had to be abandoned, as disease could no longer be 
reliably induced in the mice. Therefore, alternative means of investigating the 
pathogenic role of autoantibodies in diseases such as MS and NMO had to be 
devised. Since reports from the literature suggest that the glial cells 
(oligodendrocytes and astrocytes) appear to be the most likely targets of 
autoantibodies in these diseases, it was decided to try to generate a robust 
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protocol to investigate potential glial cell targets of autoantibodies in CNS 
demyelinating diseases in vitro. 
 
In this review, therefore, some of the features of the CNS demyelinating diseases 
of interest are first described. Subsequently, potential mechanisms of 
demyelination are described, focussing particularly on the potential roles that 
antibodies could play in this process. Finally, in vitro growth and differentiation of 
oligodendrocytes and astrocytes is reviewed. 
 
1.2 CNS autoimmune demyelinating diseases 
 
The basis of the immune response is tolerance to self-tissue and lack of 
tolerance to foreign antigens; however, in some cases there is an immune 
response to self-tissue resulting in the development of autoimmune disease. 
There are several potential mechanisms by which autoimmunity can develop 
either through failure of central T cell tolerance or peripheral tolerance 
mechanisms. During T cell development, the cells pass through the thymus and 
are exposed to self-antigen; cells that recognise self-antigen undergo a variety of 
mechanisms (clonal deletion, clonal diversion, anergy and receptor editing) to 
ensure tolerance to self (Xing and Hogquist, 2012). However, not all self-antigens 
are presented in the thymus, and so some potentially self-reactive T cells do 
escape the central tolerance mechanisms in the thymus and thus have the 
potential to react to self and cause autoimmunity. Therefore, there are peripheral 
mechanisms to stop immune cells in the periphery that react to self-antigen (Xing 
and Hogquist, 2012). The broad categories of peripheral tolerance include 
suppression (particularly by regulatory T cells (Sakaguchi et al., 2013)), anergy/ 
inactivation (which occurs when T cells are activated by antigen in the absence of 
co-stimulation (Zhang et al., 2008)), and deletion of self-reactive T cells (which 
can occur as a result of repeated antigenic stimulation, particularly with high 
doses of antigen (Alderson and Lynch, 1998)). When these mechanisms fail, 
autoimmune disease can occur. The type of autoimmune diseases that occur in a 
patient will depend on the underlying cause of the inappropriate immune 
response, the genetic background of the patient (particularly human leukocyte 
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antigen (HLA) genes, which determine the specificity of the response), and on 
epigenetic factors to which people are exposed (Greer and McCombe, 2012).  
 
Originally, the CNS was regarded as an immunologically privileged site that 
would be unlikely to be affected by autoimmune disease, as it is strongly 
protected from the rest of the body by the blood brain barrier (BBB). The BBB 
separates the CNS from the rest of the body and restricts the exchange of non-
lipid soluble molecules between the blood and CNS. It is a dynamic structure 
comprised of capillary endothelial cells, surrounded by basal lamina, pericytes 
and astrocytic perivascular end feet (Brown, 2001; Abbott et al., 2006) (Figure 
1.1). The endothelial cells are quite specialised, with tight junctions ‘sealing’ the 
spaces between endothelial cells (Louveau et al., 2015) and regulating the move-
ment of cells and other molecules between the blood and CNS.  
 
 
 
Figure 1.1. Diagram of the blood-brain barrier. Astrocytes form end feet 
connections around the basal lamina in the blood brain barrier. Image from 
(Abbott and Yusof, 2010). Used with permission: Reference 3740730644040 
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However, it is now recognised that there is much more communication between 
the CNS and the immune system than was originally thought and that activated 
lymphocytes readily traverse the BBB (Louveau et al., 2015). In most individuals, 
the lymphocytes rapidly move back out of the CNS and do no harm; in some 
people, however, the lymphocytes recognize their target antigen, and initiate an 
inflammatory response within the CNS, leading to the influx of large numbers of 
macrophages, lymphocytes and other inflammatory cells. This response 
subsequently produces targeted damage to myelin and/or neuroglial cells, 
including oligodendrocytes and astrocytes, or to neurons (Figure 1.2).  
 
It appears that, in general, the damage to myelin and surrounding cells in inflicted 
largely by bystander activation of microglia, inflammation, complement activation 
and antibody mediated cytotoxicity (Archelos et al., 2000). The myelin sheath can 
be destroyed through the release of nitric oxide, sulfoxide and other free radicals 
from macrophages (Smith and Lassmann, 2002; Hill et al., 2004). Macrophages 
also produce hydrolytic enzymes that digest proteins and lipids in the myelin. 
Cytokines produced by immune cells will attract other cells to also release free 
radicals, enabling further destruction of the myelin sheath. 
 
The CNS autoimmune demyelinating diseases show overlapping clinical features 
and potentially have some common pathogenic mechanisms (Figure 1.3). Initially 
most of these were considered variants of MS (e.g. Balo’s concentric sclerosis, 
Marburg’s disease) or precursors of MS (e.g. acute disseminated encephalo-
myelitis/ADEM), but the recent discovery of antibodies specific for the water 
channel aquaporin 4 (AQP4), occurring only in NMO patients, has led to a re-
evaluation of whether or not these diseases are actually separate disease 
entities, with different, but sometimes overlapping, underlying pathogenic 
mechanisms (Lalive, 2008). Since this thesis is primarily interested in MS and 
NMO, these two disorders will be described in more detail. 
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Figure 1.2. Proposed sequence of events leading to CNS autoimmune 
demyelinating disease. Most autoimmune responses probably start outside the 
CNS, but once the cells cross the BBB and enter the CNS, there can be a self-
perpetuating sequence of events, leading to chronic inflammation and production 
of autoantibodies in the CNS.  Modified from (Chen et al., 2012). Clinical and 
Developmental Immunology Volume 2012, Article ID 970789, permissions not 
required, creative common licence.  
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Figure 1.3 Spectrum of inflammatory demyelinating diseases of the CNS 
according to chronicity and severity. MS is the most common CNS 
demyelinating disease, but it has become clear that there are several related 
diseases that may occur through pathogenic mechanisms distinct from those 
seen in MS. Adapted from (Borel et al., 2008; Poser and Brinar, 2004) 
 
1.2.1 Multiple sclerosis (MS) 
MS was the first of the CNS autoimmune inflammatory demyelinating diseases to 
be recognized. Carswell first described the lesions typical of MS in 1835; 
however cases of diseases with similar symptoms to MS have been described as 
far back as the 14th century (Lazzarini, 2004). MS affects approximately two to 
three times as many women as men, and the onset of MS is generally between 
the ages of 15-40, although onset of MS has been described in children as young 
as two, and in adults over 70 years of age.  
 
The most common clinical course of MS, known as relapsing–remitting MS (RR-
MS), is one of relapses and remissions, often with gradual accumulation of 
disability with time. In about half of those patients who initially have RR-MS, the 
course of MS gradually changes to a progressive pattern of neurological deficit, 
called secondary-progressive MS (SP-MS) (Hawkes and Giovannoni, 2010). Ten 
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to fifteen percent of people with MS experience a progressive course of disease 
from the outset, without any discrete attacks or remissions; this is known as 
primary progressive MS (PP-MS). In addition, some patients can follow a very 
mild course (benign MS) or, at the other end of the spectrum, an acute fulminant 
course of Marburg’s type MS, which is often fatal within a few weeks to months 
after the onset of clinical signs (Pender, 2000).  
 
MS is characterised by loss of myelin and axons within the brain, spinal cord and 
optic nerves, and associated astrocytic gliosis (Constantinescu et al., 2011). The 
major cause of neurological deficits in RR-MS is conduction block due to 
demyelination in the white and grey matter of the CNS, and it has been 
suggested that clinical recovery from MS attacks is due to remyelination by the 
myelin producing cells, the oligodendrocytes. However remyelination can be 
limited and over time the oligodendrocyte progenitor cells lose the ability to 
remyelinate (due to the inhibitory inflammatory environment, removal of cells/ 
mediators that would recruit the progenitor cells etc) (Clemente et al., 2013). This 
contributes to the progressive nature of MS. In addition, in the event of demye-
lination, and no subsequent re-myelination, the axon will eventually degrade. 
Axonal loss occurs from the early phases of disease (Trapp et al., 1998), and has 
been identified as a major cause of persistent disability (Bjartmar et al., 2003).  
 
The exact causative events leading to the development of MS are unknown, but 
MS is generally considered to have an autoimmune aetiology, since it has 
similarities to other autoimmune diseases in the relapsing-remitting nature of the 
disease, female predominance, and age of onset, and people with MS often have 
other autoimmune diseases or have first degree relatives with other autoimmune 
diseases. In addition, monozygotic twins of MS patients have a frequency of 
occurrence of MS of 26%, compared to 3-10% for dizygotic twins and 2% for 
other siblings of MS patients (Ebers et al., 1986; Fagnani et al., 2015). Other 
studies have suggested the involvement of immune recognition genes. For 
example, there is a very strong relationship between certain class II major 
histocompatibility complex (MHC) (known as HLA in humans) haplotypes and 
disease. In the Caucasian population, the HLA-DRB1 allele DRB1*15:01 has 
been most closely associated with MS, while other alleles have been associated 
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with MS in Asian and Mediterranean populations (reviewed in Greer, 2014). In 
addition, large scale Genome Wide Association Studies (GWAS) have now 
identified over 100 immune related genes that also appear to be associated with 
MS susceptibility, although at a much lower significance level than the HLA 
associations (International Multiple Sclerosis Genetics Consortium, 2013). 
 
Environmental/epigenetic triggers also appear to be important in MS. It is 
recognized that there is a latitudinal gradient in MS, with the incidence of MS 
increasing the further away from the equator. This is particularly apparent in 
Australia, where there is a marked increase in the incidence of MS in Tasmania 
compared to North Queensland (Hammond et al., 1988; Hammond et al., 2000; 
Taylor et al., 2010).  Whether this is due to regulatory effects of UV radiation, 
variation in levels of vitamin D, or other mediators is still a matter of debate. 
Viruses have been suggested to play an important role in MS development, either 
by inhibiting some of the peripheral immune tolerance mechanisms, as in the 
case of Epstein-Barr virus (Pender et al., 2011; Pender et al., 2012), or by 
sensitization of the immune system through an infection or vaccination, in which 
there is cross reactivity between microbial and myelin antigens (eg Adenovirus 
and myelin basic protein (MBP)) (Steinman, 2001). Other environmental factors 
such as smoking (Ponsonby et al., 2013) or exposure to heavy metals (e.g. there 
have been reported clustering of MS cases in heavy metal mining towns) (Ingalls, 
1986, Purdey, 2004) have also been implicated in an increased risk of MS. 
   
A major immunological hallmark of MS is the presence of oligoclonal bands 
(OCB) of intrathecally synthesized immunoglobulin (Ig) G or IgM in the 
cerebrospinal fluid (CSF), but not the serum, of approximately 90% of MS 
patients (Gerson et al., 1981; Zeman et al., 1996; Villar et al., 2003). OCB were 
first identified in people with MS around the late1950s (reviewed in (Holmoy, 
2009)) and have been used since then as part of the standard diagnostic criteria 
for people with MS. Despite the presence of these OCB in MS patients, the 
specificity and functional relevance of these OCB, and of other autoantibodies 
found in MS patients, remain obscure. The original consensus was that these 
antibodies would be likely to attack components of CNS myelin (since 
demyelination is the predominant feature of MS), or the myelin-producing cells 
10 
 
(oligodendrocytes); however, it has more recently become clear that 
autoantibodies may also target other CNS cells, such as neurons and astrocytes 
(de Bock et al., 2014; Schirmer et al., 2014; Vyshkina and Kalman, 2008). In 
addition, there does not appear to be a single specific antigen that is targeted in 
all patients. 
 
Recently, on the basis of investigations using CNS tissue from patients who died 
early in the course of their MS, it has been proposed that, while autoimmunity 
might drive MS once it starts, it is actually damage to astrocytes that is the 
primary pathogenic event in the development of MS (Barnett and Prineas, 2004). 
This is of particular interest, given recent findings in relation to NMO (see below). 
1.2.2 Neuromyelitis optica (NMO) 
 
NMO was first described in 1870 by Thomas Allbutt. After further characterization 
of more patients in 1894 by Devic and Gault, the syndrome was also referred as 
Devic’s disease (Jarius and Wildemann, 2013). NMO was originally considered a 
severe monophasic syndrome of bilateral optic neuritis. However, further studies 
revealed that patients often had more than one severe attack, separated by 
months/years, and for many years, relapsing NMO was defined as a variant of 
MS (Jacob et al., 2007). NMO is distinguished from MS by the presence of 
recurrent demyelinating lesions occurring mainly in the optic nerve and spinal 
cord. In addition, at disease onset, NMO, unlike MS, is not associated with brain 
lesions (they do occur over time) and NMO patients have acute longitudinally 
extensive transverse myelitis in the spinal cord (Wingerchuk et al., 2007).  
 
Pathological studies of NMO show the presence of necrotic spinal cord lesions of 
both grey and white matter, granulocytes and eosinophil infiltration in active NMO 
lesions (Roemer et al., 2007; Lucchinetti et al., 2002), together with evidence of 
IgG, IgM, and complement activation (Jarius et al., 2008; Lennon et al., 2004; 
Wingerchuk and Weinshenker, 2014). OCB are only present in ~27% of NMO 
patients and, unlike the situation in MS, the OCB disappear over time 
(Bergamaschi et al., 2004).  
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The reclassification of NMO as a separate disease entity came about following 
the discovery of a specific serum antibody (NMO-IgG), which is not present in MS 
patients. Further analysis of the NMO-IgG has revealed that the antibody is 
against the water transport protein AQP4 (Pittock et al., 2006). Interestingly, 
although it is demyelination that causes the disability in NMO, AQP4 is not a 
myelin protein. Instead, it is expressed primarily in the end feet of astrocytes, at 
their interaction point with pericytes, on the CNS side of the BBB (Figure 1.4).   
 
 
 
Figure 1.4 Putative pathogenesis of NMO. Infiltration of plasma cells and/or 
antibodies specific for AQP4 through the BBB leads to targeting of AQP4 in the 
astrocyte end foot and complement-mediated cell death. From Papadopoulos et 
al., 2014. Used with permission: Reference 3740740730155. 
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It is likely that anti-AQP4 antibodies are pathogenic in NMO, as animal studies 
have shown that co-injection of IgG from NMO patients together with human 
complement produce NMO-like lesions with myelin breakdown and axonal injury 
in mice (Saadoun et al., 2010). The choroid plexus, which is thought to be a 
major entry point for attack in MS, does not appear to be a site of attack in NMO, 
and this could be because aquaporin 1 is expressed in the choroid plexus, rather 
than AQP4 (Speake et al., 2003). 
 
1.3 Demyelination - Pathogenic mechanisms in autoimmune 
CNS disease  
 
Demyelination, the removal of myelin, could occur due to primary attack on the 
myelin sheath or on oligodendrocytes, or due to events secondary to damage of 
axons or other CNS cells. In this section, some of the potential mechanisms of 
demyelination are reviewed. But firstly, the properties of myelin are described. 
 
1.3.1 Myelin 
 
Myelin was first described in 1864 by the German pathologist Rudolf Virchow. It 
is present throughout the nervous system, but the source, composition and 
distribution of myelin differs between the CNS and the peripheral nervous system 
(PNS): myelin in the PNS is produced by Schwann cells, whereas CNS myelin is 
produced by oligodendrocytes. Here, only CNS myelin will be considered. 
 
1.3.1.1 Role of myelin 
The passage of nerve impulses down the axon is due to a series of local 
electrical events, each of which is triggered by the one immediately preceding it. 
When an area of the surface membrane is depolarised (due to the transport of 
Na+ and K+ ions, in and out respectively, across the membrane) the signal is sent 
further down the neuron. The speed of the conduction is dependent on the 
square root of the diameter of the nerve. One way to conserve energy and send 
signals even faster is to have a conductive sheath of myelin around the axon. 
The suggestion that myelin might play a functional role as a conductive sheath 
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came nearly two decades after its discovery, when, in 1878, French pathologist 
Louis Ranvier described unmyelinated gaps along the axon, which are now 
known as nodes of Ranvier (Morell and Norton, 1980). Since transport of Na+ and 
K+ across the membrane can only occur at the nodes, in myelinated neurons the 
nerve impulse jumps from node to node, making the movement of signal much 
faster and more efficient. This is known as saltatory conduction (from the French 
word saltare, meaning “to jump”). Removal of this myelin sheath from the axon 
will result in slower signal transmission. In chronically demyelinated axons the 
signal may stop completely and the axon will degrade (Bjartmar et al., 1999).  
 
1.3.1.2  Production of myelin 
 
In the CNS, myelin is particularly concentrated in areas composed mainly of fibre 
tracts, and due to the high lipid content of myelin, the highly myelinated areas 
appear white (the white matter tracts). Myelin is made up of compacted layers of 
the oligodendrocyte cell membrane, which wind around axons to aid nerve 
conduction (Figure 1.5.A). Multiple membrane extensions come from each oligo-
dendrocyte, and a single oligodendrocyte is able to ensheath 30-50 internodes on 
the axons (Morell, 1977) (Figure 1.5.B). Myelin synthesis is triggered when oligo-
dendrocyte processes make contact with nearby axons that have a diameter of ≥ 
1m.  
 
A combination of factors stimulate myelin synthesis, including nonspecific 
membrane contact with the substratum, and interaction between oligodendrocyte 
cell adhesion molecules (including myelin associated glycoprotein (MAG)) and 
neuronal membranes (Poltorak et al., 1987; Yim et al., 1986). Signalling between 
the axon and glial cells is believed to be through the Notch receptor family (Wang 
et al., 2002). Notch has also been implicated in gliogenesis, as it is strongly 
expressed during development (Wang and Barres, 2000). Notch and other 
molecular factors involved in gliogenesis have become potential targets for MS 
treatment, by inducing gliogenesis of oligodendrocyte progenitor cell populations 
in MS. 
14 
 
             
Figure 1.5. Oligodendrocyte and myelin sheath. A. Transverse section of mature CNS myelin sheath from dog spinal cord. The 
outer tongue (→) indicates the spiral nature of the sheath. The major dense line is originally the cytoplasm of the cell, and the 
intraperiod line is where two lamellae interact. B. Oligodendrocytes extend multiple sheets, ensheathing numerous myelin 
segments. Modified from (Morell and Norton, 1980). Used with permission from Scientific American. 
A B 
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1.3.1.3 Composition of the myelin membrane 
 
Myelin is rich in lipids, which allows high resistance and low capacitance, aiding 
the speed of the saltatory conduction. Figure 1.6 shows the relative proportions of 
lipids and proteins in the brain as a whole and in myelin. 
 
  
 
Figure 1.6. Lipid and protein composition of brain and CNS myelin. The 
most abundant proteins are myelin proteolipid protein (PLP) and its alternatively 
spliced isoform (DM20) and myelin basic protein (MBP). Modified from (Lazzarini, 
2004) 
 
1.3.1.3.1 Myelin lipids 
Glycolipids, a large family of membrane lipids, are amongst the most abundant 
lipids found in the plasma membrane of higher organisms. The lipid composition 
of myelin differs from that of other membranes in the body, particularly with 
respect to the percentage of glycosphingolipids in the membrane. In myelin, 
these glycosphingolipids all contain ceramide as the basic subunit, and can be 
divided into cerebrosides and gangliosides. Around 25-30% of the total CNS 
myelin lipid consists of galactocerebroside (GalC) and the sulphated derivative of 
GalC, sulfatide, with GalC being the more abundant species. The hydrophobic 
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ceramide core and the polar head groups of GalC and sulfatide are important for 
the structure and fluidity of the lipid bilayer, and they are concentrated on the 
extracellular side of the membrane (Figure 1.7). GalC is involved in the 
transduction of signals, axon-myelin interactions, membrane stabilization and 
protein trafficking (Benjamins and Dyer, 1990). 
 
 
 
 
Figure 1.7. The distribution of lipids and myelin proteins in the CNS 
compact myelin. GalC and sulphatide, the most common glycosphingolipids in 
CNS myelin are asymmetrically distributed and highly enriched on the outer 
surface of the membranes. The molar ration of each of the major classes of lipids 
is approximately as shown in the diagram. Reproduced from Greer, 2013. Article 
ID 151427. Permissions not required, creative common licence.  
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1.3.1.3.2 Myelin proteins 
The proteins that are expressed solely or at much higher levels in CNS myelin 
compared to other parts of the body have been studied extensively; however 
much is still not known regarding their role(s) in formation and compaction of 
myelin. The CNS myelin proteins are not uniformly distributed throughout com-
pact myelin, as illustrated in Figure 1.8. The integral membrane proteins myelin 
proteolipid protein (PLP) and its alternatively spliced isoform (DM20) are the most 
abundant proteins in CNS myelin, and are distributed throughout the myelin. The 
intracellular protein myelin basic protein (MBP) makes up about 30% of the total 
myelin protein and is also found throughout the myelin membrane. Oligo-
dendrocyte specific protein (OSP), and MAG each make up around 5-10% of the 
total protein. OSP, like PLP, is an integral membrane protein and is distributed 
through the myelin, particularly in the vicinity of the radial components. MAG is 
only found on the innermost surface of the myelin, and it plays a role in adhesion 
of myelin to the neuron. Myelin oligodendrocyte glycoprotein (MOG) makes up 
only 0.05% of total myelin protein, but it is only found on the outermost turn of the 
myelin membrane (reviewed in Greer, 2013). Another protein, cyclic nucleotide 3’ 
phosphodiesterase (CNP), is absent from compacted myelin, but it is located on 
the cytoplasmic face of the oligodendrocyte cell body (Trapp et al., 1988). 
 
 
Figure 1.8. Representation of the myelin protein distribution in compact 
myelin.  PLP/DM20 is shown in yellow, MBP in green, OSP in white, MAG in pink 
and MOG in dark blue. 
 Outer turn of myelin 
sheath containing MOG 
(dark blue) &  PLP (yellow) 
 
 Intraperiod line 
 
 
 Major dense line - 
compacted cytoplasm 
containing MBP (green) 
 
 
 
 Innermost loop of 
myelin contacting axon, 
containing PLP, OSP 
(white) and MAG (purple) 
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1.3.2 Primary demyelination 
 
It has been thought for many years that primary demyelination, due to attack by T 
cells or antibodies working in concert with macrophages (Figure 1.9), is the most 
likely way in which myelin could be damaged in MS, and much effort has gone 
into investigating how this could occur. Studies have focussed particularly on the 
antigenic epitopes on myelin and oligodendrocytes that could be targeted by 
autoreactive T cells or antibodies in the immune system. These are discussed 
further below.  
 
Figure 1.9. Primary demyelination in human 
CNS tissue. In some cases (e.g. the middle 
fibre), a full segment of myelin (stained red) has 
been stripped from between nodes of Ranvier 
(arrowheads) on the axon (stained green). In 
other cases, the myelin has the appearance of 
having been nibbled away; this is reminiscent of 
the appearance of microbial membranes 
following antibody-mediated attack. Adapted 
from (Trapp and Nave, 2008). Used with 
permission from Annual Reviews. 
 
It is not completely clear whether oligodendrocyte destruction in MS occurs 
through bystander damage or by specific targeting of myelin and/or 
oligodendrocytes. Histological studies provide some evidence of preservation of 
oligodendrocytes during the early stages of demyelination (Bruck et al., 1994; 
Raine et al., 1981), suggesting that demyelination alone isn’t directly responsible 
for the loss of oligodendrocytes; however, further demyelination does lead to their 
destruction. Other more recent models propose that, at least in some patients, 
demyelination is the consequence of an oligodendrogliopathy, in which the first 
step in the chain of events leading to disease is the apoptotic death of oligo-
dendrocytes and subsequent loss of myelin (Henderson et al., 2009; Barnett and 
Prineas, 2004). 
19 
 
1.3.2.1 T cell-induced primary demyelination  
 
The inflammatory infiltrate of MS lesions contains autoreactive CD4+ T cells and 
CD8+ T cells (Figure 1.10), and there is evidence that both classes of T cells are 
clonally expanded in situ (Babbe et al., 2000; Illes et al., 1999; Skulina et al., 
2004).  CD4+ T cells have been studied in more detail, but it is not thought that 
they have any direct pathogenic effects on myelin and/or oligodendrocytes; 
although production by the CD4+ T cells of cytokines and chemokines that recruit 
macrophages into the CNS and which activate the CNS resident microglia 
undoubtedly play a role in the evolution of the lesion, as these non-antigen 
specific cells are considered to be the main effector cells in demyelination.  
 
 
Figure 1.10. CD8+ T cells make up a 
large proportion of the inflammatory 
infiltrate in MS lesions. CD8+ T cells 
are stained brown, and nuclei of 
inflammatory cells are stained purple 
Modified from (Lucchinetti et al., 2002). 
 
 
 
Based on in vitro studies, it has been speculated that CD8+ T cells could directly 
target oligodendrocytes in a MHC class I-restricted manner (Friese and Fugger, 
2005), and indirectly through the spill-over of cytotoxic mediators (Melzer et al., 
2009). Only a small number of studies have investigated the specificity of CD8+ T 
cells for myelin epitopes, but they have found a similar distribution of specificities, 
(including epitopes of PLP, MBP, MOG) as have the much larger number of 
studies that have investigated CD4+ T cells (reviewed in Huseby et al., 2012). 
 
In vitro, it has been shown that recognition of heat shock proteins by  T cells 
and subsequent production of cytotoxic factors by these cells can kill 
oligodendrocytes (Selmaj et al., 1991), and it is possible that such mechanisms 
could also occur in human disease. 
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1.3.2.2 Antibodies could directly target myelin/oligodendrocytes 
Clonally-expanded B cells can be identified in cerebrospinal fluid (CSF) and in 
CNS lesions in patients with MS and ADEM (Obermeier et al., 2008; Qin et al., 
1998), and B cell follicles can develop within the meninges (Aloisi and Pujol-
Borrell, 2006; Magliozzi et al., 2007; Magliozzi et al., 2010). Increased IgG titres 
and oligoclonal IgG and IgM bands are present in the CSF, and autoantibodies 
against myelin epitopes can be detected within CNS lesions (Sospedra and 
Martin, 2005). Several studies have found that there is co-localization of IgG and 
complement in some actively demyelinating MS lesions (Genain et al., 1999; 
Lucchinetti et al., 2000; Storch et al., 1998; Barnett et al., 2009; Breij et al., 2008; 
Hosokawa et al., 1988). These data have usually been interpreted to indicate 
involvement of the IgG in the evolution of the lesion, since it is known from animal 
models that IgG specific for a variety of myelin proteins, particularly MOG, can 
induce demyelination (Linington et al., 1988; Garcia-Merino et al., 1986). 
However, others have questioned the pathogenic relevance of this in MS (Barnett 
et al., 2009; Prineas et al., 2001), and indeed it is known that disrupted myelin, 
such as is found in the active lesion, can bind IgG non-specifically (Aarli et al., 
1975) and can activate complement (Silverman et al., 1984; Vanguri et al., 1982). 
Therefore, whilst there is no doubt that antibodies are present in the CNS in 
diseases such as MS and NMO, their functional relevance to the disease process 
remains to be determined. 
 
As noted above, animal studies offer the best evidence for a direct role of 
antibodies in demyelination. Anti-MOG autoantibodies induced in marmoset 
monkeys have been shown to bind to the myelin around MS lesions (Genain et 
al., 1999). Crossing mice that are transgenic for either MOG-specific T cells or 
MOG-specific B cells, neither of which alone develop spontaneous demyelinating 
disease, leads to the production of mice that spontaneously develop demyelin-
ating disease (Pollinger et al., 2009). Inhibition of complement activation in mice 
with MOG-induced EAE results in protection against development of disease 
(Piddlesden et al., 1993), suggesting that demyelinating MOG antibodies in the 
animal model operate via activation of the classical pathway of the complement 
cascade, leading to the formation of the membrane attack complex (MAC/C5b-9) 
and eventual lysis of the target membrane (Figure 1.11).  
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A recent in vitro study utilising myelinating cultures from rat brain suggests that 
antibodies from the sera of MS patients may also act in this fashion (Elliott et al., 
2012). In that study, approximately 30% of patients with RR-MS had antibodies in 
their serum that could induce complement-dependent demyelination (as 
measured by a reduction in the percentage of myelinated axons) within 4 hours of 
addition of the serum to the cultures. The specificity of those antibodies was not 
characterised, except to show that they were not specific for MOG. 
 
However, any molecule expressed on the surface of the myelin and/or the 
oligodendrocytes could potentially be targeted by these antibodies. Studies from 
our own lab have shown a major epitope for T cells and antibodies on the second 
 
 
Figure 1.11. Activation and regulation of the classical pathway in the 
complement system on myelin membrane. Antibodies binding to surface 
antigens can (eg GalC in this example) activate the classical pathway resulting 
cell lysis through the formation of in holes in the membrane by the MAC complex. 
(Dyer et al., 2005) Used with permission: Reference 3741721188029. 
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extracellular loop of PLP, and antibodies produced against this region of the 
molecule can label the surface of oligodendrocytes (Figure 1.12.). Recent studies 
by others suggest the presence of pathogenic anti-MOG antibodies in the NMO 
spectrum disorders, but not in NMO itself (Kitley et al., 2014; Probstel et al., 
2015; Yan et al., 2016). 
 
 
 
Figure 1.12. Surface staining of a 
live cultured rat oligodendrocyte 
with a rabbit polyclonal antibody 
specific for PLP180-230, an epitope 
located on the extracellular face of the 
membrane (Sobel et al., 1994). Image 
kindly provided by Dr Elisabeth 
Trifilieff. 
 
 
 
 
 
The inwardly rectifying potassium channel, Kir4.1, has also been suggested to be 
a potential target antigen in autoimmune demyelinating disease, although 
conflicting reports have been obtained regarding the prevalence of antibodies 
against Kir4.1: one group found 47% of adult MS patients (Srivastava et al., 2012) 
and over 50% of children with ADEM or MS have elevated anti-Kir4.1 antibody 
titres (Kraus et al., 2014), whereas others report a prevalence of less than 10% 
(Nerrant et al., 2014; Brickshawana et al., 2014). In oligodendrocytes, Kir4.1 
expression is concentrated in cell bodies, rather than on myelin sheaths, implying 
a role in oligodendrocyte differentiation and the formation of myelin, not in the 
maintenance of the K+ gradient in myelinated axons (Kalsi et al., 2004). Kir4.1 
knockout mice have been shown to have abnormal development of 
oligodendrocytes and they are hypomyelinated (Neusch et al., 2001).  
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There are also several potential autoantibody targets in the lipid portion of myelin. 
Implantation of anti-GalC secreting hybridomas in the spinal cord of cyclosporine 
treated rats was shown to induce demyelination in the CNS (Rosenbluth et al., 
1999; Rosenbluth et al., 2003). Despite such findings, there have been very few 
studies on the role of anti-GalC autoantibodies in human CNS demyelinating 
diseases. One study in MS patients found that the frequencies of anti-GalC 
antibody-positive subjects were significantly elevated in RR-MS compared with 
healthy controls, and that immunoaffinity purified anti-GalC IgGs from the patients 
bound to cultured human oligodendrocytes (Menge et al., 2005). 
 
Autoantibodies targeting myelin and/or oligodendrocytes could also act via 
several other complement dependent and independent mechanisms to cause 
primary demyelination. Firstly they could opsonize the myelin to promote 
phagocytosis by macrophages. Alternatively, in vivo, they could induce antibody-
dependent cell mediated cytotoxicity (ADCC), in which binding of antibody to the 
target antigen can recruit natural killer cells (NK) cells, via binding of the Fc 
portion of the antibody to FcRIII (CD16) on the surface of the NK cells, which 
rapidly kill the target cells. In addition, the cross linking of Fc receptors through 
the binding of antibody has been shown to lead to up regulation of MHC class II 
molecules, which could enhance antigen presentation to T cells (Laszlo and 
Dickler, 1990). The effect on Fc cross liking on non-professional APC in the CNS 
is unknown, but it is a possible way in which antibodies could exert pathogenic 
effects. 
 
An important factor for whether autoantibodies could induce primary 
demyelination is the isotype of the antibodies (Table 1.1). Some of the human 
immunoglobulin (Ig) subtypes are very good at fixing complement (e.g. IgG1), 
however other subtypes are not (eg IgG4) (Bindon et al., 1988). In addition, the 
different isotypes of antibodies bind to specific Fc receptors, not all of which are 
present in the CNS. Most of the studies of the effects of anti-myelin antibodies in 
CNS demyelinating diseases have not reported the isotype of the antibodies. 
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Table 1.1. Properties of human immunoglobulin subtypes 
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IgM 1.5 +++ Fc/µR - - - 
IgA 3.5 + FcαRI (CD89), Fc/µR - - + 
IgD 0.03 - - - - - 
IgE 0.0005 - FcεRI FcεRII (CD23) - - - 
IgG1 9 ++ FcγRI (CD64), FcγRIIA (CD32), 
FcγRIIB, FcγRIIC, FcγRIIIA 
(CD16), FcγRIIIB, FcRn 
++ + +++
IgG2 3 + FcγRII-A, FcRn - - +/- 
IgG3 1 +++ FcγRI, FcγRIIA, FcγRIIB, 
FcγRIIC, FcγRIIIA, FcγRIIIB, 
FcRn 
++ + ++ 
IgG4 0.5 - FcγRI, FcγRIIA, FcγRIIB, 
FcγRIIC, FcγRIII, FcγRIIIB, 
FcRn 
- +/- + 
 
Adapted from Janeway and Travers, 1997 and Okun et al., 2010 
* High affinity binding shown in bold.  
 
Cells of the CNS express some of the Fc receptors: neurons express FcγRI,  
FcγRIIb (Purkinje cells) and FcεRI (dorsal root ganglion (DRG) neurons); 
astrocytes only express FcγR1; and oligodendrocytes express FcγR and 
FcαR/FcµR (reviewed in Okun et al., 2010). Microglia (the resident brain 
‘macrophages’) express all of the Fc receptors, as do infiltrating macrophages 
from the periphery (Okun et al., 2010). Interestingly FcRγ deficient mice injected 
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with anti-MOG antibodies developed EAE, implying that antibody mediated 
demyelination by this antibody may be Fc receptor independent (Urich et al., 
2006).  
1.3.3 Attack on other cells/tissues causing secondary demyelination  
 
There are a number of possible mechanisms by which secondary demyelination 
could occur. During many CNS demyelinating events, there is bystander 
activation of macrophages and microglia; these cells then produce significant 
quantities of reactive oxygen species, nitric oxide (NO), matrix metalloproteinases 
(MMPs) and other factors that can injure oligodendrocytes and neurons, and 
which may contribute to the observed neuropathology (Kapadia and Sakic, 2011). 
In animal models of disease, inhibition of these free radicals and enzymes can 
protect against development of inflammation and demyelination in the CNS 
(Willenborg et al., 1999).  
 
There are also intrinsic relationships between myelin or oligodendrocytes and two 
of the other major cell types in the CNS, the neurons and astrocytes; damage 
specifically targeting these cells could cause secondary demyelination. This is 
examined further below.  
1.3.3.1 Neuronal/axonal damage as a cause of secondary demyelination 
 
Axonal damage as a consequence of long-term primary demyelination is widely 
accepted in the disease course of MS (Trapp et al., 1988); this is supported by 
numerous long term demyelination EAE models showing axonal damage 
occurring following the loss of myelin support (Kornek et al., 2000). However, 
axonal damage can also occur independently of demyelination, with evidence of 
axonal transection in normal-appearing white matter (Siffrin et al., 2010; Bo, 
2009; Bjartmar et al., 2001). 
 
Neuronal and axonal targets of autoimmune attack have not been studied as 
widely as potential myelin antigens (Lily et al., 2004); however, a number of 
potential targets have been identified, including gangliosides (which are more 
abundant on neurons than on myelin) (Acarin et al., 1996; Sadatipour et al., 
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1998; Csurhes et al., 2005; Silber et al., 2002), neurofascin (Mathey et al., 2007; 
Kawamura et al., 2013), Nogo A (Reindl et al., 2003) and the neurofilament light 
chain (Puentes et al., 2013; Huizinga et al., 2008). IgM antibodies against 
neuronal antigens have been identified in some MS patients (Beltran et al., 
2012), and plasma cells producing IgA antibodies against axon proteins in others 
(Zhang et al., 2005). It has also been suggested that antibodies targeting the 
nodes of Ranvier could inhibit synaptic transmission, and disrupt impulse 
propagation along the nerve axon (Caldwell et al., 2000).  
1.3.3.2 Targeting of astrocytes to cause secondary demyelination   
 
Astrocytes are the most abundant cell type in the brain, making up approximately 
35% of the total CNS cell population. Grey matter glia are known as protoplasmic 
(type 1) astrocytes whereas the glia in white matter are fibrous (type 2) astro-
cytes. There are also specialised astrocytes such as radial glia, Bergmann glia 
(semi radial glia that interact with Purkinje cells) and Muller cells (astrocytes of 
the retina) in the CNS. Astrocytes contribute to healthy neuronal function through 
their important roles in energy metabolism, ionic homeostasis and synaptic 
signalling (reviewed in Peters et al., 1991; Ransom and Ransom, 2012). For 
example, astrocytes play a critical role in modulating glutamate levels in the 
extracellular space contributing both to the functional neuronal synapse and to 
the prevention of glutamate-induced excitotoxic cell death of neurons and 
oligodendrocytes. The extent to which many of the homeostatic functions of 
astrocytes such as the buffering of pH and glutamate are altered by their cellular 
transition into “reactive” astrocytes, which occurs in most of the demyelinating 
diseases, is not known. Whether the detrimental effects of gliosis are due to 
decreased activity of the astrocytes’ normal neuronal support activities or to their 
production of cytotoxic factors is not yet clear. 
 
Evidence has also shown that astrocytes express MHC molecules, implying that 
they may play a role in antigen recognition by T cells and in priming or affecting 
the immune response in the CNS (Hertz et al., 1990; De Keyser et al., 2003). 
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A number of potential targets of autoimmune attack on astrocytes have been 
suggested. The anti-NMO antibodies found in NMO patients are against the 
water channel AQP4. The aquaporin (AQP) family is a family of transmembrane 
proteins that can transport water or water and glycerol into cells (Agre et al., 
1993). AQP4 is concentrated on the end feet of astrocytes that are in contact with 
the pericytes and the BBB (Gonzalez et al., 2013) (see Figure 1.1). AQP4 is also 
expressed on glial and ependymal cells in the subarachnoid and ventricular CSF-
brain interface, respectively (Verkman, 2011), in skeletal muscle and epithelial 
cells in the kidney (collecting duct), airways (surface epithelia), glands (acinar 
epithelia) and stomach (parietal cells) (Knepper et al., 1996; Agre et al., 1993; 
Rutkovskiy et al., 2013).  
 
Interestingly, Hinson et al found that exposure of astrocytes to NMO-IgG and 
complement compromised the membrane integrity of CNS-derived astrocytes 
(Hinson et al., 2008). Furthermore, without complement, astrocytic membranes 
remain intact, but AQP4 was endocytosed with concomitant loss of the excitatory 
amino acid transporter 2 (EAAT2), one of the glutamate transporters, and of Na+-
dependent glutamate transport (Hinson et al., 2008). They suggested that EAAT2 
and AQP4 coexist in astrocytic membranes as a macromolecular complex. 
Further studies have also concluded that AQP4 and glutamate transporters are in 
close proximity on the astrocyte cell membranes (Vitellaro-Zuccarello et al., 2005; 
Mogoanta et al., 2014). 
 
Kir4.1 is expressed on astrocytes, as well as on oligodendrocytes, and it has 
been proposed that there is a functional colocalization of Kir4.1 with AQP4 on the 
end feet of astrocytes to regulate water homeostasis (Nagelhus et al., 2004). 
Some groups claim there is no Kir4.1 expression on astrocytes in the white matter 
(Poopalasundaram et al., 2000), but other groups show strong expression of 
Kir4.1 on the end feet of astrocytes in the optic nerve (Higashi et al., 2001; Kalsi 
et al., 2004). Various functions have been attributed to astroglial expression of 
Kir4.1, including maintenance of the electrochemical gradient across the cell 
membrane of astrocytes, which is critical to the efficient potassium buffering and 
uptake of glutamate (Kucheryavykh et al., 2007). Mice treated with human 
antibodies specific for Kir4.1 together with complement show disruption of 
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astrocyte architecture in the cerebellum, as shown by staining for the 
intermediate filament glial fibrillary acidic protein (GFAP; see Figure 1.13). 
 
 
 
Figure 1.13. GFAP staining shows disruption of astrocyte architecture in 
mice treated with human anti-Kir4.1 antibodies. Phosphate-buffered saline 
(A), serum IgG from a patient with MS depleted of KIR4.1-specific antibodies (B), 
or serum IgG with preserved anti-KIR4.1 reactivity (C&D) was injected into the 
cisternae magnae of C57BL/6 mice together with human complement. Twenty-
four hours after injection, the mice were killed and brain sections were assessed 
for GFAP expression (brown staining). Scale bars, 50 μm in A-C and 20 μm in D. 
Adapted from Srivastava et al., 2012. Reproduced with permission from 
Srivastava et al., 2012. Copyright Massachusetts Medical Society. 
 
Even though some antibodies found in patients with demyelinating disease target 
proteins (such as Kir4.1) that are present on both oligodendrocytes and astro-
cytes, one question that hasn’t really been addressed yet is whether such 
antibodies target both cell types in patients. 
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1.4 Other ways in which antibodies could act 
 
Apart from inducing primary or secondary demyelination, it is possible that 
antibodies could have other effects in CNS demyelinating disease; some of these 
effects could enhance pathogenicity, but there is also some data suggesting that 
some antibodies could play a protective role.  
 
1.4.1 Other potential pathogenic roles of autoantibodies 
 
One relatively unexplored effect of anti-myelin antibodies is their potential to 
inhibit remyelination. For example, the monosialodihexosylganglioside (GM3) is 
known to enhance oligodendrocyte differentiation towards myelin formation 
through enhancing expression of galactocerebroside, sulphatide and MAG (Yim 
et al., 1994). Interestingly the presence of anti-GM3 antibodies in PP-MS has 
been reported (Sadatipour et al., 1998). Remyelination, as mentioned earlier, is 
thought to involve the differentiation of oligodendrocyte progenitor cells attracted 
to the site of demyelination (Carroll et al., 1998), or re-differentiation of 
oligodendrocytes that previously de-differentiated after damage to their myelin 
membrane (Grinspan et al., 1996). Thus the presence of anti-GM3 antibodies (or 
other antibodies against oligodendrocyte differentiation signal proteins) may have 
an effect on the remyelination process through targeting oligodendrocyte 
maturation.  
 
Another potential mechanism by which antibodies could inhibit remyelination is by 
preventing the migration of oligodendrocyte progenitors to sites of demyelination. 
In this respect, it has been suggested that antibodies against PLP, which are 
abundant in MS patients (Greer and Pender, 2008), might play a role in this, as 
PLP has been shown to complex with adhesion molecules to facilitate cell 
migration (Gudz et al., 2006). 
 
1.4.2 Potential protective effects of autoantibodies  
 
In the serum of paediatric patients with ADEM, ~40% have antibodies against 
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MOG (Baumann et al., 2015; Brilot et al., 2009). Curiously patients with MOG 
antibodies recovered much better than their seronegative cohorts (Baumann et 
al., 2015). There have been a number of reports of the presence of anti-MOG 
antibodies in NMO and NMO spectrum disorders (AQP4 antibody seronegative 
cohorts) (Probstel et al., 2015) and in paediatric recurrent optic neuritis patients 
(Rostasy et al., 2012), and it has been suggested that these antibodies help to 
delay onset of a second attack of disease (Probstel et al., 2011). However, other 
investigators maintain that these anti-MOG-specific antibodies would always be 
pathogenic (Ramanathan et al., 2016). 
 
Studies into oligodendrocyte specific antibodies, and their effect on promoting re-
myelination have been performed; however, the antibody used most widely, 
SCH94.03, was generated in culture from spinal cord and has not been detected 
in patients (Rodriguez et al., 1987; Rodriguez and Lennon, 1990).  SCH94.03 is a 
marker for mature oligodendrocytes (Asakura et al., 1996), but further 
investigation revealed that it would bind to oligodendrocytes, induce calcium 
signals (Paz Soldan et al., 2003) and promote remyelination in murine models of 
MS, including experimental autoimmune encephalomyelitis (EAE) (Miller et al., 
1997), Theiler’s murine encephalomyelitis virus (TMEV)–induced demyelination 
(Miller et al., 1994), and lysolecithin-induced demyelination (Pavelko et al., 1998; 
Bieber et al., 2002). The SCH94.03 antibody has been proposed to be a natural 
autoantibody based on its germ line immunoglobulin sequence (Asakura et al., 
1996).  
 
A similar human antibody to SCH94.03, which was obtained from healthy donors 
and isolated directly against oligodendrocyte surface antigens, has been shown 
to promote myelination in murine MS models (Warrington et al., 2000; Warrington 
and Rodriguez, 2010). It has also been shown that human IgM anti-myelin 
antibodies can have an anti-apoptotic effect on oligodendrocytes in culture (Howe 
et al., 2004). Although it is not yet known if such antibodies play similar roles in 
vivo, it is interesting to speculate whether some of the antibodies found in 
patients with autoimmune demyelinating diseases may actually be protective 
against disease, rather than pathogenic. Further study of such antibodies is 
warranted. 
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1.5 In vitro growth and differentiation of CNS glial cells 
 
In order to assess the potential pathogenicity of antibodies targeting glial cells, a 
relevant in vitro model would be useful. Few previous studies have attempted to 
use in vitro glial cells for antibody studies, largely due to difficulties in preparing 
the cultures. However, a robustly-powered study from one group utilized glial 
tumour cell lines to study the targets of autoantibodies in serum of MS patients 
(Lily et al., 2004). Such glial-like cell lines are mostly derived from glioblastomas, 
oligodendrogliomas and astrocytomas, or primary glial cells have been 
immortalized by fusion with tumours (Feutz et al., 2001). Some of these are 
derived from animal tissue and others from humans. There are several 
immortalized oligodendrocyte-like cell lines available (e.g. HOG, MO3.13 and 
KG-1C), all of which exhibit an immature oligodendrocyte phenotype while they 
are growing and dividing (Buntinx et al., 2004). However, they can be 
encouraged to stop dividing and mature into a phenotype with a greater 
resemblance to mature oligodendrocytes by culturing them with growth factors 
such as platelet derived growth factor (PDGF), fibroblast growth factor (FGF), or 
in 4--phorbol-12-myristate 13-acetate (PMA). These oligodendrocyte-like cell 
lines have been used in a number of studies phenomena such as investigating 
the stepwise differentiation of progenitors to mature oligodendrocytes (Matsushita 
et al., 2005), oligodendrocyte injury (Buntinx et al., 2002), and myelin protein 
production (Bello-Morales et al., 2011). 
 
Astrocyte-like cell lines are also available; these have been derived from human 
astrocytomas, and from embryonic and neonatal brain and spinal cord tissue of 
rodents (Radany et al., 1992; Alliot and Pessac, 1984; Smith-Thomas et al., 
1994). Some of the cell lines exhibit differing phenotypic properties, making them 
phenotypically more similar to either type 1 or type 2 astrocytes (Alliot and 
Pessac, 1984). These astrocyte-like cell lines are commonly used as a feeder 
layer in co-culture to encourage neurite outgrowth from neuronal cells cultures or 
explants of retina tissue (Herrera-Molina et al., 2012; Smith-Thomas et al., 1994). 
Others have used type 1 astrocyte-like cell like in an in vitro blood-brain barrier 
model (Cantrill et al., 2012). 
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Whilst these cell lines are convenient and useful for a variety of studies, the 
markers expressed by these lines may not reflect markers present on glial cells in 
vivo, particularly with respect to expression of some of the proteins that are 
abundantly expressed on astrocytes or oligodendrocytes in vivo. Therefore, it 
would be preferable to use fresh glial cell cultures. In the brain, astrocytes and 
oligodendrocytes live in close proximity; therefore, we wanted to be able to 
replicate that in culture. Almost all reports utilize purified cultures of either 
oligodendrocytes or astrocytes, but optimally it would be preferable to have both 
cell types growing together in culture. In this section, the in vitro growth and 
differentiation of oligodendrocytes and astrocytes is reviewed.  
1.5.1   Glial cell development 
Neural stem cells (NSC) give rise to neurons, astrocytes and oligodendrocytes 
and other intermediate phenotypes of cells. Initially, based primarily on in vitro 
studies, it was thought that astrocytes and oligodendrocytes arose from a 
population of glial-restricted precursor (GRP) cells, which could be further split 
into oligodendrocyte-type-2 astrocyte progenitor cells (O2A) and astrocyte 
precursor cells. The O2A cells in vitro develop into type 2 fibrous astrocytes and 
oligodendrocytes, whereas the type 1 protoplasmic astrocytes appear to 
differentiate solely from the astrocyte precursor cells (Figure 1.14.). While this 
developmental pathway still appears to be the case in vitro, it seems that the 
situation in vivo may be even more complex. The finding of new transcription 
factors such as Olig2 (Lu et al., 2002), the development of antibodies against 
novel cell surface markers on progenitor cells (e.g. the neural/glial antigen 2 
(NG2) antibody, which labels an integral membrane chondroitin sulphate 
proteoglycan expressed on non-neuronal cells in the CNS (Nishiyama et al., 
2009)), and the use of conditional knockout mice (Anthony et al., 2004) have 
provided evidence of intermediate precursor cells, and suggest that the location 
of origin of NSC changes during development and that NSC from different 
regions can differentiate in various ways  (Figure 1.15). In the embryo, the 
primary NSC are neuroepithelial cells and radial glia. As an animal ages, the in 
vivo potential of neuroepithelial cells and radial glia becomes regionally restricted 
through the action of organizing signals (e.g. sonic hedgehog (SHH), fibroblast 
growth factors (FGFs), WNTs and bone morphogenetic proteins (BMPs)). 
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Figure 1.14 Stages of CNS cell differentiation in vitro. Growth factors that 
promote progression from one cell type to another are in green, those that inhibit 
progression are in red, and those that induce proliferation and maintain cells are 
in purple. Abbreviations used in this figure: A, A2B5, a monoclonal antibody that 
recognizes an epitope on type 2 astrocytes and glial progenitors; CNTF, cilliary 
neurotrophic factor; E, EGF receptor; EGF, epidermal growth factor; F, FGF 
receptor; G, glial fibrillary acidic protein; GalC, galactocerebroside; M, myelin 
basic protein, an oligodendrocyte-specific protein component of myelin; N, nestin, 
an intermediate filament protein expressed predominantly by CNS progenitors; P, 
PDGF receptor; PDGF, platelet-derive growth factor; O, O4, a marker for 
oligodendrocyte precursors; S, S100, a marker for astrocytes; V, vimentin.). From 
Holland, 2001. Used with permission: reference 3741730508487. 
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Figure 1.15. Patterns of gliogenesis in embryonic and adult progenitor 
zones showing progression from the embryo to the adult. Black arrows 
indicate self-renewal or differentiation from one cell type to another, all green 
cells are intermediate progenitors and all blue cells are neural stem cells, despite 
being different types. In the embryo (a), self-renewing neuroepithelial cells are 
transformed into radial glial cells as neurogenesis begins. These may also 
generate some neurons. After birth (b), radial glia produce intermediate 
progenitor cells and oligodendrocyte precursor cells (OPCs), which in turn 
produce neurons and oligodendrocytes, respectively. They can also produce 
ependymal cells and astrocytes. Protoplasmic astrocytes and fibrous astrocytes 
might arise from common or independent progenitors. In adults (c), 
oligodendrocytes are produced by two independent pathways: type B cells in the 
cortical subventricular zone produce transit-amplifying cells (known as type C 
cells), which in turn produce OPCs as well as neurons. The OPCs subsequently 
generate oligodendrocytes, and OPCs that are already resident in the grey matter 
also produce oligodendrocytes.  
Abbreviations used in this figure: ALDH1L1, aldehyde dehydrogenase 1 family, 
member L1; APC, adenomatous polyposis coli; GFAP, glial fibrillary acidic 
protein; MBP, myelin basic protein; PDGFR-α, platelet-derived growth factor 
receptor-α; PLP, proteolipid protein 1. From Rowitch and Kriegstein, 2010. Used 
with permission: reference 3741731300528. 
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1.5.2 Culturing glial cells 
In the laboratory setting, mature oligodendrocytes, unlike astrocytes, are unable 
to proliferate in vitro. Thus several protocols have been developed to culture 
mature oligodendrocytes from oligodendrocyte precursor cells obtained primarily 
from brains of embryonic or neonatal rats or mice (Chen et al., 2007; McCarthy 
and de Vellis, 1980). Human CNS tissues have also occasionally been used 
(Yong and Antel, 1992; Czepiel et al., 2015), however the main limitation in the 
production of human oligodendrocyte precursor cells is the lack of easy 
availability of human tissue for such studies. Most of these protocols have been 
adapted from that of McCarthy and de Vellis (1980), who pioneered the concept 
of culturing the cells extracted from brain as a mixed culture, in which immature 
oligodendrocytes and precursors grow on top of a bed of other cells (mostly type 
1 astrocytes) for 7-10 days, following which the cultures are gently agitated to 
“shake-off” the oligodendrocytes, which can then be grown as a relatively pure 
culture (Figure1.16).  
 
Some early studies used optic nerve as a source of tissue, because the high 
levels of white matter in a concentrated area, in comparison to the rest of the 
brain, suggested that there might be more oligodendrocyte precursors in those 
areas (Raff, 1989; Raff et al., 1983). However, it is now known that the majority of 
oligodendrocyte precursors in the brain arise in the sub-ventricular zone or the 
olfactory bulb, and then migrate to other regions (Rosenberg et al., 2008). 
Therefore, subsequent studies have typically used the whole brain as a tissue 
source. 
 
After oligodendrocyte precursors are shaken off, oligodendrocytes are 
subsequently grown and matured in vitro using tissue culture media 
supplemented with a variety of growth factors (see Table 1.2) (Lubetzki et al., 
1991; Skaper, 2012; Knapp et al., 1987; Chen et al., 2007). Some studies use 
low levels of serum, whereas others have adapted cultures to be serum-free, 
which can allow more flexibility to conduct other studies on the cells (Koper et al., 
1984). Other groups add conditioned media from neuroblastoma cultures to 
enhance the maturation of their oligodendrocyte cultures (Larsen et al., 2008). 
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Figure 1.16. Representation of the shake off step. This method relies on the 
differential adhesion strengths of oligodendrocytes and astrocytes. The 
oligodendrocyte precursor and O2A cells remain on the top of the cell bed, and, 
upon agitation, are loosened to float freely. In contrast, the cell bed (a mix of type 
1 astrocytes, fibroblasts and endothelial cells) remains on the original plate. The 
oligodendrocyte precursor and O2A cells can then be harvested. 
 
 
The initial steps in culturing astrocytes from rodent CNS tissue are identical to 
those used to culture oligodendrocytes (McCarthy and de Vellis, 1980). After the 
shake-off procedure, however, the bed of cells is harvested and resuspended in 
medium containing serum and various growth factors (Table 1.2). This results in 
cultures that are highly enriched for type 1 astrocytes (Goursaud et al., 2009). 
Most investigators report that the type 1 astrocytes are much easier to obtain in in 
vitro cultures than are type 2 astrocytes. Methods to selectively enrich for type 2 
astrocytes generally include size-based exclusion techniques (Juurlink and Hertz, 
1991), immunopanning (Foo et al., 2011; Cahoy et al., 2008), and different tissue 
culture media formulations compared to those used to grow type 1 astrocytes 
(Juurlink and Hertz, 1991) (Table 1.2). 
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Table 1.2 Growth factors used to culture oligodendrocytes and astrocytes 
in vitro  
Compound Oligodendrocytes Type 1 & Type 2 
Astrocytes 
Insulin  
(Chen et al., 2007, Bottenstein, 1986, 
Besnard et al., 1989) 
Yes No 
Platelet derived growth factor 
(PDGF) (Raff et al., 1988, Besnard et 
al., 1989, Bottenstein, 1986, Chen et 
al., 2007) 
Yes No 
Biotin 
(LeVine and Macklin, 1988, Komoly 
et al., 1987) 
Yes No 
Transferrin/apo-transferrin 
(Silvestroff et al., 2013) Yes No 
Sodium selenite 
(Baud et al., 2004) Yes No 
Hydrocortisone 
(Chen et al., 2007) Yes No 
Fibroblast growth factor (FGF) 
(Bottenstein, 1986, Besnard et al., 
1989, Chen et al., 2007) 
Yes No 
3,3′,5-Triiodo-L-thyronine 
(Knapp et al., 1987) 
Yes No 
Serum 
(McCarthy and de Vellis, 1980, 
Bottenstein, 1986) 
<5% 10% 
 
Almost all reports focus on isolating one specific glial cell to homogeneity, and 
thus the cells are matured in isolation, which is quite different to what is seen in 
vivo.  It has been speculated that such in vitro cultured oligodendrocytes and 
astrocytes express different markers to what is seen in vivo. One alternative to 
growing cells in isolation includes the use of myelinating cultures, and these have 
been used in one recent study to examine the demyelinating ability of antibodies 
from MS sera (Elliott et al., 2012; Dutta and Trapp, 2011); however, such cultures 
require the use of cells from day 15 embryos and a very broad mix of expensive 
cell culture additives, and are technically demanding to grow. Cultures derived 
from brain slices of adult animals have also been grown (Raineteau et al., 2004), 
but typically such cultures show extensive proliferation of reactive type 2 astro-
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cytes, microglia and fibroblastic cells, with few type I astrocytes and no evidence 
of oligodendrocyte proliferation (Cho et al., 2007). Therefore, they are not very 
suitable to study binding of antibodies to astrocytes and oligodendrocytes.   
 
 
1.6 Hypothesis development and aims 
 
This review of the literature highlights several points:  
1) autoantibodies are present in many patients with demyelinating diseases 
and have been shown to be likely to be pathogenic in NMO, although it is 
still uncertain whether antibodies present in MS patients are pathogenic;  
2) antibodies could exert their effects via multiple different mechanisms;  
3) the focus of antibody studies in MS has been almost solely on myelin 
antigens, but there is some evidence suggesting that astrocytes could also 
be targeted;  
4) there is a need for a simple but robust in vitro model to allow the testing of 
antibodies against oligodendrocytes and astrocytes. 
 
Therefore, the hypothesis to be tested in this thesis is that a cell culture model 
containing a mixture of mature glial cells would be a useful model by which to test 
the pathogenicity of the antibodies from people with MS.  
 
In order to test this hypothesis, the aims of this thesis are therefore: 
1) To develop a mature mixed culture of oligodendrocytes and astrocytes 
2) To test whether there can be specific killing of one cell type without 
impacting on the health of the other cells 
3) To use this mature mixed culture to test the pathogenicity of antibodies 
from people with MS.   
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Chapter 2. 
 
 
 
 
 
Development of a mature mixed glial cell culture system
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2.1 Introduction 
 
As noted in the literature review, there are many published protocols to grow and 
culture cells derived from brain matter, but these methods focus on separating 
out precursor cells from a mixed culture of brain cells around ten days after the 
start of culture, and then growing one cell type in isolation for further study 
through the use of specific media supplements (e.g. DeVellis and Cole, 2012). 
Whilst having cells in isolation does assist with deciphering the function of the 
cell, details can be lost when growing cells in isolation in an artificial system with 
a heavy reliance on growth factors and other cellular additives. In addition, the 
ultimate aim of this project is to be able to investigate whether antibodies in the 
serum of patients with autoimmune CNS demyelinating diseases recognize 
molecules on oligodendrocytes and astrocytes, as it is clear from the review of 
the literature that antibody targets could occur on either oligodendrocytes or 
astrocytes, or possible even on both. It therefore might be beneficial to use a 
mature mixed glial cell culture to investigate this. 
 
There are a number of papers from the 1980’s that described co-culture of 
oligodendrocytes and astrocytes (Aloisi et al., 1988), but typically these were 
short term (7-11 days) cultures containing quite immature oligodendrocyte 
precursor cells, in that they co-expressed GalC and GFAP (Figure 2.1). Several 
investigators have developed in vitro methods for the growth of myelinating 
cultures, in which the oligodendrocytes are fully mature and able to myelinate 
axons, but these cultures are technically demanding, and require the use of 
embryonic day 15 rats, and an expensive mix of growth factors to support the 
growth of neurons, oligodendrocytes and astrocytes (Fedoroff and Richardson, 
1992; Bottenstein, 1986; McCarthy and de Vellis, 1980).  
 
The aim of this first part of the project was therefore to develop a robust mixed 
glial cell culture model, containing a mixture of mature oligodendrocytes and 
white and grey matter astrocytes that could then be used in subsequent studies. 
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Figure 2.1 Schematic showing the developmental stages of cells of the 
oligodendrocyte lineage. Stage-specific markers are shown in the boxes, with 
RNAs in bold italic font and proteins in normal font. Adapted from Baumann, 2001 
(use of this image does not require publisher permission). 
 
 
2.2 Materials and methods 
 
All chemicals were supplied by Sigma, Australia, unless otherwise stated. 
 
2.2.1 Buffers and Cell culture reagents 
 
2.2.1.1  DMEM  
Phenol red-free Dulbecco’s modified Eagle’s medium (DMEM) was prepared 
from a powdered form (Sigma Cat # 56436C). The powder, together with 3.6 g 
NaHCO3 was dissolved in 900 mL of MilliQ water, the pH was adjusted to 7, and 
the final volume made up to 1 L. This base media was filtered through a 0.22 µm 
filter and stored at 4°C.  
 
2.2.1.2  Fully supplemented DMEM 
Fully supplemented DMEM was prepared by adding 10% heat inactivated 
newborn calf serum (NCS) (Bovogen, Victoria), penicillin/streptomycin (0.5 U/mL, 
Lonza, Switzerland) and 25 mM glucose to phenol red-free DMEM, and filtering 
through a 0.22 µm filter (Nalgene, Germany). The fully supplemented DMEM was 
stored at 4°C, and warmed to 37°C before use.  
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2.2.1.3 Chemically defined medium (CDM)    
CDM was prepared by adding the following components to un-supplemented 
DMEM: bovine insulin (5 µg/mL), biotin (100 µg/mL), human transferrin (50 
µg/mL), 30 mM sodium selenite and 25 mM glucose. The media was then filter 
sterilised and stored at 4°C for up to 25 days. CDM was warmed to 37°C before 
use. Before use in cell culture, CDM was supplemented with fully supplemented 
DMEM media at a ratio of 2.7 mL CDM:0.3 mL DMEM (final volume of 1% NCS 
in the media) for the first three days post shake off, then 2.3 mL CDM:0.7 mL 
DMEM (final volume of 2.3% NCS in media) for the remainder of the cell culture 
period. 
 
2.2.1.4 AMES Medium 
AMES medium was prepared from a powdered form (Sigma), following the 
manufacturer’s instructions. Briefly, to prepare one litre, MilliQ water was gassed 
with 100% CO2 whilst adding 1.9 g HCO3. The powdered media was then added, 
the pH adjusted to 7, and the volume made up to 1 L. This solution was filtered 
through a 0.22 µm filter and stored at 4°C. For use, the medium was 
supplemented with 10% heat inactivated NCS, 0.5 U/mL penicillin/streptomycin 
and 25 mM glucose, filtered through a 0.22 µm filter and stored at 4°C. The 
medium was warmed to 37°C before use.  
 
2.2.1.5 Phosphate-buffered saline (PBS) 
PBS was prepared as a 10X stock by combining 80 g NaCl, 2 g KCl, 11.5 g 
Na2HPO4 and 2 g KH2PO4 in ~900 mL dH2O. The pH was adjusted to 7, and the 
volume adjusted to 1 L with dH2O. The 10X stock was autoclaved and stored at 
room temperature. For use, the 10X stock was diluted 1 in 10 with dH2O.  
 
2.2.1.6    4% Paraformaldehyde  
A 4% paraformaldehyde (PFA) solution was prepared just prior to use. To make 
50 mL, 25 mL of tap water was heated for 1 min in a microwave oven, and then 
2g PFA (Merck Millipore, Darmstadt, Germany) was added and stirred. One to 
two drops of 5 M NaOH was added to ensure that the PFA was completely 
dissolved, and then PBS was added to 50 mL. 
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2.2.2 Animals used as a tissue and cell source 
Lewis rat pups (postnatal day 1-2) were supplied by the Herston Medical 
Research Centre (HMRC) of the University of Queensland. The original Lewis rat 
colony founders were from the Animal Resource Centre (ARC) (Canning Vale, 
Western Australia). Rats were provided with food and water ad libitum and were 
housed in a PC2 facility under a 12/12-hour light/dark cycle. Ethical approval for 
the use of the rat pups and adult rats was obtained from the University of 
Queensland Animal Ethics Committee.  
 
2.2.3 Preparation of mixed glial cultures from rat brain 
All steps were performed aseptically. One-day-old rat pups were anesthetized (by 
placing on ice), decapitated and the skin and skull removed and brains placed in 
un-supplemented DMEM. The meninges were removed from the brain, and the 
brain was placed in fresh DMEM and finely diced. A 3.5 mL transfer pipette was 
used to further break up the brain tissue. The mixture was then incubated with 
0.25% trypsin and 10 µg/mL Deoxyribonuclease 1 (DNase1) at 37°C for 10 min, 
followed by centrifugation at 170 x g for 5 min. The cell pellets were re-
suspended in fully supplemented DMEM and cells were triturated with a fine point 
transfer pipette 20-30 times. After large pieces of cell debris had settled, the cell 
suspension was transferred to a new tube and triturated another 20-30 times. 
After a second centrifugation at 170 x g for 5 min, cell pellets were re-suspended 
in fully supplemented media. The cells were plated onto untreated 90 mm2 petri 
dishes (Griener, Germany) at the ratio of 1 brain for 3 petri dishes. Cells were 
incubated at 37°C in a 5% CO2 in air atmosphere for the duration of culturing. 
The medium on the cells was changed on days 3, 7 and 10 before shake off, and 
changed every three days after shake off.  
 
Several different methods were tested for shake off (see results section) and the 
method that was selected was a follows. At day 10, cells were dislodged from the 
cell bed by flushing media with gentle force over the cells using a 10mL syringe 
or transfer pipette. The cells in suspension were added to a non-treated petri dish 
and incubated for 15min at 37°C in a 5% CO2 in air atmosphere. After this time, 
cells that had not adhered were collected and centrifuged at 150 x g for 10 min, 
resuspended in fully supplemented media and counted using a haemocytometer. 
44 
 
Cells were plated onto poly-D-lysine pre-coated 6 well plates (Greiner, Germany) 
and supplemented with fresh media at 3-day intervals. 
 
2.2.4 Immunofluorescence labelling of cultured cells 
Antibodies used for immuno-labelling of cells are listed in Table 2.1. For staining, 
tissue culture medium was removed from cultures, and the cells were washed in 
PBS, then fixed in freshly made 4% PFA for 15min. Cells were washed 3 times 
with PBS, then photo bleached at ~2000 lux units, as measured by a LM-81LX 
light intensity meter (Lutron Electronics, Taiwan), for 20 min to reduce auto-
fluorescence. After photo bleaching, cells were blocked and permeabilized with 
0.05% saponin + 1% bovine serum albumin (BSA) in PBS (S/BSA-PBS) for 15 
min, then washed 3 times in PBS. Primary antibody diluted in S/BSA-PBS was 
added, and cells were incubated overnight at room temperature, with gentle 
agitation. After that, the cells were washed 3 times with PBS, and fluorochrome-
labelled secondary antibody diluted in S/BSA-PBS was added to the cells and 
incubated in the dark for 2 hours at room temperature, with gentle agitation. After 
another round of washes, cell nuclei were stained with 4’, 6-diamidino-2-
phenylindole dihydrochloride (DAPI) for 20 min. A 1 mg/mL stock solution of 
DAPI (Sigma) was diluted 1:10,000 in 0.9% NaCl for use. Cells were then 
washed a further 3 times with PBS and stored in PBS containing 0.001% sodium 
azide at 4°C, until they were assessed microscopically.  
 
2.2.5  Brain slice preparation  
Adult Lewis rats were perfused with 100 mL saline followed by 100 mL 4% 
paraformaldehyde and the brains were removed. Brains were cut in half 
lengthwise (sagittal section) and post fixed in 4% PFA for 3 hours, then prepared 
for wax embedding. Briefly, tissue was washed in 10% picric acid (Invitrogen, 
Australia) in PBS for 8 hours on an orbital shaker. After that, the tissue was 
washed in 1 x PBS for 30 mins to remove excess picric acid, then dehydrated in 
50% ethanol for 1 hour before being stored at 70% ethanol. Wax embedding and 
sectioning was done at the Queensland Institute of Medical Research Berghofer 
(QIMR-B) histology services. Four µm and 8 µm sections of rat brain were cut 
onto Superfrost™ slides for immunofluorescence studies. 
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Table 2.1. Antibodies used for Immunofluorescence labelling of cells and whole brain slices  
Name Specificity Generated in Dilution used Source 
Primary antibodies 
GFAP Whole spinal cord homogenate (pan GFAP antibody mainly selects for GFAPα) 
Rabbit 
polyclonal 1:5,000 DAKO 
RIP 
(11-5B hybridoma clone) 
Whole isolate of human 2', 3’-cyclic 
nucleotide 3'-phosphodiesterase (CNP) 
injected into mice 
Mouse IgG 1:500 
Sigma Aldrich 
(Sprinkle et al., 
1987) 
PLP CGKGLSATVTGGQKGRGSRG (Amino acids 109-128) 
Rabbit 
polyclonal 1:2,000 Abcam 
Secondary Antibodies 
Texas Red-labelled anti-
rabbit secondary Rabbit Ig Goat 1:500 Amersham 
Fluorescein 
isothiocyanate (FITC) -
labelled anti-mouse 
secondary 
Mouse Ig Donkey 1:500 Sigma 
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2.2.6 Immunofluorescence labelling of rat brain sections  
The rat brain sections were photo bleached at ~2000 lux units for 4 hours to 
reduce auto-fluorescence. After photo bleaching, slides were de-waxed and 
rehydrated through the Tissue-Tek DRS automated system (Sakura, Japan) 
using graduated xylene and alcohol steps, as outlined in Table 2.2.  After 
dewaxing and rehydration, the slides were incubated with the antigen retrieval 
solution DIVA™ (Biocare Medical, USA) at 100°C for 20 min. The slides were 
then washed in dH2O for 5 min and melted dental wax was dabbed around the 
brain section to create a well for blocking and staining buffers and components. 
The sections were then blocked and permeabilized with S/BSA-PBS for 30 min. 
After washing 3 times in PBS, primary antibody (diluted in S/BSA-PBS) was 
added to slides and incubated overnight in a humidified container at 37°C. The 
slides were washed 3 times with PBS, and fluorochrome-labelled secondary 
antibody (diluted in S/BSA-PBS) was added to the slides and incubated in the 
dark for 2 hours at room temperature. The slides were then washed a further 3 
times with PBS and coverslips were mounted with Vectashield ™ (Vecta 
Laboratories, USA). The coverslips were sealed with clear nail polish before 
viewing.  
 
 
Table 0.2. Program details of automated de-wax program on Tissue-Tek 
DRS system used for rat brain section Immunofluorescence labelling  
Solution Time 
Xylene 4 min 
Xylene 2 min 
Xylene 1 min 
100% Ethanol 1 min 
100% Ethanol 1 min 
90% Ethanol 1 min 
70% Ethanol 1 min 
dH2O 2 min 
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2.2.7 Microscopy 
 
2.2.7.1 Phase contrast microscopy  
All cells were viewed under phase contrast with either an Olympus CKX41 
inverted microscope (OLYMPUS, Japan) with QIMAGing Micropublisher 3.3 RTV 
camera or a Nikon Eclipse TS100 inverted microscope (NIKON, Japan) with 
Nikon camera. Phase contrast images were analysed using QIMAGE or Nikon 
elements image capture and analysis program NIS Elements F3.2 (Nikon 
Elements AR), respectively.  
 
2.2.7.2 Fluorescence microscopy  
Fluorescently labelled cell cultures were viewed using a Nikon Eclipse 50i 
fluorescence microscope (NIKON, Japan) equipped with an Olympus DP70 
camera (OLYMPUS, Japan). The microscope was equipped with Nikon water 
immersion lenses at magnifications of 20X, 40X and 60X, to allow for 
visualisation of cells in the plate, without mounting cells onto slides. Fluorescence 
images were acquired as sequential single channel images, which were then 
recombined into multichannel RGB colour images in Adobe Photoshop.  
 
Fluorescently labelled rat brain tissue was viewed using a Zeiss Axio Imager 
microscope (Zeiss, Germany) equipped with an Axio 503 camera and 20X, 40X, 
63X and 100X magnification lens. Fluorescence images were acquired as 
sequential single channel images, and analysed using Zen Blue software (Zeiss). 
 
2.2.8 mRNA expression  
 
2.2.8.1 Buffers and solutions 
 
2.2.8.1.1   MOPS buffer 
A 10X MOPS buffer solution was prepared by combining 200 mM 3‐(N‐
morpholino) propanesulphonic acid (MOPS), 50 mM sodium acetate.3H2O, and 
10 mM ethylenediaminetetraacetic acid (EDTA) in dH2O (MilliQ), with pH adjusted 
to 7. A 1X working solution was prepared immediately before use by diluting 10X 
MOPS buffer 1 in 10 in dH2O. 
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2.2.8.1.2   RNA Loading buffer 
For RNA sample preparation, the loading buffer was prepared by combining 10 
µL 10X MOPS, 35 µL 6X Loading buffer (0.25% bromophenol blue, 30% glycerol 
in dH2O), 17 µL 37% formaldehyde and 50 µL formamide. Sample RNA was 
added to loading buffer 1:1, heated at 65°C, then cooled on ice before loading 
onto RNA agarose gels. 
 
2.2.8.1.3   1% RNA Agarose gel 
A 1% RNA gel was prepared by mixing 1 g DNA-grade agarose with 72 mL dH2O 
and heating in a microwave oven until the solution was clear. Ten mL 10X MOPS 
buffer and 18 mL of 37% formaldehyde were added, and mixed by swirling. This 
solution was allowed to cool slightly then poured into a gel casting set and 
allowed to set at room temperature. 
 
2.2.8.1.4   Tris-acetate EDTA (TAE) Buffer  
A 50X concentrated stock solution of TAE was prepared by dissolving 242 g Tris 
base (Sigma Aldrich) in 750 mL dH2O (MilliQ). Next, 57.1 mL glacial acetic acid 
and 100 mL of 0.5 M EDTA (pH 8.0) were added, and the final volume was 
adjusted to 1 L. The stock solution was stored at room temperature and diluted 
1:50 with dH2O prior to use.  
 
2.2.8.1.5   1% and 1.5% DNA Agarose gel 
To prepare DNA agarose gels, 1 or 1.5 g DNA-grade agarose was added to 100 
mL 1X TAE buffer and heated in a microwave oven until completely dissolved. 
Once the solution had cooled slightly, it was poured into a gel casting set and 
allowed to set at room temperature.  
 
2.2.8.1.6   PCR Master Mix 
The PCR master mix buffer was prepared just prior to each PCR reaction, using 
reagents from the BIOTAQ PCR kit supplied by Bioline (NSW, Australia). In short, 
5 µl 10X BioTaq NH4 buffer, 3µl 50 mM MgSO4, 5 µl dNTPs, 1.5 µl Forward 
primer, 1.5 µl Reverse Primer, and 2.5 U BIOTAQ DNA polymerase were added 
to 31.5 µl dH2O and stored on ice. 
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2.2.8.2 Total RNA extraction  
Total RNA was isolated from rat whole brain tissue or mixed cell cultures that had 
been harvested at the required time points into TriZol™ (Invitrogen) reagent. The 
samples (minced brain tissue or cultured cells) were homogenized using an IKA 
T25 digital ULTRA-TURRAX homogenizer (IKA, Malaysia) for 30 s at a high 
speed (setting 11), and then placed on ice for 3 min to prevent heating and 
degradation of tissue. This step was repeated until tissue was thoroughly 
homogenized. To allow complete dissociation of nucleoprotein complexes, 
homogenates were incubated on ice for 5 min following homogenization. Two 
hundred μl of chloroform was added to 1 mL of homogenate and the mixture was 
vigorously mixed for 1 min, and then incubated on ice for 5 min. Samples were 
centrifuged at 12,000 x g for 20 min and the upper aqueous phase was removed 
and transferred to a fresh tube. To precipitate the RNA, an equal volume of 
isopropanol was added, then the mixture was incubated at -20°C for 24 h. 
Samples were centrifuged at 17,000 x g for 5 min, supernatant was removed and 
the pellet re-suspended in 700 µL of 75% ethanol. The samples were centrifuged 
at 17,000 x g for 5min, supernatants were removed and the pellets were air-dried 
then re-suspended in 20 µL of dH2O and stored at -80°C until use. The 
concentration of each RNA sample was determined using a NanoDrop ND-1000 
Spectrophotometer (Coleman Technologies Inc, USA) 
 
2.2.8.3 RNA quality check  
Total RNA was run on an RNA Gel to determine if the RNA was suitable for use 
in further experiments (i.e. intact or degraded). An aliquot (~30 µg) of each RNA 
sample was mixed with RNA Loading Buffer and separated on a 1% RNA 
agarose gel in 1X MOPS Buffer using a horizontal electrophoresis system 
(Labpro Scientific, QLD, Australia). The RNA samples were separated 
electrophoretically at 70V until the dye front reached the end of the gel.  The RNA 
gels were stained with 0.5 μg/mL ethidium bromide for 1 hour then washed 3 
times for 20 min each time in fresh dH2O, before visualization under a UV trans-
illuminator (Bio-Rad,USA) connected to a computer with image capture software 
(Quantity One, version 4.6.5 - build 094). The presence of strong 28S and 18S 
ribosomal RNA bands on the gel indicated that the RNA product was not 
degraded and was suitable to use for generating cDNA. 
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2.2.8.4 cDNA generation  
Total RNA (5 μg) was reverse-transcribed into complementary DNA by adding 
RNA to 1 μl of OLIGOdT, 1 μl of dNTPs and dH2O to give a final volume of 12.5 
µl. Samples were heated to 65°C for 5 min, and then placed on ice for 3 min. 
Next, 4 µl of 5x RT Buffer (Invitrogen), 1 µl of 0.1 M DTT, 1 µl of RNase Out and 
1.5 µl of Superscript III (Invitrogen) were added to the reaction mixture, and 
samples were heated at 50°C for 60 min, followed by inactivation at 70°C for 15 
min. Following inactivation, samples were digested by addition of 1 µl 
Ribonuclease H (Invitrogen) and incubation at 37°C for 20 min. Twenty µl of 
dH2O was added to stop the reaction and the cDNA samples were stored 
at -20°C until required. 
 
2.2.8.5 Primer sequences  
Primer sequences were designed to pick up a ~1kb fragment of coding region of 
common oligodendrocyte and astrocyte proteins. The sequences were designed 
using the programs Oligo Analyzer 1.2 (Molecular Biology Freeware) and 
OligoExplorer 1.2 (Gene Link). Primers were synthesized and supplied by Sigma 
Aldrich. The sense and antisense primer sequences and the predicted fragment 
size for each gene are given in Table 2.3.  
 
2.2.8.6 PCR amplification  
The cDNA (prepared as in 2.2.8.4) was amplified by PCR. One µl of cDNA 
template was added to the PCR tube prior to adding a mastermix containing 2 
mM dNTP, 0.2 mM sense and antisense primers, 1.5 mM MgCl2, 2.5 U BIOTAQ 
DNA polymerase (Bioline Pty Ltd, Alexandria, NSW, Australia), and 1× PCR 
buffer to give a final volume of 50 μl. PCRs were performed using the following 
conditions: initial denaturation at 95 °C for 2min followed by 25 cycles of 
amplification (95 °C for 30s, 60 °C for 30s and 72 °C for 1min) then a final 
extension step (72°C for 5min). The reaction products were separated on 1.0-
1.5% DNA agarose gels, depending on the product size, and visualized by 
staining with 0.5 µg/mL ethidium bromide for 1 hour as described in 2.2.8.3. 
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Table 0.1. Primer sequences used in gene expression PCR profiling in this 
chapter 
Cell type Product Gene Bank 
Accession 
number 
Primer sequences Fragment 
size 
Astrocyte GFAP NM_017009.2 F 5’ CTG AGG CTG GAG 
GCG GAG AAC 3’ 
R 5’ GCT GGG CAC CTC 
ACA TCA C 3’ 
810 
OL RIP NM_012809 F 5’ AGC CAC ACA TTC 
CTG CCC AAG 3’ 
R 5’ AGG GCT TGT CCA 
GGT CAC TTG 3’ 
924 
OL PLP NM_030990 F 5’ CCC TGA CTG TTG 
TAT GGC TC 3’ 
R 5’ CGC AGC ACC CAC 
AAA CGC AG 3’ 
252 
Pre OL NG2 X56541 F	 5’ TGG GCT CTT TGT 
GGG CTC CT 3’ 
R	5’ GCG GGA AGA CGA 
TGC GAG GT 3’ 
1224 
House-
keeping 
gene 
β-Actin NM_001101.3 F 5’ GTT TGA GAC CTT 
CAA CAC CCC AG 3’ 
R 5’ CTG CTT GCT GAT 
CCA CAT CTG C 3’ 
711 
OL = oligodendrocyte; F = forward primer; R = reverse primer 
 
 
2.2.8.7 Gene expression Analysis  
The expression intensity of PCR products was normalized against β-actin using 
Image J software, following previously published protocols (Regeer et al., 2003). 
The expression intensity relative to β-actin was plotted and analysed using Graph 
Pad Prism software version 6.0.	
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2.3 Results 
 
2.3.1 Optimization of cell densities and shake-off methods 
Initial culturing experiments were done to compare the relative yields of 
oligodendrocytes and astrocytes following various shake off methods and plating 
at various cell densities. Cells extracted from neonatal rat brains were cultured for 
10 days in fully supplemented DMEM. Initially, poly-D-lysine coated flasks were 
compared to untreated 6 well tissue culture plates to determine if cells grew 
better in one than the other. Both flasks and plates yielded very similar results. 
These cultures, observed by phase contrast microscopy, showed beds of 
flattened cells (likely to be a mixture of type 1 astrocytes and fibroblasts) with 
phase-bright refractive cells (likely to be oligodendrocyte precursor or O2A cells, 
which can differentiate into either oligodendrocyte precursor cells or type 2 
astrocytes) growing on top of the bed (Figure 2.2). 
 
Several different shake-off methods that have previously been reported in the 
literature were tested, including rapping flasks on the bench (Greer et al., 1996), 
agitating flasks on an orbital mixer for various times ranging from 2-18 hours and 
at various speeds (Chen et al., 2007; Dyer and Benjamins, 1988; McCarthy and 
de Vellis, 1980), and washing cells off using a steady stream of fluid delivered via 
a pipette (Besnard et al., 1989; Feutz et al., 1995). The last of these methods 
(fluid agitation) was found to be the method that resulted in approximately equal 
proportions of healthy phase bright cells and astrocytes, and it was therefore 
used in all subsequent studies. 
 
The dislodged cells were grown in culture for 7 days in untreated 6 well tissue 
culture plates at a variety of cell densities, and then assessed by phase contrast 
microscopy, to determine the optimal plating density. Previous studies have used 
plating densities ranging from 104 cells/cm2 up to 2x105 cells/cm2 (Bottenstein, 
1986; Feutz et al., 1995; Chen et al., 2007). The wells of the 6 well tissue culture 
plates were 9.62 cm2 in size. Therefore, plating densities ranging from 7.5x104 
cells/well to 1x106 cells/well were tested to determine the optimal density. The 
optimal cell number resulted when 105 cells were seeded/well.  
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Figure 2.2. Phase-bright refractive cells (examples labelled with red arrow 
heads) sitting atop a bed of astrocytes in 10 day cultures of neonatal rat brain. 
Image taken at 20x magnification.  
 
 
2.3.2 Glial cell growth in different tissue culture media 
 
Different formulations of tissue culture media have been used to grow 
oligodendrocytes and astrocytes in vitro. In the current study, 3 different media 
compositions (AMES, chemically defined medium, and fully supplemented 
DMEM) were compared.  
 
Cells following shake off were re-suspended in the different media and cultured at 
105/well for 7 days. The numbers and type of cells in 10 different fields at 40X 
magnification were then counted under phase contrast microscopy. Cell numbers 
were recorded for refractive cells (which included immature oligodendrocytes 
and/or O-2A cells, that can differentiate into oligodendrocytes or type 2 
astrocytes), type 1 astrocytes (which could be clearly distinguished because of 
their flattened protoplasmic phenotype), and total number of cells in the field. 
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2.3.2.1 AMES + 10% NCS 
AMES medium was originally designed to replicate the makeup of CSF. It has 
primarily been used to culture the isolated retina and neural cells derived from 
retina, and thus it was expected that this medium might support the growth of 
astrocytes better than the growth of oligodendrocytes (Ames and Nesbett, 1981; 
Moritoh et al., 2010). As expected, culturing in AMES medium resulted in 
significantly more flattened protoplasmic type 1 astrocytes than multi-polar 
refractive cells (Figure 2.3.A). Culturing in AMES medium for longer time periods 
further increased the number of type 1 astrocytes only. AMES was therefore 
determined to be an unsuitable culture medium to support long-term maturation 
of oligodendrocytes as well as astrocytes.  
 
2.3.2.2 Chemically modified medium (CDM) 
CDM contains insulin, biotin, transferrin, sodium selenite and glucose (refer to 
section 2.2.1.3 for medium composition) and it has been used in many studies to 
help differentiate oligodendrocytes from neonatal rat brain derived cultures (Dyer, 
1993; Bottenstein, 1986). The CDM contains only very low levels of serum: 1% 
NCS for the first 3 days post shake off, which is increased to 2.3% after 3 days. 
Compared to AMES medium, there was an increase in the number of refractive 
cells/field (although they showed less branching than did cells in AMES medium), 
and a decrease in the number of flattened astrocytes (Figure 2.3.B). The total 
number of cells/field after 7 days was similar in either AMES medium or CDM. 
However, as with cells grown in AMES medium, longer term culture in CDM 
increased the number of protoplasmic astrocytes at the expense of the refractive 
cells (oligodendrocytes and O2A cells), and few mature oligodendrocytes were 
found 14 days after shake off.  
 
2.3.2.3 Fully supplemented DMEM  
Interestingly the total number of cells growing in fully supplemented DMEM (refer 
to 2.2.1.2 for composition) was higher than in either AMES medium or CDM. 
There were some regions of the culture wells which contained predominantly 
flattened astrocytes or predominantly populations of refractive multipolar cells, 
but there were also area that had a mixture of the cell types (Figure 2.3.C.).  
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Figure 2.3. Comparison of mixed neonatal rat brain derived culture (post 
shake off) cultured in different media conditions. Cells were extracted from 
neonatal rat brain and cultured for 10 days in DMEM + 10% NCS. Post shake off, 
cultures were grown in either Ames + 10% NCS media (A) CDM + 10% NCS media (B) 
or DMEM + 10% NCS (C) for a further 10 days. Cultures were then viewed under phase 
contrast microscopy and photographed. Refractive cells and type 1 astrocytes were 
counted in 10 separate fields and the numbers graphed. Scale bar = 50µm 
 
A 
 
 
 
 
B 
 
  
 
 
 
C 
56 
 
Although the proportion of refractive cells was significantly lower than the 
proportion of type 1 astrocytes after 10 days, the higher overall total number of 
cells appeared to improve the health of the culture. Importantly, when cultured for 
longer periods of time, the proportions of mature oligodendrocyte and type 2 
astrocytes appeared to remain stable. This medium was therefore used to grow 
the mature mixed cultures used for further characterisation studies. 
 
2.3.3 Maturation of mixed astrocyte and oligodendrocyte cultures and 
comparison with astrocytes and oligodendrocytes in the brain 
 
Cultures were grown in fully supplemented DMEM following shake-off. At various 
time points, cells were assessed for levels of RNA for maturation markers, and 
also stained for immunocytochemical analysis. The maturation markers assessed 
included: NG2, which is present in immature oligodendrocyte progenitor cells; 
RIP, which is the common name for the antibody targeting 2',3'-cyclic-nucleotide 
3'-phosphodiesterase (CNPase) in oligodendrocytes (Watanabe et al., 2006); 
PLP, which is only expressed in mature oligodendrocytes; and GFAP, one of the 
most widely used markers of astrocytes in brain and cell cultures. In culture, there 
are phenotypic differences between type 1 (large, flat, fibrous astrocytes) and 
type 2 (finely branching, stellate) astrocyte morphologies. In the brain, astrocytes 
often appear stellate, but the morphology of astrocytes is highly heterogeneous, 
and includes distinct populations such as the radial glia, and the Bergmann glia in 
the cerebellum. 
2.3.3.1 Comparative time-course of mRNA expression profiles in cell 
cultures and in brain 
The cells that appeared as multi-polar, highly refractive cells under phase 
contrast microscopy could be precursors of oligodendrocytes or astrocytes. In 
order to assess the makeup of the cultures in more detail, RNA was collected at 
varying time points in the culturing process, from day 3, 7, 10, 17, and 24 after 
setting up the cultures (shake off was done at day 10). As a comparison, RNA 
was extracted from rat brain tissue at newborn (day 0), days 3, 7, 10, 17, 24 of 
age, and from adults at 6-8 weeks. The quality of the RNA was tested by running 
the samples on 1% agarose gels and then staining them with ethidium bromide to 
detect 28S and 18S ribosomal RNA bands (Figure 2.4). Samples showing clear 
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Figure 2.4: Intact RNA extracted from brain and mixed cultures at different 
time points on a 1% RNA agarose gel. Total RNA (30ng) was separated on a 
1% agarose MOPS denaturing gel and counter stained with ethidium bromide. 
The 18S and 28S ribosomal bands are well defined, indicating intact RNA 
product ready to use for conversion to cDNA for further analysis.  
 
18S and 28S bands indicated that the RNA was intact and suitable for conversion 
to cDNA for further analysis. RNA was reverse transcribed to cDNA. Primers 
were designed for the coding regions of NG2, RIP, PLP and GFAP, and were 
used to amplify the samples from each time-point. Primers for β-actin were also 
used with each sample, as a housekeeping gene. Initial trials showed that 25 
PCR cycles was sufficient to show varying levels of gene expression at the 
different time points. All PCR products ran at their expected size on the agarose 
gels. Each time point was assessed in triplicate. 
 
In the cultures, NG2, RIP and GFAP expression could be detected from day 3, 
and for RIP and GFAP, expression increased with time (Figure 2.5). In contrast, 
NG2 expression gradually decreased as the cells matured. Very little PLP was 
detected until day 17 in culture, but then it markedly increased, correlating with 
the maturation of oligodendrocytes in vitro. In the brain, expression of GFAP and 
RIP increased steadily over time, with a slight dip at day 10. PLP showed low 
expression until day 7, and then increased steadily. Interestingly, there was a 
major increase in levels of NG2 at day 7, which was replicated in 3 separate 
samples, suggesting that their may be a wave of migration of NG2 cells into the 
rat brain at this timepoint. 
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Figure 2.5 Gene expression profile for astrocyte and oligodendrocyte 
markers over time. (A) RNA was extracted from rat brain and cell cultures at 
nominated time points and converted to cDNA. Primers for GFAP, RIP and PLP 
were used in PCR against the cDNA and their level of expression against the 
house keeping gene β-actin was calculated and graphed. (B) Representative gels 
from which results were results were detemined. Assays were performed in 
triplicate.  
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2.3.3.2 Expression of molecules involved in oligodendrocyte maturation  
In order to confirm that the differences seen in the time course of RNA 
expression of RIP and PLP in maturing oligodendrocytes correlate with 
differences in protein expression, cultures of cells at day 7, 17 and day 24 were 
co-stained with antibodies against RIP and PLP (Figure 2.6). The RNA 
expression of PLP was very low in cultured cells at day 7, but by day 17 had 
increased markedly and remained high for the remainder of the culture period. 
Level of RIP expression was relatively high at all stages. Corresponding to that, 
in day 7 cultures, RIP positive oligodendrocytes only showed a very low level of 
PLP immunolabelling in the perinuclear region of the cell body (Figure 2.6.A). By 
day 17, however, oligodendrocytes showed almost complete co-localization of 
PLP and RIP in the cell body and processes, as indicated by the yellow co-
stained image (Figure 2.6.B): this correlated with the mRNA expression profile in 
Figure 2.5.  By day 24, the oligodendrocytes had extended extensive membrane 
sheets: RIP did not stain the membrane sheets as broadly as did PLP antibody; it 
appeared to be confined to the centre of the membrane sheet (Figure 2.6.C). 
 
2.3.3.3 Immunolabelling with glial cell markers 
The cultures were also immunolabelled to show the relative proportions of oligo-
dendrocytes (or their precursors) and type 1 and type 2 astrocytes in the mixed 
cultures as they matured. Before commencing that part of the study, the 
antibodies to be used to determine these cell types in the mixed cultures (specific 
for GFAP and RIP) were initially used on perfused adult rat brain tissue in order 
to demonstrate that there was clear delineation between cell types with the 
different antibodies used. The brain tissue was fixed with 4% paraformaldehyde, 
wax embedded, and 8µm sections were cut and immunolabelled. In the 
cerebellum of the adult rats (Figure 2.7), GFAP labelled fibres of the Bergmann 
glia in the molecular layer (indicated with * in Figure 2.7.A), and stellate 
appearing cells in the granular layer. In both white and grey matter (Figure 2.7.B), 
the majority cells that labelled positive for GFAP were stellate in appearance. 
There was no co-labelling of astrocytes and oligodendrocytes/myelin, 
demonstrating the specificity of the antibodies. 
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Figure 2.6 Oligodendrocyte maturation in mixed cell culture over time. 
Cultures at day 7, 17 and 24 time points were fixed and immunolabelled with 
antibodies against oligodendrocyte markers RIP (green) and PLP (red). RIP 
labeling was strong throughout the cultures at all time points. Oligodendrocytes at 
day 17 and 24 were positively labeled for PLP and RIP. Scale bar = 50µm. 
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Figure 2.7 Comparison of  immunolabelling with markers for oligodendro-
cytes and astrocytes using RIP, PLP and GFAP antibodies in the adult rat 
brain. A) 8 µm section of the cerebellum co-labelled with antibodies specific for 
RIP (green) and GFAP (red), and with DAPI (Blue) to show the cell nuclei. The 
Bergmann glia staining can be clearly seen in the areas indicated by the *. Scale 
bar = 200µm. B) Adult rat brain (8 µm thickness), at the border between white 
and grey matter, was immunolabelled with RIP (green) and GFAP (red) specific 
antibodies  and with DAPI. Scale bar = 50µm.  
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Next, the mixed cultures were assessed with the same antibodies, to determine 
the frequency of GFAP+ astrocytes and RIP+ oligodendrocytes and oligodendro-
cyte precursors in the cultures at days 7, 17 and 24 of culture. Cells from a total 
of 10 fields for each culture were counted and the average number of cells 
stained with each marker was determined (Figure 2.8.). For astrocytes, the total 
number, and the number of type 2 astrocytes per field was recorded. At day 7, 
the majority of cells were type 1 astrocytes, and type 2 astrocytes appeared to be 
fairly immature, with many still appearing as bi-polar cells. The RIP+ immature 
oligodendrocytes also had few processes, and no extensive membrane sheets. 
(Figure 2.8.A). By day 17 (7 days post shake-off; Figure 2.8.B), the type 2 
astrocytes matured into fibrous glia, and the oligodendrocytes had extended 
multiple processes and showed some arborisation. Interestingly, while processes 
from the type 2 astrocytes and oligodendrocytes frequently grew over the top of 
each other, oligodendrocyte processes were seldom seen to cross over type 1 
astrocyte bodies, instead, processes more typically grew along the edge of the 
type 1 astrocytes. At day 24 (Figure 2.8.C), oligodendrocytes were fully matured, 
but still appeared reluctant to cross boundaries set by type 1 astrocyte 
processes.  
 
Co-immunolabeling of cells with antibodies for GFAP and PLP showed almost 
identical results for day 17 and day 24 cultures (data not shown), but showed few 
PLP+ cells at day 7, as expected from the results shown in Figures 2.5 and 2.6.  
Taken together, these results show that it is possible to grow a mature mixed 
culture containing mature oligodendrocytes and both type 1 and type 2 
astrocytes.  
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Figure 2.8 Enumeration of numbers of oligodendrocytes and astrocytes in 
the mixed cultures at day 7, day 17 and day 24. Culture were labelled with RIP 
(green; oligodendrocyte marker) GFAP (red; astrocyte marker) to demonstrate 
the numbers of oligodendrocytes and astrocytes, and with DAPI (blue) to identify 
nuclei. Both type 1 and type 2 astrocytes were present.  
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2.4 Discussion:    
 
There are many variations to the methods to extract and grow pure cultures of 
oligodendrocytes or astrocytes. In the current chapter, the aim, however, was not 
to grow pure cultures of either mature oligodendrocytes or mature astrocytes, but 
to find a way to grow a culture containing mature cells of both types. The results 
presented show the development of a method that could be used to reliably 
obtain cultures containing a mixture of mature oligodendrocytes, type 1 and type 
2 astrocytes within 3-4 weeks.  
 
The main differences between the culture protocol used in this thesis and 
previous protocols for culturing oligodendrocytes are the concentration of new 
born calf serum added to the cultures and the absence of additional growth 
factors. In early studies on in vitro culture of oligodendrocytes, McCarthy (1980) 
used medium containing 15% foetal calf serum (FCS) and obtained ~99% pure 
oligodendrocyte cultures. However, subsequent studies stated that a high 
percentage of serum in the growth medium inhibited the maturation of both 
oligodendrocytes and type 2 astrocytes, and resulted in glial cells remaining in 
the precursor state (Eccleston and Silberberg, 1984). Therefore, most media 
used for the growth of oligodendrocytes (for example, the CDM used in this 
chapter) contain no more than 2-3% serum (Koper et al., 1984), and typically 
newborn calf serum is used in preference to FCS. In addition, media additives 
such as insulin, biotin, transferrin and sodium selenite are reported to be 
necessary for maturation of oligodendrocytes in vitro (Bottenstein, 1986; Chen et 
al., 2007). However, as indicated by the results in this chapter, fully matured 
oligodendrocytes and type 2 astrocytes could be grown in the fully supplemented 
DMEM with 10% newborn calf serum. For growth and differentiation of 
astrocytes, a higher percentage of serum (~10%) is usually recommended, but 
most recent protocols recommend the use of FCS, rather than newborn calf 
serum (Souza et al., 2013). 
 
The most likely reason to explain the different media requirements for the co-
cultures described in this chapter, in comparison to when cells of only one type 
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are grown, is that these cells are each producing growth factors that support the 
growth and maturation of the other cells in the culture. Astrocytes are known to 
produce many factors that can support the growth of other neural cells, and 
conditioned media from astrocyte cultures, or feeder layers of astrocytes, have 
been used widely in the growth of neurons (Banker and Goslin, 1991; Fedoroff 
and Richardson, 1992; Melli and Hoke, 2009), purified astrocyte cultures (Foo et 
al., 2011), and myelinating cultures (Thomson et al., 2006; Thomson et al., 2008). 
 
Astrocytes produce fibroblast growth factors 1 and 2 (FGF1, FGF2) (Ferrara et 
al., 1988; Ito et al., 2005), nerve growth factor (NGF) (Houlgatte et al., 1989), 
ciliary neurotrophic factor (CNTF) and brain derived neurotrophic factor (BDNF) 
(Rudge et al., 1992; Langan et al., 1995), plus members of the neurotrophin gene 
family such as neurotrophin 3 (NT-3) (Rudge et al., 1992), which enhance the 
proliferation, survival and differentiation of both neurons and oligodendrocytes 
(Schwartz and Nishiyama, 1994; Langan et al., 1995). It is also known that 
astrocytes can produce factors such as platelet-derived growth factor (PDGF) 
that can inhibit the development of oligodendrocytes (Raff et al., 1988).  
 
Oligodendrocytes have also been found to produce factors that can support the 
growth of neurons, such as glial cell line-derived neurotrophic factor (GDNF) 
(Wilkins et al., 2003), brain derived neurotrophic factor (BDNF) (Dougherty et al., 
2000), and insulin-like growth factor-1 (IGF-1) (Du and Dreyfus, 2002), but there 
has been little focus on whether they might produce trophic factors for astrocytes. 
Recently, however, it has been shown that mature brain astrocytes, which are 
mostly type 2-like astrocytes, require heparin-binding epidermal growth factor 
(HBEGF) and Wnt7a for in vitro survival (Foo et al., 2011). HBEGF has been 
reported to be expressed by oligodendrocytes (Nakagawa et al., 1998), and 
Wnt7a is expressed at high levels in oligodendrocyte precursor cells, although it 
is downregulated in mature oligodendrocytes (Yuen et al., 2014). Therefore, the 
increased number of type 2 astrocytes observed in the cultures produced in this 
chapter (compared to most astrocyte cultures, which are generally reported to 
consist almost entirely of type 1 astrocytes (Kerstetter and Miller, 2012)) might 
have been due to the presence of oligodendrocytes in the cultures. 
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Whilst the mature mixed cultures were not immunolabelled for the NG2 marker 
(specific for the integral membrane chondroitin sulfate proteoglycan 4 that is 
expressed on oligodendrocyte progenitors and pre-oligodendrocytes (Nishiyama 
et al., 1996) and also on some astrocytes in the cerebellum (Leoni et al., 2009)), 
RNA for NG2 showed a gradual decrease in the culture system over time. 
Although the PCR method used to compare RNA levels at different time points is 
only semi-quantitative, this result suggests that the NG2 cells did not proliferate 
and replenish in the cultures, but either differentiated into oligodendrocytes or 
astrocytes, or underwent apoptosis. There is a steady self-replenishing 
population of NG2+ pre-oligodendrocytes in the brain, which are thought to be 
recruited to sites of damage (Nishiyama et al., 2009). However, in the mixed glial 
culture environment the trophic factors released by the maturing 
oligodendrocytes and astrocytes did not encourage NG2+ cells to remain in this 
progenitor state.   
 
There are a number of other markers that are often used to identify 
oligodendrocytes and astrocytes in vitro and in vivo. For oligodendrocytes, these 
include the PDGF receptor  (PDGFR) (Pringle and Richardson, 1993), Olig2 (a 
transcription factor required for oligodendrocyte specification and differentiation) 
(Zhou and Anderson, 2002), and myelin components such as MBP and MOG. 
For astrocytes, other markers that are used are S100, and the excitatory amino 
acid transporters EAAT1 and EAAT2. The rationale for using GFAP to identify 
astrocytes and RIP and PLP to identify oligodendrocytes and myelin in the 
current chapter was that these markers are well defined, and are present on the 
mature cells, as the main purpose of this chapter was to obtain a mature mixed 
culture of glial cells that could be used in further studies looking at whether serum 
from patients with autoimmune demyelinating disease can target both 
oligodendrocytes and astrocytes. 
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Chapter 3. 
 
 
Antibody-mediated killing of cells in the mature mixed glial 
cell culture: can one cell type be targeted without causing 
death of the other cell types? 
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3.1 Introduction  
 
The previous chapter outlined the development and characterisation of a mature 
mixed glial culture containing mature oligodendrocytes and type 1 and type 2 
astrocytes. The ultimate aim in developing this mature mixed culture is so it can 
be used as a tool to identify if antibodies in the serum of patients with MS are 
pathogenic to either oligodendrocytes or astrocytes, or to both. One of the main 
conclusions from the preceding chapter was that the cells are co-dependent on 
each other for their health and growth, likely due to the production of growth 
factors by the different cells in the mature mixed culture which can support the 
growth and maturation of the other types of cells. Because of this co-
dependency, it is important to show that there can be targeted death of one cell 
type over the other in the mixed culture, without impacting the health of the 
neighbouring cells. The aim of this chapter was to test if either oligodendrocytes 
or astrocytes could be killed through antibody mediated cell killing (using 
antibodies that are specific for extracellular molecules reported to be expressed 
only on one of those cell types), without killing off the other cell type.  
As mentioned in the introduction, some people with MS, NMO or NMO spectrum 
disorders harbour antibodies that recognize proteins on oligodendrocytes or 
astrocytes, which can then be targeted for cell destruction. Because complement 
complexes have been reported to co-localize with antibody in lesions of people 
with MS and NMO (Phuan et al., 2012; Ingram et al., 2014), it is likely that 
complement-mediated attack is the cause of damage to the cells and to myelin. 
In order to target the membranes of live oligodendrocytes or astrocytes 
specifically, antibodies would have to recognize antigens expressed solely on the 
extracellular portion of molecules at the cell surface of the particular cell type.   
Therefore, it was necessary to select specific targets on oligodendrocytes and on 
astrocytes that could be targeted in the experiments in this chapter. Sulfatide, a 
glycolipid expressed on oligodendrocytes but not astrocytes, was selected as a 
potential target for antibody mediated killing in vitro, as an antibody against 
sulfatide (the O4 antibody) has previously been used successfully as a control to 
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kill oligodendrocytes in myelinating cultures (Elliott et al., 2012), and the O4 
antibody is available commercially.  
For astrocytes, it is more challenging to identify a cell surface-expressed 
astrocyte-specific cell marker; the molecule usually used to identify astrocytes, 
GFAP, is an intermediate filament only expressed inside the cell. One group of 
proteins that is very highly expressed on the surface of astrocytes are the 
Excitatory Amino Acid Transporters (EAATs), which are a family of molecules 
involved in the uptake of glutamate into astrocytes for conversion to glutamine 
(Danbolt, 2001). There are at least 5 members of the EAAT family, which are 
labelled EAAT1 through to EAAT5 in humans. In rodents, however, EAAT1 is 
known as GLAST, EAAT2 is known as GLT-1, and EAAT3 is known as EAAC1.  
 
The EAATs are differentially expressed, with GLAST and GLT-1 being the EAATs 
most abundant on astrocytes in the rodent brain (Domercq et al., 1999; DeSilva 
et al., 2009). There are variable reports of GLAST expression on 
oligodendrocytes. Some early studies state that GLAST is expressed by 
oligodendrocytes (Kondo et al., 1995; Domercq et al., 1999), but others have not 
been able to replicate this (Lehre et al., 1995, Schmitt et al., 1997, Cahoy et al., 
2008, Jungblut et al., 2012, Zhou and Danbolt, 2013), or have found that GLAST 
is only transiently expressed on immature oligodendrocytes (DeSilva et al., 2009) 
or only on subgroups of oligodendrocytes in specific brain regions (van 
Landeghem et al., 2007). It has recently been speculated that oligodendrocytes 
probably do not express GLAST, but that the literature regarding GLAST 
expression has become confusing, largely due to poorly controlled 
immunocytochemistry (Zhou and Danbolt, 2013). Therefore, GLAST was chosen 
as a potential target for antibody-mediated killing of astrocytes. At the time when 
the experiments in this chapter were being done, no commercial antibodies for 
extracellular epitopes of GLAST were available (although one antibody, ACSA-1, 
has since become available; Jungblut et al., 2012). Therefore, the first step for 
the astrocyte part of this chapter was to generate an antibody against an 
extracellular epitope of EAAT1/GLAST, which could then be used as an astrocyte 
only target to for specific killing of astrocytes in the mature mixed culture. 
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3.2 Materials and Methods 
All chemicals were supplied by Sigma Aldrich (Australia) unless otherwise stated. 
 
3.2.1 Animals  
New Zealand white rabbits were supplied from ARC Australian Research Centre, 
Western Australia, and housed in appropriate conditions at HMRC. Ethical 
approval to use the rabbits was obtained from The University of Queensland, 
Animal Ethics committee.  
3.2.2 Mixed glial cell culture  
Refer to Chapter 2.2.1 for cell culture reagents used, and Chapter 2.2.3 and 2.2.4 
for the method followed to generate mature mixed glial cell culture from neonatal 
rat brains.  
3.2.3 Antibodies 
Table 3.1 lists the antibodies used in this study. Primary antibodies were either 
purchased from a commercial source or generated in the laboratory of Prof David 
Pow. Polyclonal GLAST loop antibody was prepared as described outlined in 
3.3.2.1. Polyclonal secondary antibodies used for immunohistochemistry were 
specific for mouse or rabbit immunoglobulin and labelled with FITC or Texas Red, 
as listed in Table 3.1.  
 
3.2.4 Immunolabeling of cells 
The method used for immunolabeling of mature mixed glial culture cells was as 
described in chapter 2.2.7.  
3.2.5 Enzyme linked immunosorbent Assay (ELISA) 
Nunc Maxisorp 96 well plates were coated with 500 ng/well of the peptide of 
interest (overnight at room temperature in a humidified container). Peptide coated 
plates were blocked with 0.5% skim milk in PBS containing 0.05% Tween20 
(PBST-SM) for 2 h at room temperature. Plates were then washed 3 times in 
PBS/0.05% Tween20, and the primary rabbit antibody was diluted in PBST-SM 
and added to the plates. The plates were then incubated overnight in a humidified  
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Table 3.1 Primary and secondary antibodies used in study 
Name Specificity Isotype Generated in Dilution 
used 
Source Reference  
Primary antibodies  
RIP (clone
11-5B) 
White matter isolate of 
whole CNPase 
monoclonal IgG Mouse 1:200 Sigma Aldrich 
 
(Sprinkle et al., 
1987) 
GFAP Bovine GFAP polyclonal Rabbit 1:5,000 DAKO (Eng et al., 2000) 
O4  Sulfatide from bovine 
corpus callosum 
monoclonal IgM Mouse N/A Sigma Aldrich 
 
(Sommer and 
Schachner, 1981) 
N-GLAST  
 
MTKSNGEEPRMGSRME
RFQQGVRK (αα 1-24) 
polyclonal Rabbit 1:10,000 D.Pow 
 
(Pow and Barnett, 
1999) 
C-GLAST KPYQLIAQDNEPEKPVA
DSETKM ( 521-543) 
polyclonal Rabbit 1:5,000 D. Pow  
GLAST152-
172 
KENMYREGKIVQVTAAD
AFLD ( 152-172) 
polyclonal Rabbit  generated in 
this chapter 
 
Lucifer 
Yellow 
Lucifer Yellow Polyclonal Rabbit N/A D.Pow  
Secondary antibodies 
 
FITC conjugated anti mouse IgG  polyclonal Goat 1:500 Sigma Aldrich 
 
 
Texas Red conjugated anti rabbit IgG  polyclonal Donkey 1:500 Amersham  
HRP-conjugated anti-rabbit IgG polyclonal Donkey 1:10,000 Amersham  
 IF – Immunofluorescence; αα – amino acid
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container at room temperature. Next day, plates were washed 4 times with 
PBST-SM, then HRP conjugated anti-rabbit IgG (diluted 1 in 10,000) was added 
to the wells and the plates were incubated at room temperature for 2 h. The 
plates were then washed 3 times with PBST and once with dH2O. SigmaFAST 
OPD (Sigma) was prepared according to manufacturer’s instructions and added 
to each well. Plates were incubated in the dark for 30 min before being read at 
450 nm on the Beckman Coulter Paradigm™ Plate reader.  
 
 
3.2.6 Treatment of mature mixed cell cultures with antibody and 
complement 
The O4 antibody was used at a concentration of 10 µg/mL, as previously 
described (Elliott et al., 2012). Anti-GLAST loop and anti-Lucifier yellow 
antibodies were added to the cells at dilutions ranging from 1/1,000 – 1/25. The 
cultures were incubated with antibody at 37°C for 30 min to allow antibodies to 
bind to cells. After that, a 1/20 dilution (final concentration) of guinea pig serum 
(as a source of complement) was added to some of the cultures, and they were 
incubated overnight at 37°C. Cells were then washed in 1X PBS, and fixed in 
freshly made 4% paraformaldehyde for 15 min. The cells were then immuno-
labelled with GFAP and RIP antibody for further analysis, following the protocol 
outlined in 2.2.7. 
 
3.2.7 Cell counting 
RIP and GFAP immunolabelled cells were viewed using an Olympus 
fluorescence microscope, and images of the cell populations at 20X magnification 
in 10 separate fields were captured. The total number of DAPI stained nuclei and 
the number of RIP positive oligodendrocytes and GFAP positive astrocytes were 
recorded for each field. The number of cells per field averaged 16 ± 2 for 
astrocytes and 6 ± 0.7 for oligodendrocytes. For analysis, the percentage of 
specific cells divided by the total number of DAPI positive nuclei was calculated 
and graphed to give the percentage of cells remaining after a particular 
treatment. The percentages were compared by ANOVA, with Dunnett’s multiple 
comparison test applied to take into consideration the number of comparisons 
that were being done. P<0.05 was considered to be significant. 
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3.3 Results 
The aim of this chapter was to use targeted methods of specific cell killing to 
isolate one cell type from the others in the mixed glial culture, so as to ensure 
that removal of one cell type would not result in the death of the other cells in 
culture.  
3.3.1 Oligodendrocytes can be specifically depleted from mixed cultures 
using O4 antibody and complement 
To test the effects of specific killing of oligodenodrocytes in the mixed culture, the 
O4 monoclonal antibody, which recognizes an epitope of GalC and which is 
expressed at all stages from pre-oligodendrocytes to mature oligodendrocytes, 
was added to day 24 mature mixed cultures at a concentration of 10 µg/mL, with 
complement at 1/20 dilution, and incubated overnight. Cells were then immuno-
labelled with RIP and GFAP to stain oligodendrocytes and astrocytes, respect-
ively. As shown in Figure 3.1.A, O4 plus complement treatment resulted in the 
death of 100% of oligodendrocytes, whereas complement alone had no effect 
compared to cultures not containing complement. Only cell debris positively 
labeled for RIP remained in the cultures; this RIP+ immunolabelled debris did not 
surround DAPI-labelled nuclei, indicating that the stained material was cell debris 
and not intact cells. In contrast, type 1 and type 2 astrocytes in the culture were 
unaffected by the O4 antibody treatment, either in the presence or absence of 
complement, and maintained the same phenotype as seen in the control cells. 
GFAP labeling of the astrocytes was well defined and continuous throughout the 
cells (Figure 3.1.B.).   
 
3.3.2 Effects of anti-GLAST antibodies on mature mixed cell cultures 
As noted in the introduction, the literature contains variable reports of the ability 
of anti-GLAST antibodies to label oligodendrocytes. The first step was therefore 
to use an available anti-GLAST antibody (directed against the intracellular N-
terminus of GLAST) to see whether GLAST was expressed on the oligodendro-
cytes in the mature mixed glial cultures. If that showed that GLAST was not 
present on the oligodendrocytes, then the next step would be to make an 
antibody recognizing an extracellular epitope of GLAST, to investigate whether 
killing astrocytes in the mixed cultures affected the growth of oligodendrocytes.  
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Figure 3.1. Overnight incubation with O4 antibody in the presence of 
complement (C’) specifically targets and kills oligodendrocytes in the day 
24 mature mixed cultures. A) Graph showing the effects of O4 antibody on 
percentages of oligodendrocytes and astrocytes in mature mixed cultures. Each 
symbol represents the percentage of oligodendrocytes or astrocytes out of the 
total number of cells (as indicated by the number of nuclei) in a field; 10 fields 
were counted for each treatment group. O4 + C’ treatment caused a significant 
decrease in the number of oligodendrocytes (P<0.001), but did not significantly 
affect astrocyte numbers. B) Representative images of oligodendrocytes and 
astrocytes in the presence or absence of O4 antibody. Scale bar = 50µm.  
A 
 
 
 
 
B 
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3.3.2.1  Labeling mixed glial cell cultures with N-GLAST antibody shows 
specificity for astrocytes  
In order to determine whether GLAST would be a useful target to use to 
specifically target astrocytes in culture, day 17 and day 24 mixed cultures were 
co-labelled with an antibody generated against the N-terminal portion (amino 
acids 1-24) of GLAST (N-GLAST) and the RIP antibody to label oligodendro-
cytes. N-GLAST antibody was found to label only astrocytes (both type 1 and 
type 2); there was no labeling of the RIP-positive oligodendrocytes (Figure 3.2.). 
N-GLAST staining of type 1 astrocytes showed an interesting staining pattern, 
with clearly demarcated domains adjacent to the outer edge of the membranes 
(indicated by white asterisks in Figure 3.2). From this staining, it appeared that 
GLAST would be a suitable molecule to target in order to specifically kill 
astrocytes in the culture. 
 
 
 
Figure 3.2. N-GLAST is present only on astrocytes. Immunolabelling of fixed 
and permeablized mixed cultures shows that the N-GLAST antibody strongly 
labeled astrocytes in the mixed culture, but there was no colocalization of N-
GLAST staining (red) with RIP (green), or with the mature oligodendrocyte 
membrane faintly stained by RIP in the Day 24 culture (membrane edges outlined 
with small yellow arrows). In the Day 17 culture, in particular, clearly demarcated 
domains adjacent to the cell membrane of type 1 astrocytes were strongly 
stained by the N-GLAST antibody (examples indicated by white asterisks). Scale 
bar = 50 µm  
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3.3.2.2  Anti-GLAST152-172 antibody production and validation 
At the time when these experiments were commenced, there were no 
commercially available antibodies targeted against extracellular epitopes of 
GLAST. The next step in this part of the project was therefore to select a relevant 
part of GLAST, to produce an antibody against it, and to test the specificity of the 
antibody. GLAST has 8 transmembrane-spanning domains with a large extra-
cellular loop between domains 3 and 4 (Figure 3.3.). It was decided to prepare an 
antibody against amino acids 152-172 of GLAST, which forms part of this extra-
cellular loop. The GLAST152-172 peptide was synthesized commercially (Gene-
script, Victoria, Australia). Two mg of peptide in 1mL dH2O was coupled to 
porcine thyroglobulin (10 mg in 1 mL dH2O) using 100 µL of 4% paraformalde-
hyde at room temperature for 30 min. The conjugate was stored at -20C until 
required. 
 
 
 
Figure 3.3. Topology of the GLAST/EAAT1 protein. GLAST has 8 
transmembrane spanning regions with 3 extracellular regions that could 
potentially be targets for antibody mediated cell cytotoxicity. It was decided to use 
a peptide covering amino acids 152-172 (the positions of the amino acids K152 
and D172 are shown on the figure) to prepare an antibody. Figure adapted from 
(Seal et al., 2000). 
K152 
D172 
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For the initial immunization, 500 µL of the peptide conjugate (i.e. 500 µg peptide) 
was emulsified in an equivalent volume of Freund’s complete adjuvant 
(containing an additional 5 mg/mL M. tuberculosis H37Ra). For booster 
immunizations, 500 µL of peptide conjugate was emulsified in Freund’s 
incomplete adjuvant (no mycobacterium). Prior to injection into a rabbit, the 
stability of the emulsion was tested by placing a drop of the emulsion onto a dish 
of dH2O; if the emulsion remained as a droplet and did not disperse into the 
dH2O, it was considered to be ready for use. 
  
Prior to immunization of NZW rabbits, pre-immune blood samples were collected. 
For induction of anti-GLAST152-172 antibody, the emulsion was injected 
subcutaneously into the haunch of the rabbit, just above the hind limb. The 
subsequent booster immunizations were performed at monthly intervals for 3 
months. Test bleeds were taken from the rabbit one week after each of these 
subsequent immunizations. Blood samples were collected from the rear marginal 
ear vein into a heparinized centrifuge tubes, centrifuged for 10min at 1,000 x g to 
pellet red blood cells, and the plasma were collected from the top phase, 
aliquoted and stored at -80C.  
 
The antibody titre was monitored by dot-blotting against GLAST152-172 conjugated 
to bovine serum albumin (BSA). This conjugate was prepared by mixing 1 mL of 
2 mg/mL GLAST152-172 peptide in dH2O with 1 mL of 10 mg/mL BSA and 100 µL 
of 4% paraformaldehyde. The conjugated peptide (1.5µL) or similarly conjugated 
control peptides were blotted onto nitrocellulose membrane at room temperature 
and allowed to dry (10 min). Non-specific sites on the membrane were blocked by 
soaking the membrane in PBS-BSA-saponin (0.5%) for 10 min. Plasma samples 
were diluted 1:50 – 1:50,000 in 10% BSA in PBS and added to membranes and 
incubated overnight on a rotating rocker (Stuart, UK) at 4°C. Membranes were 
washed three times in 1X PBS. HRP conjugated anti-rabbit secondary antibody 
(GE Healthcare, Castle Hill, Australia), was diluted in to 1:5,000 in PBS-saponin-
BSA solution and incubated with membrane for 2 h at room temperature on a 
rotating rocker. The membranes were washed three times with PBS. The 
chromagen 3,3’-diaminobenzidine (DAB) was prepared by combining DAB (1 mL 
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20X DAB aliquot) + H2O2 (10 µL) and PBS (20 mL). Membrane strips were 
placed in DAB solution until spots started to develop a brown colour. Strips were 
washed in PBS and dH2O and allowed to dry at room temperature.  
 
Once the antibody titre had increased so that the 1:10,000 dilution of plasma 
gave a strong signal in the dot blots, the rabbit was anaesthetised using 100 
mg/kg Lethabarb™ (Virabac, Australia). When the reflexes gradually ceased 
(tested by pinching the foot pad of the hind paw), the chest cavity was opened 
and a sterile 19G needle and syringe were used to collect blood from the heart. 
Blood was collected into heparinized tubes, centrifuged at 1,000 x g for 10 min, 
and the clear plasma was collected from the top phase, separated into 1 mL 
aliquots and stored at -80°C.  
 
The specificity of the GLAST152-172 antibody from the final bleed was then tested 
by ELISA. The N-GLAST antibody that was used for staining in Figure 3.3 had 
been previously generated in the same way (by Associate Advisor Prof David 
Pow); therefore N-GLAST antibody and the GLAST1-24 peptide against which it 
was generated were also tested as specificity controls. ELISA plates were coated 
with either GLAST1-24 or GLAST152-172 peptides, and the specificity of the peptides 
were tested in a crisscross design. Table 3.2 shows that the N-GLAST antibody 
was specific for GLAST1-24, and that the GLAST152-172 antibody was specific for 
the GLAST152-172 peptide only. Therefore, the GLAST152-172 antibody was next 
used in the same manner as the O4 antibody, in order to see if it would 
specifically kill astrocytes. 
 
Table 3.2. GLAST antibody specificity as determined by direct bound 
ELISA. The numbers represent the mean ± SE 450nm absorbance data of 
triplicate wells. 
 
Antibody 
Peptide 
GLAST1-24 GLAST152-172 
N-GLAST 1.721 ± 0.574 0.116 ± 0.039 
GLAST152-172 0.171 ± 0.057 1.163 ± 0.387 
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3.3.2.3 Anti-GLAST152-172 antibody-mediated killing in mature mixed glial 
cell cultures  
The anti-GLAST152-172 antibody was tested for its ability to kill astrocytes in 
culture. A polyclonal rabbit antibody against the fluorescent protein Lucifer Yellow 
(LY; kindly provided by Prof David Pow) was used as a negative control. Day 24 
mixed cultures were treated with antibodies against LY or GLAST152-172, at 
dilutions ranging from 1/25 to 1/100, plus complement overnight. The cultures 
were then fixed, stained with RIP and anti-GFAP antibodies to show oligodendro-
cytes and astrocytes, respectively, cell numbers were counted, and the percent-
age of each cell type remaining were calculated, as described in section 3.3.1. 
 
Cells treated with complement only (Figure 3.4.A, top left panel) were 
indistinguishable from untreated cells. Similarly, anti-LY antibodies plus comple-
ment had little effect on the cultures, even at a 1:25 dilution (Figure 3.4.A, top 
right panel), indicating that the rabbit antibodies alone were not toxic to the cells. 
The results for the treatments with anti-GLAST152-172 antibody, however, were 
somewhat unexpected.  
 
For the astrocytes, there were some fields where astrocyte cell death and 
fragmentation was occurring (particularly in Type 2 astrocytes) when the plasma 
was used at a 1:25 dilution (Figure 3.4.A. lower left panel). There was also a 
marked increase in the GFAP staining density in the remaining live type 1 
astrocytes and a condensation of the nuclei (Figure 3.4.A. lower left panel). There 
was a significant decrease in the number of live astrocytes in culture at the 1:50 
dilution (Figure 3.4.B). When tested at 1:100 dilution, the number of GFAP+ cells 
was also slightly (but not significantly) decreased compared to the controls, but 
the 1:500 dilution of anti-GLAST152-172 antibody had no effect on the cultures.  
 
Surprisingly, however, there was a dramatic loss of oligodendrocytes in the 
cultures treated with anti-GLAST152-172 antibody (particularly at the 1:25 dilution) 
plus complement, where no live oligodendrocytes remained after 24 h (Figure 
3.4.A. lower left panel, and 3.4.B).  
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Figure 3.4 Effects of rabbit polyclonal antibodies + complement (C’) treat-
ment on mature mixed cultures of astrocytes. A) Immunocytochemical 
assessment of astocytes (red) and oligodendrocytes (green) following different 
treatments, as indicated on each panel. Scale bars = 50µm. B) Graph 
summarizing the results for the effects of -LY and -GLAST152-172. 
B 
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3.3.2.4 Anti-GLAST152-172 antibody labels astrocytes & oligodendrocytes  
Given that N-GLAST antibody showed complete specificity for astrocytes, with no 
staining of oligodendrocytes (Figure 3.2.), the effects of the anti-GLAST152-172 
antibody on oligodendrocytes were quite unexpected. In order to investigate the 
reasons underlying this further, day 17 (Figure 3.5.A.) and day 24 (Figure 3.5.B) 
mixed glial cell cultures were stained with the anti-GLAST152-172 antibody, together 
with RIP antibody. Astrocytes stained with a diffusely speckled pattern (Figure 
3.5.), significantly different to the pattern of staining seen with the N-GLAST 
antibody (Figure 3.2.). RIP+ oligodendrocytes showed a much denser pattern of 
staining with the anti-GLAST152-172 antibody than did the astrocytes (Figure 3.5.). 
 
 
A 
 
 
B 
82 
 
Figure 3.5. Antibody against GLAST152-172 immunolabels both oligodendro-
cytes (co-labelled with RIP antibody) and astrocytes. A) Day 17 and B) Day 
24 mixed cultures. Arrows indicate oligodendrocytes. Scale bar = 50 µm. 
 
The staining with anti-GLAST152-172 in oligodendrocytes appeared to be largely 
restricted to the cell body and major “veins” of the membrane sheet, whereas 
astrocyte staining was diffuse throughout the cells. 
 
In addition, an antibody against the C terminus of GLAST was also obtained, and 
tested for its ability to label oligodendrocytes. As with the anti-GLAST152-172 
antibody, the C-GLAST antibody also labeled oligodendrocytes as well as 
astrocytes, although in the case of this antibody, some membrane domains within 
the membrane sheet of oligodendrocytes appeared to be stained in addition to 
the cell body and major “veins” of the membrane sheet (Figure 3.6).  
 
 
 
 
Figure 3.6. Antibody specific for the C-terminus of GLAST (C-GLAST) also 
labels both astrocytes and oligodendrocytes. Day 24 culture co-stained with 
RIP and C-GLAST, showing co-localization of C-GLAST and RIP around the cell 
body of the oligodendrocyte and in domains scattered throughout the membrane 
sheet. Staining of astrocytes showed a more diffuse pattern throughout the cells. 
Scale bar = 50 µm.  
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To confirm that the oligodendrocyte staining seen with the anti-GLAST152-172 and 
anti-C-GLAST antibodies in vitro was not just an artefact of the culture conditions, 
4µm sections of adult rat brain were co-stained with antibodies against RIP and 
GLAST152-172 (Figure 3.7) or against RIP and C-GLAST (Figure 3.8). In the brain 
section labelled with anti-GLAST152-172 antibody, there was staining of 
interfasciculating oligodendrocytes in white matter tracts (Figure 3.7). Myelinated 
fibres did not appear to be stained by this antibody.  
 
In contrast, sections stained with antibody specific for C-GLAST stained both 
myelin and oligodendrocytes (Figure 3.8). In the cerebellum (Figure 3.8A), there 
was strong staining for C-GLAST in the white matter tract, the granule cell layer, 
the Purkinje cell layer (possibly Bergman glia cell bodies), and more scattered 
staining in the molecular layer. In less densely packed white matter regions, co-
labelling of RIP and anti-C-GLAST antibodies could be clearly seen, together with 
co-labelling of some myelinated axons (Figure 3.8B). 
 
 
Figure 3.7. Staining of oligodendrocytes in rat brain tissue with anti-
GLAST152-172 antibody. Sections of adult rat brain (4 m) stained for RIP and 
GLAST152-172. Rows of RIP+ oligodendrocytes in a myelinated tract stained for 
GLAST152-172 (arrowheads). Scale bar = 50 m.  
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Figure 3.8. Anti-C-GLAST antibodies label oligodendrocytes and myelin. A) 
Low-magnification image showing staining in the cerebellum. B) Higher 
magnification image showing labelling of RIP+ oligodendrocytes with anti-C-
GLAST antibody. 
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3.4 Discussion  
 
The overall aim of this chapter was to use antibody mediated cell cytotoxicity to 
kill one cell type over the other, in order to determine whether the death of 
oligodendrocytes would adversely affect the numbers of astrocytes in the culture 
and vice-versa. O4 antibody-mediated cell cytotoxicity was 100% effective in 
removing oligodendrocytes from culture, and did not appear to cause any 
morphological changes in the astrocytes remaining in culture. Thus, it can be 
concluded that it should be possible to test sera that contain antibodies specific 
just for oligodendrocytes and not cause non-specific effects on astrocytes in the 
cultures.  
 
It has proven harder, however, to identify a molecule that is expressed only on 
the surface of astrocytes to use as a target for killing just astrocytes. From reports 
in the literature, it was expected that GLAST might prove to be a useful target, as 
it is highly expressed on astrocytes. Even though there have been a small 
number of reports that GLAST is expressed on immature (A2B5+) oligodendro-
cytes, a recent review by one of the leading groups in this field concluded that 
those reports were likely to be due to non-specific effects caused by poorly-
controlled immunohistochemistry (Zhou and Danbolt, 2013), and indeed, when 
looking at some of the images in those papers, it is difficult to ascertain whether 
or not the staining is reliable. The results described in this chapter, however, 
suggest that the precise specificity of the antibodies used to stain for GLAST 
might be causing the variability of results reported in the literature with respect to 
staining of oligodendrocytes. N-GLAST antibody did not label oligodendrocytes in 
either Day 17 or Day 24 mixed cultures (Figure 3.2). In contrast, the GLAST152-172 
antibody and an antibody against the C terminus of GLAST were both able to 
label oligodendrocyte cell bodies, both in the in vitro cultures, and in adult rat 
brain tissue (Figures 3.5 and 3.6), and the GLAST152-172 antibody killed both 
astrocytes and oligodendrocytes in culture in the presence of complement. There 
are several possible reasons for the discrepancy between anti-N-GLAST staining 
and the staining results obtained with the other antibodies in oligodendrocytes.  
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One possibility is that epitope against which the N-GLAST antibody is directed is 
accessible in astrocytes, but not in oligodendrocytes, potentially due to cell-
specific post-translational modifications. One paper has suggested that both the 
N-terminus and the C-terminus of GLAST can be modified in astrocytes that have 
been cultured in the presence of phorbol 12-myristate 13-acetate (PMA) (Susarla 
et al., 2004). In that paper, immunoreactivity to GLAST, using antibodies directed 
against GLAST3-15 (N-terminus) and GLAST524-543 (C-terminus), was lost upon 
incubation with PMA: this was not due to the epitopes being cleaved from the full-
length GLAST, but appeared to represent a specific loss of immunoreactivity, due 
to activation of protein kinase C, and (the authors speculate) to subsequent 
phosphorylation of serine or threonine residues in the N- and C-termini that mask 
the epitopes recognized by the antibodies (Susarla et al., 2004).  
 
Alternatively, there could be novel splice variants present in oligodendrocytes that 
are not present in astrocytes, as it is known that several different GLAST splice 
variants do exist (Huggett et al., 2002; Macnab and Pow, 2007a; Macnab and 
Pow, 2007b; Lee et al., 2012). This possibility is explored further in the next 
chapter of this thesis. 
 
An interesting observation in this chapter is that the anti-GLAST152-172 antibody 
appeared to kill oligodendrocytes more readily than astrocytes. Immunocyto-
chemistry experiments suggest that the density of receptors for this antibody is 
higher on oligodendrocytes than on astrocytes (Figure 3.5). A higher receptor 
density, leading to a greater amount of antibody bound, might enhance 
complement-mediated lysis of the oligodendrocytes. Alternatively, it has been 
shown that there is heterogeneity of glutamate transporters expressed in 
astrocytes in culture, and that they will either express GLAST or GLT1 as their 
glutamate transporter, but not both (Perego et al., 2000; Kondo et al., 1995). 
There is no sequence homology between GLAST152-172 and any part of GLT1. 
Therefore, it may be that the apparent variability in how the astrocytes in the 
cultures were affected by the anti-GLAST152-172 antibody could be due to the 
cultures containing a relatively high proportion of GLT1-expressing cells. 
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It was also notable in the experiments investigating the in vitro effects of anti-
GLAST152-172 antibody and complement that astrocytes exposed to the highest 
concentrations of antibody, while still viable, showed a condensed GFAP staining 
pattern, and a reduction in the size of their nuclei (Figure 3.4.A. lower left panel). 
This is of interest, as it has previously been reported that GFAP anchors GLAST 
in the plasma membrane of astrocytes, via a pathway involving the PDZ-binding 
protein Na+/H+ Exchanger Regulatory Factor  (NHERF1), and ezrin (Sullivan et 
al., 2007). It could be speculated that binding of the anti-GLAST152-172 antibody on 
the extracellular surface of the astrocytes induces a signal that results in the 
rearrangement of GFAP within the cell. In addition, it has recently been reported 
that immune activation of astrocytes is linked to altered cortical astrocyte 
morphology, as identified by GFAP staining, in an infection model (Lee et al., 
2014). Therefore, even though some of the astrocytes in the cultures treated with 
anti-GLAST152-172 antibody plus complement were not killed, the resulting 
observations suggest that the antibody did indeed have some potentially 
pathogenic effects on the astrocytes. 
 
The N-GLAST antibody used in this study, which is specific for the first 24 amino 
acids of GLAST shows an interesting labeling pattern, with clearly demarcated 
domains adjacent to the outer edge of the membranes (Figure 3.2). The role of 
these domains remains unknown, and it is currently being further analyzed by our 
collaborators, using stimulated emission depletion (STED) microscopy and 
confocal microscopy. This N-GLAST antibody is different to another available N-
GLAST antibody, which is specific for the first 16 amino acids of GLAST (Perego 
et al., 2000). Interestingly, that antibody labels only the tips of short processes in 
the astrocytes.  
 
In summary, there are 2 main conclusions from this chapter. Firstly, antibodies 
directed against a marker expressed solely by oligodendrocytes can specifically 
kill oligodendrocytes, without affecting astrocytes. Secondly, GLAST is not a 
useful marker to use to specifically kill astrocytes, as it is also expressed by 
oligodendrocytes in the cultures (and also in brain tissue). The findings with 
GLAST, which run contrary to current beliefs, were thought to be worth following 
up, and so, as reported in the next chapter, the expression of alternatively spliced 
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isoforms of GLAST in oligodendrocytes and astrocytes was investigated. 
However, a method to test whether selective killing of astrocytes in the mixed 
cultures would cause non-specific death of oligodendrocytes was still needed. 
Therefore, an alternative approach to selective astrocyte killing was tested, using 
the chemical α-amino adipic acid. The results of that part of the study are 
reported in Chapter 5 of this thesis. 
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Chapter 4. 
 
 
Further investigation of glutamate transporter 
expression in oligodendrocytes 
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4.1 Introduction 
In the previous chapter an antibody against an extracellular epitope of GLAST 
(amino acids 152-172 of the first extracellular loop; GLAST152-172) was produced, 
as a tool to investigate antibody-mediated killing of astrocytes. However both 
astrocytes and oligodendrocytes were killed upon treatment with the anti-
GLAST152-172 antibody and complement. Further investigation with this antibody 
showed that, in contrast to the commercially-available antibody specific for the N-
terminus of GLAST, which did not label oligodendrocytes, the anti-GLAST152-172 
antibody could label oligodendrocytes in in vitro cultures (Figure 3.5), and in adult 
brain tissue (Figure 3.7.A). This finding of GLAST expression on oligodendro-
cytes is of interest, as the majority of recent publications state emphatically that 
GLAST is only present on astrocytes (Zhou and Danbolt, 2013). However, 
several earlier publications have reported GLAST expression in cultured oligo-
dendrocytes (Kondo et al., 1995) and in oligodendrocytes of the rat optic nerve 
(Domercq et al., 1999) and human white matter (Pitt et al., 2003), although the 
staining of cells and tissues was not extremely convincing in these papers.  
 
One possible explanation for these results is that a novel splice variant of GLAST 
is present on oligodendrocytes; such a variant might not be recognized by the 
commercially-available anti-N terminus GLAST antibodies. The gene encoding 
EAAT1/GLAST, SLC1A3 (found on chromosome 2 in rats and chromosome 5 in 
humans), is complex, with multiple alternative splice sites that give rise to many 
alternative transcripts (Figure 4.1). Full length GLAST found on astrocytes is a 
542 amino acid protein in humans (543 amino acid protein in rats) encoded by 9 
exons (exons II to X of SLC1A3); however, the findings from Chapter 3 of a lack 
of staining of oligodendrocytes with an antibody directed against the N terminus 
(encoded by exon II), but staining with antibodies directed against GLAST152-172 
(encoded by exon IV) and the C-terminus (encoded by exon X), suggest that a 
variant with a deletion of part of the N-terminus might be present in 
oligodendrocytes. (In support of this idea, results very recently obtained in the 
laboratory of D. Pow during the final stages of editing of this thesis suggest the 
existence of an a N-terminally truncated form of GLAST in cortical astrocytes (A. 
Lee, personal communication)).  
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Figure 4.1. Structure of the SLC
1A
3 gene (hum
an gene is show
n, as m
ore alternatively sliced isoform
s have been 
identified in hum
ans than in rats). The upper portion of the figure show
s the different alternatively spliced isoform
s found 
in the hum
an gene. The low
er portion of the figure show
s an expanded version of the structure of full-length 
E
A
A
T1/G
LA
S
T (tan colour) and three alternatively sliced isoform
s that have been described in astrocytes (show
n in red), 
nam
ely G
LA
S
T 1a (deletion of exon III), G
LA
S
T1b (deletion of exon IX
), and G
LA
S
T 1c (deletion of exons V
 and V
I), and 
the conserved dom
ains for the sym
porter function of G
LA
S
T (in blue).  Figure is adapted from
 the E
nsem
bl data base: 
http://asia.ensem
bl.org/H
om
o_sapiens/G
ene/S
plice?db=core;g=E
N
S
G
00000079215;r=5:36606355-36688334 
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Within the N terminus of GLAST, there are 3 different potential start sites in the 
same open reading frame (Figure 4.2.). In the full length GLAST molecule 
expressed in astrocytes, the first start site is used. However, it is conceivable that 
an isoform with a truncated N-terminus could exist in oligodendrocytes, through a 
novel variant formed by use of these alternate start sites. 
 
 
Figure 4.2. The coding region of exon II of EAAT1/GLAST showing the 3 
potential transcription start sites (in blue) and the transcription stop site (in 
pink).  In full-length GLAST, the first start site is used. Start and end sites were 
identified from the full length DNA sequence of exon II of SLC1A3 using the NCBI 
Open Reading Frame (http://www.ncbi.nlm.nih.gov/projects/gorf/). 
 
Several GLAST splice variants, namely GLAST 1a, GLAST 1b and GLAST 1c 
(see Figure 4.1.), are also known to be expressed in astrocytes, and differentially 
expressed in other cell types. The exon(s) and amino acids deleted in these 
isoforms are shown in Figure 4.1. and Table 4.1., and their patterns of expression 
(as at the time when this study was commenced) are summarized in Table 4.1. 
One of the aims of this chapter was to investigate whether these splice variants 
are present on oligodendrocytes, in order to try to define what EAAT1/GLAST on 
oligodendrocytes might look like. In addition to EAAT1/GLAST, EAAT2/GLT-1 is 
also abundantly expressed on astrocytes in the CNS. GLT-1 has also been 
reported in a small number of studies to be present on oligodendrocytes (DeSilva 
et al., 2009; Domercq et al., 2005; Werner et al., 2001). This will also be 
assessed in the current chapter. 
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Table 4.1. GLAST/EAAT1 splice variants present in astrocytes and other 
cells. 
Splice variant Region deleted Expressed in: 
GLAST 1a Exon III  
(αα 61-106) 
Astrocytes and bone (Huggett et al., 
2000; Macnab et al., 2006) 
GLAST 1b Exon IX  
(αα 430-475) 
Astrocytes and neurons (Vallejo-
Illarramendi et al., 2005; Sullivan et al., 
2007) 
GLAST 1c Exons V an VI  
(αα 175-286) 
Astrocytes (Lee et al., 2012)* 
* Part of the work done in the current chapter (showing that oligodendrocytes 
express GLAST 1c) was used in this publication. 
 
If glutamate is being transported into oligodendrocytes, then the oligodendrocytes 
would also need to contain some of the machinery necessary to convert 
glutamate, which is toxic, to glutamine, which is not toxic. This conversion occurs 
through the action of the enzyme glutamine synthetase (GS). Therefore, the final 
part of this chapter will also assess whether GS is present in oligodendrocytes, 
as that would be another confirmatory piece of evidence for the presence of 
glutamate transporters on oligodendrocytes. 
 
4.2 Materials and Methods 
4.2.1 Buffers and solutions  
Buffers and solutions used in this chapter are as outlined in Section 2.2.2. 
4.2.2 Mature mixed glial cell culture  
Cells were grown as described in Chapter 3. 
4.2.3 mRNA expression  
Basic methods used in this chapter are as outlined in Section 2.2.8. The primer 
sequences to amplify a region common to all of the EAAT1/GLAST isoforms, 
EAAT2/GLT-1, GS, and -actin were designed using the programs Oligo 
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Analyzer 1.2 (Molecular Biology Freeware) and OligoExplorer 1.2 (Gene Link). 
Primers were synthesized by Sigma Aldrich. The sense and antisense primer 
sequences and the predicted fragment sizes are shown in Table 4.2. The 
expression intensity of PCR products was normalized against β-actin using 
Image J software, following previously published protocols (Regeer et al., 2003), 
and was plotted using Graph Pad Prism software.  
 
Table 4.2. Primer sequences used for PCR profiling of expression of 
GLAST, GLT-1 and GS in the mature mixed cultures. 
Product GenBank 
Accession 
number 
Primer sequences Size
(bp)
EAAT1/ 
GLAST 
AY954110 F 5’ ATGGAGACTCTGACCCGGATC 3’ 
R 5’ GGAGGCGGTCCCTTATTGTTAT 3’ 
640 
EAAT2/ 
GLT-1 
X67857.1 F 5’ GCTCGTCGCCACTGTCTCCA 3’ 
R 5’ CATAAGATACGCTGGGGAGTT 3’ 
1824
GS BC087131.
1 
F 5’ AGAAGTACCTGGAGGAGCTGAAGATGAAGA 3’ 
R 5’ CAGTGCGTGGATGGCTGCGGTGACA 3’ 
649 
β Actin NM_00110
1.3 
F 5’ GTTTGAGACCTTCAACACCCCAG 3’ 
R 5’ CTGCTTGCTGATCCACATCTGC 3’ 
711 
 
4.2.4 Immunofluorescence labelling of cells and tissue sections 
4.2.4.1 Antibodies 
Primary antibodies were either purchased from a commercial source or 
generated in the laboratory of Prof David Pow, or in the current study (for anti-
GLAST 1c antibody), and are listed in Table 4.3. Antibodies against the different 
GLAST isoforms were generated against novel peptides formed through the 
deletion of the residues encoded by the deleted exons. Monoclonal and 
polyclonal secondary antibodies used in the immunolabelling were specific for 
mouse (Sigma) or rabbit (Amersham) immunoglobulin.  Anti-mouse secondary 
antibody was labelled with FITC and anti-rabbit secondary antibodies were 
labelled with Texas Red.  
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Table 4.3 Antibodies used in this chapter. 
Designation and specificity Made in Isotype Dilution Source 
Primary antibodies 
anti-GLAST 1a 
VSAVIVGMAALD   
(αα 55-60 and 107-112 of full 
length GLAST) 
Rabbit polyclonal 1:5,000 D. Pow 
anti-GLAST 1b 
QIITIRDRLRT  
(αα 425-429 and 476-480 of full 
length GLAST) 
Rabbit polyclonal 1:5,000 D. Pow 
(Sullivan 
et al., 
2007) 
anti-GLAST 1c 
FLDLIRYAPLG  
(αα 170-175 and 208-212 of full 
length GLAST) 
Rabbit polyclonal 1:5,000 This thesis 
chapter 
anti-GLT-1α 
KSADCSVEEEPWKREK (αα 
558-573) 
Rabbit polyclonal 1:5,000 D. Pow 
anti-GS 
TCLLNETGDEPFQYKN  
(αα 357-373) 
Rabbit polyclonal 1:50,000 Sigma 
Aldrich 
anti- xc– cystine/glutamate 
antiporter (C/GAP) 
KGGYLQGNVSGRLPSVGDQE
PPGHE 
(αα 475-499) 
Rabbit polyclonal 1:5,000 D. Pow 
(Lee et al., 
2012) 
RIP antibody 
11-5B clone 
Mouse mono-
clonal 
IgG1 
1:200 Sigma 
Aldrich 
Secondary antibodies 
FITC-labelled anti-mouse Ig  Goat polyclonal 1:500 Sigma 
Aldrich 
Texas Red-labelled anti-rabbit 
Ig  
Donkey polyclonal 1:500 Amersham
HRP-conjugated anti-rabbit IgG Donkey polyclonal 1:10,000 Amersham
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4.3 Results 
4.3.1 Glutamate-associated transporter and enzyme mRNA expression in 
mixed culture  
Initially, the time-course of expression of RNA for GLAST, GLT-1 and GS in the 
mixed cultures was assessed. The results in Section 2.3.5 showed that, at the 
RNA level, the developing cultures contained maturing astrocytes and 
oligodendrocytes, with a small residual population of immature oligodendrocytes 
expressing NG2. Using the same RNA samples as those used in the earlier 
experiments, the changes in levels of expression of GLAST, GLT-1 and GS were 
assessed as the cultures matured (from day 3 to day 24). As shown in Figure 4.3, 
the level of RNA for GLAST was relatively higher than levels of RNA for GLT-1 
and GS at all time-points tested, but dropped gradually with time. 
 
Using the same PCR conditions, which involved 25 PCR cycles, RNA for the 
other known EAATs (EAAC/EAAT3, EAAT4 and EAAT5) was also tested; 
however, expression levels for these EAATs in the mixed culture were 
undetectable under these conditions (data not shown), indicating that they are 
either not expressed at all, or are only expressed at very low levels. 
  
4.3.2 Production of anti-GLAST 1c antibody and confirmation of the 
specificity of anti-GLAST isoform-specific antibodies 
At the time that the work in Chapter 3 was being undertaken, and it was 
becoming clear that oligodendrocytes in culture did appear to express GLAST, 
the GLAST 1c splice variant (which has a deletion of exons V and VI), was 
discovered (in the laboratory of my Associate Advisor, Prof David Pow). 
Therefore, an antibody was generated against the peptide formed by the deletion 
of exons V and VI (see Table 4.3), by immunization of rabbits with the peptide 
coupled to BSA (using the same methods as outlined in Chapter 3.3.2.2 for the 
generation of the anti-GLAST152-172 antibody), in order to determine the 
expression patterns of GLAST isoforms in the mature mixed cultures and in rat 
brain tissue. 
   
97 
 
 
 
Day 3 7 10 17 24 
GLAST          
GLT-1          
GS          
-actin          
 
Figure 4.3 Gene expression profile for GLAST, GLT-1 and GS in the mixed 
cultures over the culture period. A) RNA was extracted from cell cultures at 
nominated time points and converted to cDNA. Primers for GLAST, GLT-1 and 
GS were used in PCR against the cDNA and their level of expression against the 
house keeping gene β-actin was calculated and graphed. B) Representative gels 
from which results were determined. Assays were performed in triplicate.  
 
ELISA was used to test that the rabbit antibody generated against GLAST 1c was 
specific for the peptide against which it was developed. Two other rabbit 
antibodies, specific for GS357-373 and for a peptide of the xc– cystine/glutamate anti-
porter (C/GAP475-499) were also used to test if non-specific binding was occurring. 
ELISA plates were coated with either GLAST 1c, GS or C/GAP peptides which 
were sequence independent, and the specificity of the peptides tested in a criss-
cross design, similar to that described in Section 3.3.2.2. As shown in Table 4.4, 
each antibody was specific only for the peptide against which it was developed.  
A 
 
 
 
 
B 
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Table 4.4  ELISA data showing the specificity of the antibodies against the 
GLAST 1c, GS, and C/GAP. The numbers represent the mean ± SE absorbance 
at 450 nm of triplicate wells. 
 
Antibody 
Peptide 
GLAST 1c GS C/GAP 
GLAST 1c 1.501 ± 0.020 0.004 ± 0.001 0.025 ± 0.007 
GS 0.014 ± 0.001 0.343 ± 0.045 0.015 ± 0.002 
C/GAP 0.041 ±  0.001 0.036 ± 0.011 0.906 ± 0.014 
 
 
The next step, therefore, was to use the antibodies specific for the GLAST 
isoforms, GLT-1 and GS to investigate their ability to label cells in the mature 
mixed cultures and in adult rat brain tissue. 
4.3.3 GLAST 1a is expressed in oligodendrocyte cell bodies  
The GLAST 1a splice variant has a deletion of exon III, leading to deletion of 
amino acids 61-106 from the full-length GLAST. GLAST 1a has previously been 
reported to be expressed in astrocytes, as well as in bone (Huggett et al., 2000). 
In the mixed cultures, GLAST 1a stained both type 1 and type 2 astrocytes, but 
also co-stained RIP+ oligodendrocytes (Figures 4.4). Interestingly, the distribution 
of GLAST 1a in type 2 astrocytes and oligodendrocytes (which are thought to 
derive from the same O2A precursor cells) was similar, with staining restricted 
largely to the cell bodies.  
 
In adult rat brain, some oligodendrocytes within myelinated tracts were also 
labelled with the anti-GLAST 1a antibody (Figure 4.5); however, there was less 
oligodendrocyte staining in grey matter regions of the brain (not shown), 
suggesting that there may be regional differences in expression throughout the 
CNS.  
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Figure 4.4  RIP+ oligodendrocytes labelled with anti-GLAST 1a antibody. A) 
Day 17 culture labelled with antibodies against RIP and GLAST 1a. Type 1 
astrocytes exhibited diffuse labeling throughout the cell (). In contrast, for type 2 
astrocytes and oligodendrocytes, GLAST 1a labeling was restricted primarily to 
the cell body (arrowheads). B) In mature (day 24) mixed cultures, RIP+ 
oligodendrocytes stained with anti-GLAST 1a antibody. The labelling was 
restricted largely to the cell body and the proximal reaches of the major “veins” of 
the myelin sheet. Scale bar = 20 m  
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Figure 4.6. Myelinated tract in mature rat brain tissue showing staining of some 
oligodendrocytes (arrowheads) with anti-GLAST 1a antibody. Scale bar = 20 m  
 
Figure 4.5. Some RIP+ oligodendrocytes in mature rat brain express GLAST 
1a. Section of a myelinated tract in rat brain showing staining of some inter-
fascicular oligodendrocytes (arrowheads) with anti-GLAST 1a antibody. Scale bar 
= 20 m  
 
4.3.4 Investigation of expression of GLAST 1b in oligodendrocytes  
 
GLAST 1b has a deletion of exon IX, resulting in a deletion of amino acids 430-
475 of the full-length GLAST. Previously, the GLAST 1b splice variant has only 
been reported to be expressed in astrocytes and neurons in the brain under 
hypoxic conditions or other pathological states such as Alzheimer’s disease 
(Macnab and Pow, 2007a, Macnab and Pow, 2007b).  
 
In both the mature mixed cultures and adult rat brain tissue, no staining of 
oligodendrocytes or astrocytes was observed with the anti-GLAST 1b antibody 
(Figure 4.6). In the brain sections, there was some staining of cells that appeared 
to be neurons, based on the size of their nuclei (Figure 4.6.B). The level of 
background staining with the anti-GLAST 1b antibody in the brain tissue was 
reasonably high, which could potentially mask very low levels of specific staining. 
However, given the low levels of staining in the cultured cells, this was probably 
unlikely to be the case. 
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Figure 4.6   Antibodies specific for the GLAST 1b isoform do not label oligo-
dendrocytes or astrocytes. A) There was no staining of RIP+ oligodendrocytes 
in day 24 mature mixed cultures. B) In the brain tissue, RIP+ oligodendrocytes 
(arrowheads in B) were not labelled with anti-GLAST 1b antibodies; however, 
there was some staining of cells with relatively large nuclei (probably neurons). 
Scale bar = 20 m.  
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4.3.5 Expression of GLAST 1c in oligodendrocytes  
 
The final GLAST variant, GLAST 1c, has a deletion of exons V and VI, resulting 
in a loss of amino acids 175-286. Using the anti-GLAST 1c antibody, it was found 
that both oligodendrocytes and astrocytes in the mature mixed cultures 
expressed GLAST 1c (Figure 4.7.A). Anti-GLAST 1c antibody strongly labelled 
the oligodendrocyte cell body, and the major processes stained as well, although 
they were not stained as intensely as was the cell body. In astrocytes, the 
staining had a much more punctate appearance than in the oligodendrocytes, 
and the outline of the oligodendrocytes was not distinct.  
 
Labelling of adult rat brain with the anti-GLAST 1c antibody showed that, in 
myelinated regions, oligodendrocytes expressed GLAST 1c (Figure 4.7.B). Some 
of the myelinated fibres also stained relatively strongly for GLAST 1c, which 
might be expected, given that GLAST 1c was present not only in the 
oligodendrocyte cell body, but also throughout the membrane processes in the 
cultured cells. 
 
 
4.3.6 Immunolabelling with anti-GLT-1 antibody 
 
Previously it has been reported that immature oligodendrocytes in cell culture 
label with an antibody directed against the first 15 amino acids of GLT-1 (DeSilva 
et al., 2009), although reports of staining of mature oligodendrocytes are variable. 
Using the anti-GLT-1558-573 antibody, RIP+ oligodendrocytes from Day 17 and Day 
24 cultures were found to be strongly labelled, as were the astrocytes in the 
cultures (Figure 4.8).  
 
Unfortunately it was not possible to determine whether the anti-GLT-1558-573 
antibody also labelled oligodendrocytes in the adult rat brain, as the antibody did 
not prove to be compatible with the fixed tissue in the brain sections, and it was 
not possible to definitely say whether or not oligodendrocytes were positively 
stained in those sections (data not shown). 
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Figure 4.7   RIP+ oligodendrocytes stain with anti-GLAST 1c antibody.  A) 
There was strong cell body staining of RIP+ oligodendrocytes in day 24 mature 
mixed cultures. B) In mature rat brain tissue, RIP+ oligodendrocytes and some 
myelinated axons stained for GLAST 1c. Scale bar = 20 m. 
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Figure 4.8. Antibody specific for the GLT-1a (wildtype GLT-1) labels both 
astrocytes and oligodendrocytes in mixed culture. A) Day 17 culture co-
stained with antibodies specific for RIP and GLT-1, showing co-localization of 
GLT-1 and RIP around the cell body of the oligodendrocyte. B) Day 24 culture co-
stained with RIP and GLT-1, showing co-localization of GLT-1 and RIP around 
the cell body and major processes of the oligodendrocyte. Scale bar = 50 µm. 
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4.3.7 Glutamine synthetase (GS) expression in mixed cultures 
 
After glutamate is taken up by into cells via the EAATs, it needs to be converted 
to a less toxic molecule. This is achieved through the action of the enzyme GS, 
which converts glutamate to glutamine. The glutamine can then either be used by 
neurons to produce more glutamate, or it can be exported out of the CNS 
(glutamine can cross the blood-brain barrier, whereas glutamate cannot). As with 
GLAST expression in oligodendrocytes, there is some dispute in the literature as 
to whether or not oligodendrocytes contain GS (recently reviewed in Anlauf and 
Derouiche, 2013); the majority of authors state that astrocytes, but not 
oligodendrocytes, express GS.   
 
Using a commercially available antibody specific for GS357-373, the staining of 
oligodendrocytes and astrocytes in the mature mixed cultures was assessed. In 
both Day 17 (Figure 4.9) and Day 24 (Figure 4.10.A) cultures, anti-GS antibody 
labelled both RIP+ oligodendrocytes and astrocytes. GS was present throughout 
the astrocytes, and in the cell body and major processes of the oligodendrocytes. 
The antibody also co-labelled RIP+ oligodendrocytes (but not myelin) in adult rat 
brain tissue (Figure 4.10.B).  
 
 
Figure 4.9. Both oligodendrocytes and astrocytes in Day 17 mixed cultures 
were labelled by the anti-GS antibody. Scale bar = 50 m. 
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Figure 4.10. GS is expressed in oligodendrocytes in culture and in brain 
tissue. A) Day 24 mature mixed culture, showing strong labelling of both 
astrocytes and oligodendrocytes with GS. The major processes of the 
oligodendrocyte, but not the lacey network of finer processes, were labelled by 
anti-GS antibody. Scale bar = 50 m. B) In rat brain tissue, RIP+ 
oligodendrocytes, but not myelin, co-labelled with anti-GS antibody. 
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4.4 Discussion  
 
The objective of this chapter was to investigate further the expression of the 
different isoforms of the glutamate transporter GLAST on oligodendrocytes in 
mature mixed glial culture and in healthy brain. As mentioned in the previous 
chapter there is dispute in the literature regarding whether or not only astrocytes 
express GLAST. One possible reason for the discrepancy in results from different 
groups is that GLAST present on oligodendrocytes might not be exactly the same 
as GLAST that is present on astrocytes, and that antibodies that recognize one 
form might not necessarily recognize the other. Therefore, even though we did 
not find that antibodies specific for the N terminus of GLAST stained 
oligodendrocytes, an antibody specific for the C-terminus and an antibody 
generated against GLAST152-172 (in the first extracellular loop) both strongly 
labelled oligodendrocytes in vitro cultured cells, and in adult rat brain tissue, 
suggesting that some forms of GLAST are expressed in oligodendrocytes.   
 
The results of this current chapter strongly suggest that forms of GLAST with a 
deletion of exons III, V and VI (in addition to a truncated N terminus) exist in 
oligodendrocytes. Whether oligodendrocytes express at least 3 different isoforms 
of GLAST, or a single isoform with all of these deletions in the one protein, 
remains to be determined. It has been proposed that the various deletions in 
GLAST isoforms might affect the orientation of the protein in the membrane 
(Figure 4.11), and the function of the protein. Based on the results of staining in 
this chapter and in Chapter 3, there are a number of potential isoforms of GLAST 
expressed in oligodendrocytes, and they could sit in the membrane in a variety of 
orientations (shown in red in Figure 4.11), depending on the specific 
combinations of deleted exons that are present. While it is outside of the scope of 
the current thesis, the work in this chapter suggests many possible future 
experiments, aimed at defining the exact form(s) of GLAST in oligodendrocytes, 
their orientation in the membrane, and their potential functional effects. 
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Figure 4.11. Putative orientation of native full-length GLAST and the known 
isoforms of GLAST (all shown in blue), and the potential forms in which GLAST 
could exist in oligodendrocytes, based on the results of staining in this chapter. 
The grey bar represents the cell membrane. 
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The functionality of the GLAST splice variants is as yet unknown, and is beyond 
the scope of this study. Early transfection trials with these splice variants in the 
COS-7 cell lines are currently being undertaken in the laboratory of my Associate 
Advisor, Prof David Pow, in an attempt to determine the effects that removal of a 
significant portion of the protein (ranging from a deletion of 67 amino acids in 
GLAST 1a to 176 amino acids in the GLAST 1c splice variant) will have on the 
function of the protein. 
 
The orientation of GLAST and its variants in the astrocyte and oligodendrocyte 
cell membranes would also be critical for the potential of autoantibodies directed 
against these molecules to kill the cells. Given that the anti-GLAST152-172 antibody 
used in Chapter 3 was able to damage both oligodendrocytes and astrocytes in 
the live cultures, it is likely that both cell types express isoforms in which the 
region of the protein against which the antibody is directed are on the outside of 
the membrane, so that they can be targeted by the antibodies: this would mean 
that the inverted forms would be unlikely to be targeted in that situation, as in all 
of them GLAST152-172 would lie on the inside of the cells.  
 
It has been previously reported that levels of GLAST are typically higher in 
immature brain, but that as an animals develop, GLT-1 levels become higher 
than those of GLAST (Swanson et al., 1997). GLT-1 also has several known 
isoforms, which have been found to be differentially distributed at the regional, 
cellular and subcellular level in astrocytes in the hippocampus, lateral septum, 
cerebral cortex and striatum, in neurons, in photoreceptors of the retina, and in 
the liver (Patel and Klein, 2011; Jitoku et al., 2011; Magnotti et al., 2011; Lehre et 
al., 1995; Schmitt et al., 2002; Schreiner et al., 2014; Rauen et al., 2004). Several 
studies have reported GLT-1 expression by mature oligodendrocytes (DeSilva et 
al., 2009; Domercq et al., 2005; Werner et al., 2001), although that has been 
disputed by other investigators, who have reported that GLT-1 expression is lost 
in mature oligodendrocytes. One study found that mature oligodendrocytes in 
culture, but not in brain tissue, expressed GLT-1, and suggested that an in vivo 
signaling mechanism controlling loss of GLT-1 was absent in vitro (DeSilva et al., 
2009). In the current study, the presence of GLT-1 on mature oligodendrocytes in 
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vitro was confirmed; however, due to the lack of specific staining with the 
antibody generated in this study on paraffin-embedded sections of adult rat brain, 
the expression of GLT-1 in oligodendrocytes in brain tissue was not able to be 
ascertained. 
 
The expression of GS in oligodendrocytes has also been debated in the literature 
(Hassel et al., 2003); even in cultured oligodendrocytes, a small number of 
studies have stated that pure cultures of oligodendrocytes can express GS, but 
only after the addition of thyroid hormones or hydrocortisone to cultures 
(Fressinaud et al., 1991; Baas et al., 1998). One explanation for the strong 
expression of GS in oligodendrocytes in the mature mixed cultures described in 
this chapter, which were grown without addition of any additives such as thyroid 
hormones to the culture, was that the astrocytes in the culture were able to 
provide other growth factors that facilitated GS expression. There have also been 
reports stating that a hypoxic environment causes an increase in GS expression; 
however, the cell culture conditions (5% CO2 in air) should not result in a hypoxic 
environment.  
 
Whilst the presence of glutamate transporters on oligodendrocytes is still a matter 
of debate in the literature, it is much more wildly accepted that oligodendrocytes 
express glutamate receptors, in particular the ionotropic glutamate receptors, 
which include the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
(AMPAR), the N-methyl-D-aspartate receptor (NMDAR), and the kainate 
receptor, and can respond to glutamate. There has been a concerted effort over 
the past 20 years to examine the expression and function of these receptors on 
oligodendrocytes in culture and in the brain (Barres et al., 1990; Berger et al., 
1992; Patneau et al., 1994; Burzomato et al., 2010; De Biase and Bergles, 2011; 
Fannon et al., 2015; Gautier et al., 2015; Harlow et al., 2015; Li et al., 2013; 
Lundgaard et al., 2013; Xiao et al., 2013; Kolodziejczyk et al., 2010).  
 
There appear to be regional and subcellular differences in the expression of the 
glutamate receptors on oligodendrocytes (Figure 4.12.A), and at different stages 
of their development (Figure 4.12.B).  
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Figure 4.12. There are regional, subcellular and stage-specific differences 
in glutamate receptor expression in oligodendrocytes and their precursors. 
A) Proposed spatial segregation of NMDAR and AMPAR/kainite receptors on 
oligodendrocyte cell bodies and on compact myelin. Reproduced from Karadottir 
and Attwell, 2007. Permission for use granted under Creative Common 
Attribution License (CCBY). B) It is thought that the distribution of glutamate 
receptors changes as oligodendrocytes mature from precursors to fully mature 
myelinating cells. Reproduced from Kolodziejczyk et al., 2010. Permission for use 
granted under Creative Common Attribution License (CCBY) 
A 
 
 
 
 
B 
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The oligodendrocyte NMDARs appear to differ slightly in their composition in 
comparison to other NMDARs in the CNS, in that they lack the NR3B subunit 
(Salter and Fern, 2005; Karadottir et al., 2005). The NR3B subunit reduces 
calcium permeability (Matsuda et al., 2002), thus making oligodendrocytes 
susceptible to cell death following calcium influx. A number of research groups 
have shown that blocking AMPA and kainate receptors attenuate white matter 
injury in hypoxia (Tekkok and Goldberg, 2001) and an animal model of MS (Pitt et 
al., 2000).  
 
Irrespective of the exact role of the glutamate receptors on oligodendrocytes, 
their presence suggests that glutamate is being released in the vicinity of the 
oligodendrocytes, and that it would be in the best interest of the oligodendrocytes 
to express transporters that could mop up the excess glutamate before it does 
too much damage to the cell. Therefore, the presence of the glutamate 
transporters on oligodendrocytes, as described in this chapter and the previous 
chapter, is rational. Unfortunately, however, it makes it more difficult to find an 
astrocyte-specific membrane-expressed molecule that could be used to test 
whether astrocytes in the mixed cultures can be killed, without killing the 
oligodendrocytes (the original aim of Chapter 3 of this thesis). Therefore, in the 
next chapter, a different approach is taken to try to answer that question. 
 
 
  
113 
 
 
 
 
 
Chapter 5. 
 
 
 
Chemical-targeted killing of glial cells  
in mature mixed glial cultures  
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5.1 Introduction 
 
Chapter 3 outlined the use of antibodies targeted to extracellular portions of 
proteins plus the addition of complement for targeted killing of one cell type over 
the other. As shown in that Chapter, it was difficult to specifically kill astrocytes, 
as the molecule used as a “specific” target, GLAST, was found to also be 
expressed on oligodendrocytes. Another approach to selective killing of specific 
cell types is through the addition of chemical agents to the culture. Several 
chemicals have previously been described as selective inhibitors of astrocyte cell 
growth. Some of these (e.g. FdU) merely inhibit the fastest growing cells (Rosen 
et al., 1989; Greer et al., 1996); however, others work via specific receptors and 
channels. α-Amino adipic acid (αAAA) is one of the latter type of chemical 
inhibitors.  
 
αAAA is a glutamate homologue that differs from glutamate by a single 
methylene group (Figure 5.1) and has been used in numerous studies as a toxin 
for astrocytes in tissue culture, brain slices and whole animal studies in rodents  
(Huck et al., 1984; Brown and Kretzschmar, 1998; Karlsen, 1978; Pow, 2001). 
   
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Relationship between AAA, glutamate and cystine. Chemical 
structures of the A) L-isomer of α-AAA (wedged bond for NH2) B) D-isomer of α-
AAA (hatched bond NH2), C) Glutamate, and D) Cystine 
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αAAA is toxic to astrocytes, as it is a potent inhibitor of the xc– cystine/glutamate 
antiporter (C/GAP) (Pow, 2001). C/GAP is another glutamate exchanger found on 
astrocytes, which, unlike the EAATs, does not rely on an electrochemical gradient 
to transport glutamate across the membrane. C/GAP has reported to be present 
in a number of CNS cells other than astrocytes, including retinal Muller cells and 
microglia, and also in cells found outside the CNS (fibroblasts, hepatocytes, 
macrophages and endothelial cells) (Bannai and Kitamura, 1980; Sato et al., 
1999; Burdo et al., 2006; Kato et al., 1993). 
 
C/GAP is a member of the heteromeric amino acid transporter (HAT) family and 
is composed of two subunits, xCT and 4F2hc. The 4F2hc subunit is also found in 
other HATs (Palacin and Kanai, 2004), whereas the xCT subunit (502 amino 
acids) is only found in the transporters for cystine and glutamate and this subunit 
holds the transporter activity (Burdo et al., 2006). C/GAP mediates the exchange 
of extracellular L-cystine and intracellular L-glutamate at a ratio of 1:1 across the 
cellular plasma membrane (Figure 5.2). 
 
 
 
Figure 5.2 Diagrammatic representation of C/GAP, which facilitates exchange 
of one cystine for one glutamate across the cell membrane. Adapted from 
(Lewerenz et al., 2013). Used with permission, Mary Ann Liebert publishing.  
Cystine
   Cysteine 
  Glutathione 
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Cystine transported into the astrocyte is reduced to cysteine and incorporated 
into glutathione (GSH) or protein fractions. GSH is not only used by the astrocyte 
but is also released and degraded extracellularly through the multidrug 
resistance-associated protein (MRP-1) transporters providing an extracellular 
source of cysteine that neurons internalize for their own GSH production (Bridges 
et al., 2012). Treatment of cells with αAAA results in depletion of intracellular 
cystine. Without cystine, the de novo synthesis of GSH is reduced and there is 
prolonged inhibition of protein synthesis, contributing to apoptotic cell death 
(Nishimura et al., 2000). 
 
There are 2 stereo-isomers of α-AAA, L and D, which vary in their potency for 
C/GAP. Some reports state that only L-αAAA is toxic to astrocytes (Sugawara et 
al., 1990); however others report that both isomers are toxic to astrocytes, 
although the L-αAAA isomer potency is higher than D-αAAA (Huck et al., 1984). 
Neurons in culture have been reported to be unaffected by exposure to αAAA, 
even after 5 days of treatment (Huck et al., 1984; Garthwaite and Regan, 1980). 
There have not been any reports of any toxic effects of αAAA on 
oligodendrocytes in culture, brain slices or whole animal models, although it does 
not appear that any studies have specifically addressed that question. For the 
current study, the racemic mix DL-αAAA (an equal amount of both isomers) was 
used to attempt to selectively deplete the mixed glial culture of astrocytes.  
 
The objective of this chapter was to test chemical mediated killing of astrocytes in 
the mixed culture, as a means of determining if removal of astrocytes impacts on 
the survival of the mature oligodendrocytes in the system. As noted in previous 
chapters, the reason for wanting to know this is so that we will be able to 
determine whether serum from people with MS is able to specifically target not 
only oligodendrocytes, but also astrocytes. 
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5.2 Materials and Methods 
 
All chemicals were supplied by Sigma Aldrich (Australia) unless otherwise stated. 
5.2.1 Buffers and solutions  
Buffers and solutions used in this chapter are as outlined in Section 2.2.2. 
5.2.2 Mature mixed glial cell culture  
Cells were grown as described in Chapter 3. 
5.2.3 Antibodies 
Table 5.1 lists the antibodies used in this study.  
 
 
 
Table 5.1. Antibodies used in this chapter. 
Name and Specificity Type 
Dilutions 
used for 
IF 
Source 
Primary antibodies 
RIP (11-5B clone), specific for 
CNPase  
Mouse 
monoclonal 
IgG 
1:200 Sigma Aldrich 
(Sprinkle et al., 
1987) 
Anti-C/GAP antibody 
xCT475-499 : KGGYLQGNVSGRLP 
SVGDQEPPGHE  
 
Rabbit 
Polyclonal 
1:5,000 D.Pow 
(Lee et al., 2012) 
Secondary antibodies 
FITC conjugated anti-mouse IgG  Goat 
polyclonal 
 
1:500 Sigma Aldrich 
 
Texas Red conjugated anti-rabbit 
IgG (whole molecule) 
 
polyclonal 
Donkey 
1:500 Amersham 
IF = immunofluorescence staining 
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5.2.4 mRNA expression  
Basic methods used in this chapter are as outlined in Section 2.2.8. The primer 
sequences to amplify the gene encoding xCT subunit of C/GAP (Gene Bank 
Accession number NM_001107673) were: forward 5’CTG GGC ATG AGA AGG 
TGG TT 3’ and reverse 5’GCA GGA GAG GGC AAC AAA GAT 3’, with a 
predicted fragment size of 884 base pairs. Primers for -actin were the same as 
those described in Chapter 2. The expression intensity of the xCT PCR product 
was normalized against β-actin using Image J software, and was plotted using 
Graph Pad Prism software. 
5.2.5 DL-α- amino adipic acid (DL-αAAA) treatment 
The DL-αAAA solution was prepared prior to each treatment by dissolving 0.161 
g of DL-αAAA (Sigma) in 200 µL-300 µL of 1 M HCL. DMEM was added to 1 mL 
to give a 1 M stock solution. This stock solution was diluted to 100 mL in DMEM, 
to give a final concentration of 10 mM, and stored at 4°C until required. 
 
For use, the stock solution of DL-αAAA was further diluted in fresh tissue culture 
medium, to give a final concentration of 200 µM, 500 µM, 1 mM, 2 mM or 5 mM, 
and added to the mixed glial cell cultures, commencing at day 17 or day 24 of 
culture. Seventy two hours after the first treatment, some of the cells were fixed in 
4% PFA for 30 min, washed with 1X PBS and immunolabeled with RIP and 
GFAP antibodies to immunolabel oligodendrocytes and astrocytes, respectively. 
Fresh medium and DL-αAAA was added to the remaining cells for another 72h, at 
which point, another portion of the cells were immunolabeled. This process was 
repeated one more time, so that the DL-αAAA treatment groups were either day 
17 or day 24 cultures that had been exposed to DL-αAAA for 72 h, 144 h or 216 
h.  
5.2.6 Immunolabeling of cells 
The method used for immunolabeling of mixed glial cell cultures was as 
described in Chapter 2.2.7.  
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5.3 Results  
 
5.3.1 RNA expression of the cystine/glutamate antiporter in the mixed 
culture 
To check that the cultured astrocytes expressed C/GAP, the expression of RNAs 
encoding the xCT subunit of C/GAP and GFAP over time were initially assessed, 
using the same protocol as described in Chapters 2 and 4. xCT and GFAP 
followed the same pattern of expression until day 24, when there was a drop in 
xCT, whereas GFAP slightly increased (Figure 5.3).   
 
 
Day 3 7 10 17 24 
GFAP  
xCT  
-actin  
 
Figure 5.3 Gene expression profile for xCT and GFAP over the culture 
period. A) The expression levels of the proteins were compared to the 
housekeeping gene β-actin and graphed. B) Representative gels from which data 
were derived. Assays were performed in triplicate. 
 
A 
 
 
 
 
B 
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5.3.2 DL-αAAA treatment of mixed culture impacts the viability of both 
astrocytes and oligodendrocytes 
As mention in the introduction, αAAA has been reported to be specifically toxic to 
mature astrocytes; therefore, the effects of DL-αAAA on astrocytes in the mature 
mixed glial cell cultures at day 17 and day 24 were tested. Cultures were treated 
with freshly made DL-αAAA for 72 h, at final concentrations of 0 mM, 0.2 mM, 0.5 
mM, 1 mM, 2 mM and 5 mM. The DL-αAAA concentration range used for 
treatment (0-5 mM) was based on a previous paper (Huck et al., 1984).  
 
In initial experiments using phase contrast microscopy to assess the cells, the 
total cell number in both day 17 and day 24 cultures gradually decreased as the 
concentration of DL-αAAA increased (Figure 5.4). It had been expected that a 
decrease in the number of astrocytes would be seen, but that the number of 
phase-bright oligodendrocytes would not vary significantly from one group to 
another. However, contrary to expectations, the numbers of all of the cells 
decreased.  
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Effects of DL-AAA on mature mixed glial cell cultures. Day 17 
cultures were exposed to A) no DL-AAA, B) 1 mM DL-AAA, or C) 2 mM DL-
AAA for 72 hours. The cells not exposed to DL-AAA looked healthy, and were 
a mixture of type 1 and type 2 astrocytes and oligodendrocytes. After DL-AAA 
treatment, the cultures looked quite unhealthy, and there was a decrease in all of 
the different cell types. Scale bar 50µm. 
 
A.  No DL-AAA                  B.  1 mM DL-AAA              C.  2 mM DL-AAA 
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Next, Day 17 and Day 24 cultures were treated with DL-AAA for 72 h and then 
stained with RIP and GFAP to allow the enumeration of the different cell types. 
The numbers of the different cell types present per field are given in Table 5.2 
(treatment commencing at Day 17) and Table 5.3 (treatment commencing at Day 
24). Representative images from these cultures at the different time points are 
shown in Figure 5.5. A graphical representation of these results, showing the 
LD50 of DL-AAA for each cell type is shown in Figure 5.6. As can be seen in 
Figure 5.6, type 2 astrocytes appear to be the most sensitive to the effects of DL-
AAA, followed by oligodendrocytes, with type 1 astrocytes being the most 
resistant to the effects of DL-AAA. 
 
Table 5.2. Summary of numbers of cells per field following treatment with 
concentrations of DL-AAA ranging from 0 to 5 mM commencing at Day 17. 
 DL-AAA concentration (mM) 
 0 0.2 0.5 1 2 5 
Type 1 
astrocyte 
22.4 ± 2.1 19.1 ± 3.3 18.5 ± 1.7 16.6 ± 1.2 16.4 ± 1.4 10.2 ± 3.8
Type 2 
astrocyte 
6.1± 0.6 4.8± 0.3 2.4± 0.3 1.5± 0.4 1.4± 0.5 0.7± 0.4 
Oligo-
dendrocyte 
6.3± 2.2 5.2± 1.4 3.9± 1.3 3.3± 1.1 3.2± 0.7 1.2± 0.2 
 
 
Table 5.3. Summary of numbers of cells per field following treatment with 
concentrations of DL-AAA ranging from 0 to 5 mM commencing at Day 24. 
 DL-AAA concentration (mM) 
 0 0.2 0.5 1 2 5 
Type 1 
astrocyte 
26.7 ± 1.9 24.5 ± 2.8 20.4 ± 3.2 17.9 ± 2.0 15.5 ± 2.4 10.3 ± 0.2
Type 2 
astrocyte 
4.8± 0.8 2.6± 0.7 1.6± 0.4 1.3± 0.4 1.8± 1.4 0± 0 
Oligo-
dendrocyte 
5.2± 0.9 3.2± 0.4 2.2± 0.4 1.6± 0.2 0.5± 0.2 0± 0 
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Figure 5.5. Representative images from DL-AAA-treated cultures, as 
indicated. All images are taken using a 10x objective, scale bar 20µm. 
[DL-AAA] 
 
none 
 
 
 
0.2mM 
 
 
 
0.5mM 
 
 
 
2mM 
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Figure 5.6 Sensitivity of type 1 and 2 astrocytes and oligodendrocytes to 
DL-AAA. The graphs show the percentage of cells surviving after 72 h 
treatment with DL-AAA at the indicated concentrations, and the LD50 for each 
cell type.    
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The half-life of DL-αAAA is 72 h (Nishimura et al., 2000), therefore, other 
experiments were also undertaken, in which cells were cultured for either 144 h 
(with fresh DL-αAAA added after the first 72 h) or 216 h (with fresh DL-αAAA 
added after the first 72 h and at 144 h). However, the longer treatment period did 
not have any significant effects on the numbers of cells surviving: the rate at 
which cells died remained consistent for each cell type at specific concentrations 
of DL-AAA (data not shown). 
 
5.3.3 Oligodendrocytes express C/GAP 
 
Since oligodendrocytes were being killed at a lower dose of DL-AAA than were 
type 1 astrocytes, it seemed unlikely that the oligodendrocytes were dying 
because of a lack of trophic support from the astrocytes in the culture. One other 
possibility to account for the death of the oligodendrocytes was that, because 
C/GAP on astrocytes was being blocked by DL-AAA, there was excess 
glutamate in the medium, leading to death of the oligodendrocytes due to 
excitotoxicity. Another alternative was that oligodendrocytes might express 
C/GAP.  
 
Therefore, mature mixed glia cell cultures (Day 17 and Day 24) were co-labelled 
for C/GAP and RIP, using the anti-C/GAP antibody produced in Chapter 4, which 
is specific for amino acids 475-499 of the xCT subunit of C/GAP (Table 4.4). As 
shown in Figure 5.7, RIP+ oligodendrocytes do indeed express C/GAP. 
Interestingly, the density of C/GAP staining was higher on the oligodendrocytes 
and type 2 astrocytes (labelled with  in Figure 5.7) than on type 1 astrocytes at 
both timepoints, although this was more obvious in the Day 17 cultures, 
supporting the RNA expression data in Figure 5.3. The increased density of 
C/GAP on oligodendrocytes and type 2 astrocytes might help to explain why 
lower concentrations of DL-αAAA were more toxic to these types of cells, than to 
type 1 astrocytes. Similarly, the greater surface area of C/GAP+ oligodendrocyte 
membrane in Day 24 cultures compared to Day 17 cultures might be one reason 
for the reduced LD50 of DL-αAAA for oligodendrocytes at Day 24. 
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Figure 5.7.  Oligodendrocytes, type 1 astrocytes and type 2 astrocytes all 
express C/GAP. A) Day 17 and B) Day 24 mixed cultures, immunolabeled with 
RIP and anti-C/GAP antibody. Type 2 astrocytes are indicated with . Scale bar = 
50µm. 
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5.4 Discussion 
 
Previous studies have not reported the presence of C/GAP on oligodendrocytes, 
and those that have studied the effects of DL-αAAA on brain slice cultures have 
not noted that oligodendrocytes are killed (Huck et al., 1984, Pow, 2001). 
However, none of these studies appear to have used any markers that would 
specifically label oligodendrocytes, and have assumed that such molecules are 
only expressed by astrocytes. However, in light of the findings in Chapter 4, it 
seems likely that oligodendrocytes express the full complement of receptors and 
transporters necessary for moving glutamate in and out of the cells.  
 
Interestingly, the findings in the current chapter, with respect to the sensitivity of 
type 1 and type 2 astrocytes to DL-αAAA, are the opposite of those that have 
been reported in one other study that used cultured astrocytes (Brown and 
Kretzschmar, 1998). They reported that type 1 astrocytes were more sensitive to 
either D-αAAA or L-αAAA than were type 2 astrocytes; however, the cells stated 
to be type 2 astrocytes in their paper did not have the typical morphological 
features of type 2 astrocytes (in light microscope pictures shown in the paper). In 
our hands, the cells derived from the O2A lineage, i.e. type 2 astrocytes and 
oligodendrocytes, expressed a greater density of C/GAP, and were more 
sensitive to the effects of DL-αAAA than were type 1 astrocytes. 
 
While the results in this chapter represent a novel and interesting finding, both 
from the point of view of glutamate biology within the CNS, and because they 
show that oligodendrocytes and astrocytes express a lot more molecules in 
common than was previously appreciated, unfortunately they do not help much to 
address the principal aim of this study, which was to investigate whether 
oligodendrocytes would be able to survive if the astrocytes in the mature mixed 
culture were killed off. Therefore, it was decided to re-focus back on the original 
aim of this thesis, and next test the effects of antibodies from patient sera on the 
mature mixed cultures. 
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Chapter 6 
 
 
 
  
 
Using the mature mixed glial cell cultures to test for the 
presence and potential functional effects of antibodies against 
oligodendrocytes and astrocytes in human serum 
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 Introduction 6.1
 
The role that autoantibodies might play in MS has been debated in the literature 
for many years, and possible targets for these antibodies have been widely 
investigated. As discussed in the Chapter 1, most research groups have focused 
on myelin antigens as the most likely targets of antibodies: only a small number 
of studies have suggested antibody targets on neurons, and only one antigen that 
is known to be expressed on astrocytes, namely Kir4.1 (which is also present on 
oligodendrocytes), has been the subject of investigation. The results from the 
previous 2 chapters suggest that there might be many more antigenic targets 
than previously appreciated that are shared between astrocytes and oligodendro-
cytes. 
 
Despite the large number of published studies on antibodies in MS, most have 
just looked at whether or not antibodies are present: only a relatively small 
number of papers have attempted to investigate whether the autoantibodies 
could exert functional effects. The functional role examined has usually been the 
ability of the antibodies to cause demyelination. The earliest of these studies go 
back over 50 years, when it was reported that sera from MS patients with active 
disease caused demyelination of in vitro cultured slices of rat cerebellum 
(Bornstein and Appel, 1965). However, subsequent studies in the 1970s and 
1980s either reported that the toxicity observed in the earlier studies was an 
indicator of chronic disease, but not linked specifically to MS (Ulrich and Lardi, 
1978), or else that both control and patient sera caused demyelination in culture 
(Wolfgram and Duquette, 1976; Lumsden, 1971; Bradbury et al., 1984; Suzumura 
et al., 1986; Silberberg et al., 1984), even after heat inactivation (Ruijs et al., 
1990). Few follow up studies were done until quite recently. In all of the 
abovementioned studies, human sera were typically applied to the cultures at 
very high concentrations (25-50% human serum), which may account for some of 
the non-specific toxic effects observed. A more recent publication using 
myelinating cultures grown from embryonic day 15 rat embryos found that 
addition of 100 g of purified human IgG and complement caused significant 
(>10%) demyelination in 12/34 MS samples, 0/10 samples from patients with 
other neurological diseases and 0/13 healthy individuals (Elliott et al., 2012).  
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In the current chapter, the aim was twofold. Firstly, it was to determine whether 
antibodies in serum from MS patients could recognize epitopes not only on 
oligodendrocytes and myelin, but also on astrocytes, by investigating labelling of 
these cell types in the mature mixed cultures. Secondly, it was to determine if 
antibodies in MS sera could potentially play functional roles in MS, by 
investigating a number of parameters, including whether MS sera could opsonize 
myelin for uptake by macrophages, and whether MS sera added to mature mixed 
glial cell cultures could specifically kill either oligodendrocytes or astrocytes. 
 
 
 Materials and methods 6.2
 
 Human sera  6.2.1
Ethical approval for this study was obtained through the Human Ethics 
Committees of the Royal Brisbane and Women’s Hospital and the University of 
Queensland. Two to 5 mL of blood was obtained from healthy controls, patients 
with MS, and patients with other diseases of the CNS (CND patients), after 
informed consent had been obtained. Blood was allowed to clot at room 
temperature for 1 h, centrifuged at 600 x g for 5 min, and the clear serum was 
collected and stored at -80°C until required. Details of the individuals used in 
each part of the study are shown in Table 6.1. None of the MS patients had 
received any immunotherapy in the 3 months prior to sample collection.   
 
 Absorption of sera with liver extracts 6.2.2
In order to remove components from human sera that could potentially bind non-
specifically to cultured rat mixed glial cells, sera were pre-absorbed using freeze-
dried liver powder from normal Lewis rats. Liver powder was prepared in the 
laboratory of Prof David Pow, and 10 mg in 900 μL DMEM was incubated with 
100 μL serum overnight at 4C. Samples were centrifuged to remove the tissue 
powder prior to use. 
 
 Purification of IgG from serum 6.2.3
IgG from 10 human serum samples was purified using a Melon™ Gel IgG 
Purification Kit (Thermo scientific, USA), as per the manufacturer’s instructions.  
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Table 6.1. Demographics of patients and controls used in this study. 
Group Number 
Age 
(years) 
% Female 
MS Duration 
(years) 
Cell staining  
MS patients 
 RR-MS 
 SP-MS 
 PP-MS 
10 
4 
2 
4 
45.3 ± 2.1 
42.3 ± 4.4 
47.5 
47.3 ± 2.7 
60% 
75% 
50% 
50% 
  9.9 ± 2.8 
  3.8 ± 2.1 
14.5 
13.6 ± 5.5 
Healthy controls 4 38.0 ± 7.0 75% NA 
Opsonization assays  
MS 
 RR-MS 
 SP-MS 
 PP-MS 
55 
26 
13 
16 
44.8 ± 1.4 
37.9 ± 2.0 
50.9 ± 1.2 
51.2 ± 1.9 
76.4% 
88.5% 
84.6% 
50.0% 
11.5 ± 1.1 
  6.7 ± 1.1 
19.5 ± 1.8 
12.8 ± 2.0 
Healthy controls 16 33.8 ± 2.4 75.0% NA 
CND patients 14 46.0 ± 3.6 42.9% NA 
Killing of mature mixed glial cells  
MS 
 RR-MS 
 PP-MS 
6 
3 
3 
50.3 ± 3.7 
43.3 ± 3.3 
57.3 ± 2.9 
100% 
100% 
100% 
21.3 ± 6.6 
11.7 ± 3.7 
31.0 ± 10.5 
Healthy controls 4 38.5 ± 5.4 100% NA 
 
Data for age and MS duration are shown as the mean ± SE (data were normally 
distributed). RR-MS = relapsing–remitting MS; SP-MS = secondary progressive 
MS; PP-MS = primary progressive MS; NA = not applicable. 
 
 
The Melon Gel IgG Purification System purifies antibodies from serum by 
removing non-relevant proteins often present in high abundance. The Melon Gel 
IgG Purification Support binds non-antibody serum proteins, such as albumin and 
transferrin, using physiological pH allowing the antibody to flow through in a mild 
buffer. In brief, columns were packed with 4 mL Melon™ Gel slurry and 40 mL of 
1X Melon™ Gel purification buffer was added and allowed to flow through the 
column. The serum samples were thawed at 4C, then centrifuged for 2 min at 
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full speed in an Eppendorf bench top centrifuge to pellet debris and allow lipids in 
the serum to form a layer at the top of the serum. The cleared serum samples 
were collected, avoiding the lipid layer, and 900 μL of serum was added to each 
column. The serum was allowed to enter the gel under gravity, and then 1X 
Melon™ Gel Purification buffer was run through the column under gravity flow. 
The absorbance of the material coming through the column was measured using 
a Pharmacia Uvicord S11 spectrophotometer (Pharmacia, Sweden) and recorded 
on a Pharmacia LKB REC101 chart recorder. As soon as the absorbance started 
to increase, collection of the effluent into tubes was commenced, and the effluent 
was collected until the absorbance returned to baseline. The collected effluent 
(~20-25 mL) was filtered through a 0.22 µm syringe filter and then dialysed at 4C 
against 1L volumes of PBS, which were changed 3 times. The solution was filter- 
sterilized again and stored at 4C. The absorbance at A280 nm was measured on 
a Nanodrop™, using the IgG reference option, which calculates the IgG protein 
concentrations using the mass extinction coefficient of 13.7 at 280 nm for a 1% 
(10 mg/ml) IgG solution. Samples were diluted in buffer or tissue culture medium, 
as required, prior to use in the experiments.  
 
 Other antibodies used in this chapter 6.2.4
Antibodies used in this chapter (in addition to the human sera above) are listed in 
Table 6.2. 
 
 Mature mixed glial cell cultures 6.2.5
Mature mixed glial cell cultures were prepared as described in Chapter 2, section 
2.2.3. Assays to assess the ability of antibodies in human sera to kill 
oligodendrocytes and/or astrocytes in culture were performed as described in 
Chapter 3, section 3.2.6. 
 
 
 Opsonization assays 6.2.6
 
6.2.6.1 Preparation of DiI labelled myelin  
Human myelin was prepared using the method of Norton & Poduslo (1973). In 
brief, 4.5 g of human white matter was homogenized in 90 mL of 0.32 M sucrose 
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Table 6.2. Antibodies used in this chapter 
Name and specificity Generated 
in 
Dilution 
used 
Source 
Primary Antibodies  
anti-GFAP 
Developed against whole spinal 
cord homogenate (pan GFAP 
antibody, mainly selects for GFAPα)
Rabbit 1:5,000 DAKO 
RIP antibody 
Developed against whole isolate of 
human 2', 3’-cyclic nucleotide 3'-
phosphodiesterase (CNP)  
Mouse 1:500 Sigma 
Aldrich 
FITC-labeled F4/80 
CI:A31 clone, IgG 
Mouse 1:10 Serotec 
Secondary Antibodies  
ALK-conjugated anti-human 
polyvalent immunoglobulins 
antibody 
Mouse 1:10,000 Sigma 
Texas Red-labelled anti-rabbit 
antibody 
Goat 1:500 Amersham 
FITC-labelled anti-mouse antibody Donkey 1:500 Sigma 
 
 
in a Dounce homogenizer. The homogenate was layered over 0.85 M sucrose (at 
a ratio of 15 mL homogenate to 11.25 mL 0.85 M sucrose) and centrifuged at 
75,000 x g for 30 min. The crude myelin was collected at the interface, 
suspended in dH2O by homogenization, brought to a final volume of 157.5 mL, 
and centrifuged again at 75,000 x g for 15 min. The myelin pellet was once again 
suspended in dH2O by homogenization and brought to a final volume of 180 mL, 
then centrifuged at 12,000 x g for 10 min. The cloudy supernatant was discarded, 
and the loosely packed pellets homogenized in dH2O, brought to a final volume of 
180 mL, and centrifuged at 12,000  x g for 10 min. The pellets were suspended in 
90 mL 0.32 M sucrose, layered over 0.85 M sucrose as before, and centrifuged at 
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75,000 x g for 30 min. Purified myelin was removed from the interface, and 
washed 5 times by suspending the myelin in 65 mL of dH2O and centrifuging at 
75,000 x g for 5 min each time. Finally, the purified myelin pellet was freeze 
dried, and stored at -80C. To label with the lipophilic dye, DiI (1,1'-dioctadecyl-
3,3,3',3'-tetramethylindocarbocyanine perchlorate), 1 mg of freeze dried myelin 
was added to dH2O and sonicated for approximately 1 hour to break up clumps. 
The protein concentration of the myelin was determined using a BCA assay 
(Pierce). A stock solution of 2 mg/mL DiI in ethanol was prepared, and incubated 
for 30 min at 37°C with the myelin solution at a concentration of 12.5 μg DiI per 
mg of protein in the myelin preparation. The DiI-labelled myelin was washed 2 
times with PBS (13,000 x g for 15 min at 4C each wash) and resuspended finally 
at a concentration of 0.2 mg/mL in PBS. Five mL aliquots were stored at -20°C 
until required.   
6.2.6.2 Murine peritoneal macrophages 
Female SJL mice were bred in-house at the Herston Medical Research Centre, 
the University of Queensland, and were used at 6-8 weeks of age. Ethical 
approval to use the mice was obtained from the University of Queensland Animal 
Ethics Committee. To collect peritoneal macrophages, mice were killed by CO2 
inhalation, and 10 mL Dulbecco’s PBS was injected into the peritoneal cavity. 
The abdomen was massaged gently for 30 seconds. An incision was made 
through the skin, and a pocket formed between the skin and peritoneum. A small 
cut was made through the peritoneum at the base of the pocket, and the PBS 
containing peritoneal cells was collected from the pocket. Cells were washed 
twice in Dulbecco’s PBS prior to use. 
6.2.6.3 Uptake of opsonized DiI-labelled myelin by macrophages 
One hundred μg (0.5 ml of 0.2 mg/mL stock solution) of DiI-labelled myelin was 
centrifuged to pellet the myelin, which was then resuspended in 250 μL of serum 
from MS patients, healthy controls, or CND patients and mixed on a rotary mixer 
overnight at 4C. The next day, the myelin was washed 5 times in PBS (by 
centrifugation at 13,000 x g at 4C for 15 min), resuspended finally in 0.25 mL 
Dulbecco’s PBS containing 106 mouse peritoneal cells, and incubated for 1 h at 
37°C in a 5% CO2 in air atmosphere. After the incubation, the cells were washed 
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3 times in PBS (by centrifugation at 600 x g for 5 min) and incubated 30 min at 
4C with FITC-conjugated F4/80 antibody (Serotec, USA) to label macrophages. 
Cells were then washed 3 times with PBS-azide wash buffer (PBS + 2% FCS 
+0.01% azide) and resuspended to a final volume of 300 μL in PBS-azide wash 
for flow cytometric analysis.  
6.2.6.4 Flow cytometry 
Flow cytometry was performed using a FACScalibur flow cytometer (BD 
Biosciences, USA). The percentages of FITC+ macrophages that were also 
positive for DiI (which fluoresces in the FL2 channel) were assessed. 
 
 Enzyme linked immunosorbent assay (ELISA)  6.2.7
ELISA was used to test for the presence of antibodies in the purified human IgG 
samples (from 6.2.3.) against a variety of antigens present on oligodendrocytes 
and/or astrocytes. All samples were tested in triplicate.  
 
When peptides were used as the antigen, the method used to coat ELISA plates 
when peptides was similar to that described in Chapters 3 and 4. In brief, PLP180-
230, GLAST1-24, GLAST152-172, GLAST1c peptide (αα 170-175 and 208-212 of full 
length GLAST) and C/GAP475-499 were dissolved in bicarbonate buffer and coated 
onto Nunc Maxisorp 96 well plates (500 ng/well) by overnight incubation at room 
temperature in a humidified container. The peptide coated plates were blocked 
with 0.5% skim milk powder in PBS containing 0.05% Tween20 (PBST-SM) for 2 
hours at room temperature. Plates were then washed 3 times in PBS/0.05% 
Tween20 (PBS-T), and the human IgG (from 6.2.3.) was diluted in PBST-SM and 
added to the plates, which were then incubated overnight in a humidified 
container at room temperature. Next day, plates were washed 3 times with PBS-
T, and 100 μL/well of alkaline phosphatase conjugated anti-human polyvalent 
immunoglobulin (Sigma) in PBS-T was added and incubated 2 h at room 
temperature. After incubation, the plates were washed 4 times with PBS-T and 
once with dH2O, 100 μL/well of p-Nitrophenyl phosphate (pNPP) solution (Sigma) 
was added, and plates were incubated in the dark for 15 min. After incubation, 
the colourmetric change in the wells was read at 405 nm absorbance using a 
Beckman Coulter Paradigm™ Plate reader. The raw absorbance values for 
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control wells containing no antigen were subtracted from the absorbance values 
for wells containing antigen to give the specific absorbance values. The specific 
absorbance values were graphed and analysed using Graph Pad Prism 6.0. 
 
ELISA was also used to investigate the presence of antibodies against several 
gangliosides (GM1 and GM3 and GD1b) and sulfatide, which are present on 
oligodendrocytes and myelin. Stock solutions of bovine GM1, GM3, GD1b and 
sulfatide were prepared as 1mg/mL stocks in ethanol, and stored at -20°C. For 
use, the stock solutions were diluted to final concentrations of 500 ng/ml in 
methanol and 100 μL of the solution (or methanol only as a control) was added in 
triplicate to wells of a 96 well plate. The plates were placed at room temperature 
in the fume hood until all methanol had evaporated. Blocking, washing, 
incubation with secondary antibody and development of plates were all done as 
above for the peptides, except that Tween 20 was not included in the PBS at any 
of the steps.  
 
 
 Results  6.3
 
  Labelling of cells in mature mixed glia cell cultures using pre-6.3.1
absorbed human sera 
Sera from MS patients and controls were tested for their ability to label fixed and 
permeabilized oligodendrocytes and/or astrocytes in mature mixed glial cell 
cultures. Initially, sera was tested without any preabsorption, but a high level of 
background staining was seen with all sera using that method (data not shown). 
Therefore, sera from 10 MS patients and 4 healthy individuals were treated with 
rat liver powder prior to use, to absorb out any molecules that might bind none-
specifically to rat cells. The pre-absorbed sera were then tested at dilutions of 
1/10, 1/100 and 1/1000. At the 1/10 dilution, sera from both MS patients and 
healthy controls stained most cells; however, at the higher dilutions, the sera from 
healthy controls showed no staining above background, but 6 of the 10 sera from 
MS patients stained oligodendrocytes or astrocytes (particularly type 2 
astrocytes) (Figure 6.1). 
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 No primary antibody 1/1000 serum dilution 
HC-PG 
F 
 
MS261 
F 
RR-MS 
 
 
MS325 
F 
SP-MS 
Figure 6.1. Staining of mature mixed glial cell cultures with human serum.
The left hand panel shows cells stained without primary antibody (i.e. secondary
antibody only controls). The right hand panel shows cells stained with a 1/1000
dilution of human serum, from either healthy controls (HC) or MS patients. At
1/1000 dilution,  HC  sera  did  not  show strong labelling of oligodendrocytes or 
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 No primary antibody 1/1000 serum dilution 
HC-KR 
F 
 
MS330 
F 
RR-MS 
 
MS241 
M 
PP-MS 
(Fig 6.1 con’t) astrocytes. In contrast 6 out of 10 human sera at 1/1000 dilution 
labelled either oligodendrocytes (e.g. MS261 and MS241 sera), astrocytes (e.g. 
MS325 serum) or a mixture of cells (e.g. MS330). All pictures were taken using a 
20X objective. The gender of the serum donor is indicated by M (male) or F 
(female), and for MS patients, the type of MS is shown. 
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This finding suggested that some MS patients carried antibodies in their serum 
that had the potential to bind to antigens on oligodendrocytes and/or astrocytes. 
The next step was therefore to determine if the antibodies in patient sera showed 
any functional effects. 
 
 Complement-mediated killing of glial cells 6.3.2
In section 6.3.1. above, it was shown that antibodies from some patients had the 
ability to label oligodendrocytes and/or astrocytes in culture. However, as noted 
in the introduction, there has been some dispute in the literature as to whether 
the non-antibodies components of serum can non-specifically kill cultured brain 
cells. Elliott and colleagues (Elliott et al., 2012) circumvented this potential 
problem by purifying immunoglobulin from serum, before using it to test for the 
ability of antibodies to induce demyelination in myelinating cultures. Therefore, in 
the current study, it was decided to purify IgG from sera in order to test its ability 
to induce complement-mediated killing of oligodendrocytes and/or astrocytes in 
the mature mixed cultures.  
 
Ten additional sera were selected (6 from MS patients and 4 from healthy 
controls) on the basis of previous studies in our laboratory which showed that 
these sera had elevated levels of reactivity against a peptide of myelin proteolipid 
protein (PLP180-230). This region of PLP is expressed on the external face of the 
oligodendrocyte cell membrane (see Figure 1.12), and the rationale for using 
sera from these individuals was that these sera might be expected to be able to 
bind to oligodendrocytes and kill them selectively. In addition, sufficient amounts 
of these sera were also available for the IgG purification. 
 
The sera were coded by my supervisor, so that I was not aware of whether the 
sample came from an MS patient or control. Samples were purified using the 
Melon™ IgG system, which removes non-IgG components from the serum. The 
protein concentration in each of the samples was measured, and the purified IgG 
samples were added to day 24 mature mixed glial cell cultures at concentrations 
of 100 μg/mL and 500 μg/mL, in the absence or presence of guinea pig comple-
ment for 12 hours. The concentrations of purified IgG used equate to approxi-
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mately 1/40 and 1/200 dilutions of the original serum samples. After incubation, 
cells were fixed with 4% PFA and labelled with antibodies specific for RIP and 
GFAP. The numbers of healthy oligodendrocytes and astrocytes in each of 10 
fields per sample were counted, and the percentages of remaining oligodendro-
cytes and astrocytes compared to untreated (no complement) cultures were 
calculated. Following completion of cell counting, the samples were uncoded. 
The results are summarized in Figure 6.2 (oligodendrocytes) and Figure 6.3 
(astrocytes) and representative images from the mature mixed glial cell cultures 
following incubation with patient IgG samples are shown in Figure 6.4. 
 
For oligodendrocytes, anti-O4 antibody killed all cells, as expected. When 100 
μg/mL of IgG from human samples was used, one healthy control sample (#15) 
and 2 MS samples (#6 and #14) induced significant decreases in the numbers of 
oligodendrocytes (Figure 6.2A). In the presence of 500 μg/mL of IgG from all 
except one of the MS samples (#5), oligodendrocyte numbers were significantly 
decreased (Figure 6.2B). Two of the healthy control samples (#4 and #15), also 
killed a significant proportion of oligodendrocytes. These two healthy control 
samples were from people who worked in the laboratory and who used brain 
samples in their work: it has been previously reported that controls obtained from 
laboratory staff do not make particularly good “healthy” controls, as they often 
tend to respond to antigens that they are exposed to in the laboratory. That 
appears to be the case for these two individuals. It is of interest to observe that 
for both the MS patients and the 2 lab-based healthy controls, there appears to 
be a dosage effect, with a higher antibody concentration leading to more 
oligodendrocyte death. 
 
Only one of the MS patient samples and one of the lab-based healthy control 
samples significantly affected astrocyte cell numbers at a concentration of 100 
g/mL, but three of the MS patient samples killed astrocytes at the higher 
concentration of 500 g/ml (Figure 6.3). It is not clear why the IgG from one of the 
lab-based healthy controls (#15) killed a significant proportion of astrocytes at the 
100 g/mL concentration, but not at the 500 g/mL concentration; however, this 
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was a reproducible finding in all wells tested. Type 2 astrocytes appeared to be 
more susceptible to antibody effects than were type 1 astrocytes. 
 
 
 
Figure 6.2. Effects of human sera on oligodendrocyte numbers in the 
mature mixed cultures. The percentages of oligodendrocytes remaining in 
cultures following overnight treatment with either 100 g/mL (A) or 500 g/mL (B) 
of IgG from healthy controls or patients with RR-MS or PP-MS are shown. 
Significant differences, compared to no complement (no C’) wells, are indicated 
by asterisks: *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. The dotted line 
separates healthy controls who were lab-based (#4 and #15) from other healthy 
controls (#9 and #12). 
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Figure 6.3. Effects of human sera on astrocyte numbers in the mature 
mixed cultures. The percentages of astrocytes remaining in cultures following 
overnight treatment with either 100 g/mL (A) or 500 g/mL (B) of IgG from 
healthy controls or patients with RR-MS or PP-MS are shown. Significant 
differences, compared to no complement (no C’) wells, are indicated by asterisks: 
***P<0.001 
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Figure 6.4.  Examples of the effects of human IgG on oligodendrocytes and 
astrocytes in vitro. Cells were incubated with A) medium alone; B) medium plus 
complement; C) 500 g/mL of sample #8 IgG plus complement; and D) 500 
g/mL of sample #14 IgG plus complement, and then stained to show RIP+ oligo-
dendrocytes and GFAP+ astrocytes. All cells photographed at 40X magnification. 
A                                    B 
 
 
 
 
 
 
 
C                                    D 
 
 
 
 
          RIP 
          GFAP 
          DAPI 
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 Testing antigen-specificity of IgG samples by ELISA 6.3.3
The results in the previous section indicated that some IgG samples from patients 
could bind to and kill oligodendrocytes and/or astrocytes in the mature mixed glial 
cell cultures. In order to begin to assess the specificity of antibodies that might be 
mediating these effects, ELISA was used to screen the samples. 
 
6.3.3.1 Antibodies against glutamate transport molecules 
From work in previous chapters, components of the glutamate transport system 
had emerged as molecules that are present on both oligodendrocytes and 
astrocytes: they could therefore represent novel targets for antibody attack in 
both of these cell types. The IgG samples were therefore tested for reactivity 
against the N-terminus of GLAST (GLAST1-24), the putative first extracellular loop 
of GLAST (GLAST152-172), GLAST1c, and C/GAP. Preliminary studies were done 
to find a concentration of IgG that did not bind non-specifically to the wells: these 
showed that 50 g/well was a suitable amount of IgG to use in the ELISAs (data 
not shown). This amount is approximately equal to what would be found in a 1/40 
dilution of serum. 
 
When the IgG samples used in the killing assays in Section 6.3.3. were tested 
against the glutamate transport related molecules, half of the MS patients and 
one of the lab-based controls showed elevated levels of reactivity to some of 
these molecules (Figure 6.5). Reactivity to C/GAP and GLAST1-24 was only 
observed in the MS patients. It was not unexpected that sample #5 did not show 
any binding to the glutamate transporters, since it was not able to kill either 
oligodendrocytes or astrocytes at the concentrations tested. Of the 3 MS samples 
that were able to kill both oligodendrocytes and astrocytes (#6, #7 and #14), only 
sample #6 contained antibodies specific for the glutamate transporters, indicating 
that they could be a potential target of attack on the oligodendrocytes and 
astrocytes. However, the lack of anti-glutamate transporter antibodies in samples 
#7 and #14 suggests that there are other, as yet unidentified, targets of the 
antibodies that are able to mediate complement-dependent ADCC in the mature 
mixed glial cell cultures. 
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Figure 6.5. Some MS patients and controls have antibodies that recognize 
molecules involved in glutamate transport in their serum. Assays were done 
in triplicate, and the results are reported as the mean specific absorbance of 
triplicate well ± SE. 
 
6.3.3.2 Isotype of antibodies specific for PLP 
As noted earlier, all of the sera from which the IgG samples were purified were 
selected because those serum samples had previously been found to show 
elevated levels of reactivity to PLP180-230. It was therefore expected that most of 
the samples might have been able to target oligodendrocytes, as PLP is a major 
transmembrane protein on oligodendrocytes. Since not all purified IgG samples 
killed oligodendrocytes, some potential reasons for this were explored. The 
original anti-PLP180-230 antibody screen had been done using a secondary 
antibody with specificity for polyvalent human Ig, and so it was possible that the 
anti-PLP antibodies in the serum samples were not IgG, and therefore were not 
purified using the Melon™ IgG system. To test this, ELISA using isotype-specific 
HRP-conjugated secondary antibodies (specific for human IgG1, IgG2, IgG3, 
IgG4, IgA and IgM – all from Invitrogen) were performed on the sera from the 
patients and controls used in 6.3.3. The ELISA was identical to that used for the 
identification of antibodies to the glutamate transporters, except the isotype 
specific antibodies were conjugated to HRP, rather than ALK, and so OPD was 
used as the substrate and plates were read at an absorbance of 450 nm. 
 
As shown in Table 6.3, not all of the anti-PLP180-230 antibodies were of the IgG 
isotype, and they would therefore not have been in the purified IgG fraction used 
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in Section 6.3.3. This was confirmed by ELISA using the purified IgG fractions of 
each sample. In addition, anti-PLP180-230 antibodies in sample #13 were found to 
be of the IgG4 isotype: this isotype does not bind complement (Bindon et al., 
1988), and therefore, even though these antibodies were present in the IgG 
fraction purified using the Melon™ IgG system, they would not have been 
responsible for the complement-mediated antibody-dependent killing of 
oligodendrocytes seen with this sample (Figure 6.3.B).  
 
These results suggested that anti-PLP180-230 antibody could potentially have been 
responsible for the oligodendrocyte cytotoxicity seen in samples #4 and #15 
(from lab-based controls) and #7 and #14 (from MS patients), but were unlikely to 
be the cause of the oligodendrocyte cytotoxicity induced by samples from MS 
patients #6, #8, and #13. As concluded earlier for the anti-glutamate transporter 
antibodies, there are likely to be additional antibodies of other, as yet unknown, 
specificities in the IgG fractions that can mediate the complement-dependent 
ADCC observed. 
 
 
Table 6.3. Isotype of PLP180-230 specific antibodies in the serum samples 
used in the antibody mediated cell killing assay in this chapter. 
Group Sample # Killing of 
oligodendrocytes 
Isotype of anti PLP180-230 
specific antibodies 
HC 4 +++ IgG1 
15 +++ IgG1 
9 - IgA 
12 - IgM 
RR-MS 7 +++ IgG1 
8 + IgM 
13 ++ IgG4 
PP-MS 5 - IgG1 
6 +++ IgM 
14 +++ IgG1 
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 Opsonisation of myelin by antibodies from MS sera enhances its 6.3.4
uptake into murine peritoneal macrophages 
The results above show that some antibodies from patients and controls can 
exert functional effects on oligodendrocytes. However, the results from the earlier 
chapters also show that the distribution of particular antigens varies between the 
cell body of the oligodendrocyte and the membrane sheet in the cultured cells in 
vitro, and in the compact myelin in vivo. One of the most characteristic features of 
an MS lesion is the presence of “foamy” macrophages, i.e. macrophages laden 
with the fatty remains of myelin, and studies in both humans and in mice with 
EAE have shown that IgG is also present on the myelin engulfed by the 
macrophages, suggesting that the myelin could be being opsonized by the 
antibodies (Storch et al., 1998, Genain et al., 1999). Therefore, the potential of 
sera from MS patients (n=53), healthy controls (n=18), and CND patients (n=14) 
to bind to human myelin, thereby enhancing the uptake of the myelin by 
macrophages, was tested. Five of the MS serum samples that were used in 
Section 6.3.1. were also tested in this section. The myelin was labelled with the 
lipophilic dye, DiI, in order to be able to assess uptake of myelin into 
macrophages by flow cytometry. Cells were assessed for the expression of F4/80 
(to indicate macrophages) and the presence of DiI in the cells (Figure 6.6).  
 
Some macrophages (~10%) took up myelin that had been pre-incubated with 
sera from healthy controls and CND patients. The percentage of cells taking up 
myelin was significantly increased following pre-incubation of human myelin with 
sera from patients with MS. The type of MS (relapsing–remitting (RR-MS), 
secondary progressive (SP-MS) or primary progressive (PP-MS)) did not make a 
major difference: the only 3 MS patients whose sera did not cause an increase in 
the percentage of macrophages that could take up myelin all had very mild MS, 
with an Expanded Disability Status Scale (EDSS) score of 1 or less (on a 10 point 
scale) after a duration of disease of >10 years. There was a slight trend towards 
a correlation between the percentage of macrophages taking up myelin and the 
EDSS scores of patients, but this did not reach statistical significance (data not 
shown). Also, disease duration did not appear to have any significant effect on 
the results. These results indicated that the majority of MS patients carried 
antibodies that could bind to human myelin and opsonize it.  
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A      B 
 
 
Figure 6.6. Sera from MS patients opsonize human myelin to increase its 
uptake by murine peritoneal macrophages. DiI-labeled myelin was incubated 
with serum from healthy controls (HC), patients with other central nervous system 
disorders (CND) or MS patients with relapsing–remitting (RR), secondary 
progressive (SP) or primary progressive (PP) disease courses.  A) Percentages 
of DiI-containing F4/80+ peritoneal macrophages (red circle on flow plot) were 
assessed by flow cytometry and B) graphed. *** P < 0.001 compared to both 
healthy controls and CND patients. 
 
 
 Antibodies against glycosphingolipids in the IgG fraction samples 6.3.5
As discussed in Chapter 1 of this thesis, myelin is composed largely of lipid, with 
novel glycosphingolipids being abundantly expressed in myelin. It is therefore 
possible that antibodies against molecules such as gangliosides or sulfatide, 
either in compact myelin or in oligodendrocyte membrane sheets, could be 
present in sera of MS patients. The O4 antibody that was used as a positive 
control for killing oligodendrocytes targets sulfatide.   
 
ELISA was used to test whether antibodies from the IgG samples tested in 
section 6.3.2. were able to bind to a number of gangliosides or to sulfatide. The 
results are presented as baseline-corrected absorbances, which have been 
corrected against absorbance values for the two non-laboratory based healthy 
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controls. The majority of samples did not show higher than baseline reactivity 
against any of the antigens tested, apart from sample #7 (RR-MS patient), which 
showed significantly higher than baseline reactivity against sulfatide, GM1 and 
GM3 (circled symbols in Figure 6.7). 
 
 
 
Figure 6.7 Responses to gangliosides and sulfatide. The absorbances of IgG 
samples from lab-based controls (blue symbols), RR-MS patients (green 
symbols) and PP-MS patients (purple symbols) were baseline corrected 
compared to the mean absorbances of the 2 non-laboratory healthy controls. 
Only the responses of patient #7 (circled in red) were significantly increased 
above the baseline. 
 
 
 Discussion 6.4
 
The main aim of this chapter was to determine if the mature mixed glial cell 
culture was a useful model to investigate serum antibodies directed against 
oligodendrocytes and astrocytes in autoimmune demyelinating diseases such as 
MS. The results show that sera from patients can bind to these cells in a specific 
manner, and that IgG from some of the patients can kill oligodendrocytes and 
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astrocytes in the presence of complement. In total, of the six MS patient samples 
tested, five samples showed significant killing of oligodendrocytes and/or 
astrocytes. The only MS sample that did not show significant effects on the 
mature mixed glial cell cultures was sample #5, which was from a 62-year-old 
female who had had PP-MS for 42 years. It is possible that there is some clonal 
exhaustion of the antibody response in this patient after such a long time with 
MS: this concept is often considered in relation to T cell responses (Yi et al., 
2010) but it is likely that it could also happen with B cell responses. 
 
Early studies that found that serum from patients with any sort of chronic disease 
(and even from healthy controls) could bind to brain slices and cause 
demyelination in cerebellar slice cultures typically used serum dilutions of 1/2 or 
1/4 in their experiments (Bradbury et al., 1984, Lumsden, 1971, Ruijs et al., 1990, 
Silberberg et al., 1984, Suzumura et al., 1986, Ulrich and Lardi, 1978, Wolfgram 
and Duquette, 1976). In the work presented in this chapter, high concentrations 
of serum (1/10 dilution) did have a tendency to bind non-specifically to all cells, 
irrespective of whether the sera came from healthy individuals or MS patients, so 
it is not surprising that the earlier studies reported non-specific effects with such 
high serum concentration. However, as shown in 6.3.1, at much lower 
concentrations (e.g. 1/1000 dilution), the binding of antibodies to 
oligodendrocytes and astrocytes was specific to sera from MS patients. 
 
The non-specific results reported in the early studies did dampen enthusiasm for 
using live cells to determine the potential pathogenic effects of antibodies, and 
most studies turned to methods such as solid phase assays like ELISA or 
Western blotting to assess whether autoantibodies were present in patient sera. 
There are, however, many benefits to using whole cells as targets for 
investigating antibodies. Firstly, you don’t need to know the “right” antigenic 
target: the cells express a multitude of antigenic targets. Secondly, antibodies 
generally recognize conformational rather than linear epitopes, and so using a 
cell, where the antigens are present in their natural conformation in the cell 
membrane is advantageous. Thirdly, using a live cell model can provide 
information about the potential pathogenicity of autoantibodies, which most other 
methods cannot do. However, even though it is preferable to use cell-based 
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assays, rather than solid phase assays, to detect autoantibodies, ELISA is a 
useful quick preliminary screening tool, and therefore it was used for an initial 
appraisal of whether or not antibodies against GLAST and C/GAP might be 
present in the samples used in this study. Furthermore, analysis with whole cell-
based assays would be warranted, but it would be necessary to used cells 
transfected with the human sequences of these molecules, which were not 
available for use in this thesis. The peptides used in the ELISA assays were 
identical between rodents and humans.  
 
Since this thesis was commenced, one paper has published results looking at the 
pathogenicity of antibodies from MS patients against cultured rat myelinating 
cultures (Elliott et al., 2012). Myelinating cultures have the advantage over the 
mature mixed glial cultures used here in that the cultures contain nerve axons, 
and so the oligodendrocytes will wrap and compact their membrane sheets 
around the axons, instead of just having the myelin sheets spreading out around 
the oligodendrocytes. However, the disadvantages of the myelinating cultures 
compared to the method used in this chapter are that they are much more difficult 
to prepare, as they require oligodendrocyte and neuronal cell precursors grown 
from embryonic day 15.5 rats, together with feeder cells sourced from newborn 
rats, and a complex medium with many expensive additives required for the 
development and maintenance of the cultures. In addition, the myelinating 
cultures do not allow the observation of pathogenic effects on astrocytes.  
 
One question that arises from the current study is why the antibodies in patient 
sera did not kill 100% of cells, similar to the effects observed when the O4 
monoclonal antibody was used to induce killing of the oligodendrocytes. The 
most likely reason is that the antibodies that were inducing the damage to the 
oligodendrocytes and/or astrocytes were not at a high enough concentration in 
the total IgG preparations to induce similar effects to those induced by the 
monoclonal antibody. This is supported by the observation that the degree of cell 
damage was generally increased in the cultures treated with 500 μg/mL of IgG, 
compared to those treated with 100 μg/mL. The total IgG preparations would 
contain antibodies of multiple specificities, not just antibodies directed against 
oligodendrocytes or astrocytes. In the first experiment in this chapter, it was 
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shown that cells could be brightly immunolabelled with MS sera used at a 1/1000 
dilution; however, the amount of IgG used for the killing assays would be 
equivalent to approximately a 1/200 down to 1/40 dilution, for the 100 and 500 
μg/mL concentrations, respectively. This higher concentration of antibody 
required for cell killing probably reflects the need to have a greater density of 
labelling, so that antibody crosslinking could induce the classical complement 
cascade, and thereby lead to formation of the MAC and lysis of the cells. It may 
be that if higher concentrations of antibody had been used, more 
oligodendrocytes and astrocytes might have been killed. Another possibility is 
that all of the cells in culture were not at the correct maturational stage to express 
the antigens targeted by the antibodies. This was seen in paper using myelinating 
cultures, where patient sera induced a greater degree of demyelination as the 
cultures matured (Elliott et al., 2012). Additionally, the isotype and/or avidity of 
the antibodies in the purified IgG preparations might affect the ability of the 
antibodies to kill cultured cells, e.g. if IgG is of the IgG4 subtype, which cannot fix 
complement, it is unlikely that the cells would be killed. 
 
Recently, the gold standard for studies investigating autoantibodies in a wide 
variety of diseases has been to use cells transfected with the antigen of interest, 
so that the antigen is in the correct conformation in the cell membrane: these 
transfected cells can also be used to assess putative functional roles of 
antibodies, such as antibody-mediated cell lysis. The main disadvantage of 
transfected cells is that you have to know the antigen of interest – if the incorrect 
antigen is chosen, then the results will not be informative. This was the case with 
antibodies from patients with autoimmune encephalitis, who were thought to have 
autoantibodies against the voltage-gated potassium channel (VGKC). However, 
when cells were transfected with the VGKC itself, the autoantibodies would not 
stain the cells, and further investigation revealed that the antibodies were actually 
directed against 2 subunits that form a complex with the VGKC, rather than the 
VGKC itself.  
 
The opsonization assay used in this chapter assesses a different pathogenic 
aspect of autoantibodies. The results of that experiment showed that almost all 
MS patients had antibodies in their serum that could increase the amount of 
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myelin taken up by macrophages. It is likely that a wide variety of different 
antigen specificities are involved in this effect: preliminary studies recently 
undertaken by others in the lab show that in some patients, the opsonizing 
activity can be absorbed out by pre-incubating serum with one or more peptides 
of myelin proteins, prior to incubation with the DiI-labelled myelin. However, the 
particular peptides that can absorb out the antibody reactivity differs from one 
patient to another, and for some patients, no antigens thus far tested have been 
able to absorb out the antibody reactivity. Thus, there is still a very large body of 
work that needs to be done to understand why different antibodies arise in 
different patients, and whether they can all play a pathogenic role in MS. 
 
The results from this chapter provide the foundation for many potential future 
experiments. First amongst these would be the identification of the antigens that 
the antibodies are targeting on the oligodendrocytes and astrocytes. As indicated 
in the results section, we have a number of putative targets; however, it would be 
necessary to do studies such as pre-incubating these antigens with sera or 
purified IgG, prior to adding them to the cells, in order to show whether the 
antibody-induced affects could be blocked in an antigen-specific fashion. 
Alternatively, a pull-down method could be used to purify the antigens to which 
the antibodies bind, or separation methods such as 1D or 2D polyacrylamide gel 
electrophoresis of cell membrane preparations followed by blotting with patient 
sera could be used to select target proteins, that could then be identified by mass 
spectroscopy. Given the findings in the current chapter, another potential future 
direction would be to transfect cells with the glutamate transporter molecules 
against which some patient sera appear to show strong antibody reactivity, and 
screen much larger panels of sera. Finally, it has to be remembered that the 
potential functional roles of autoantibodies in MS and other autoimmune 
demyelinating diseases don’t necessarily stop at complement-mediated ADCC or 
opsonization: there are many other ways in which antibodies could act (recently 
reviewed in Beasley and Greer, 2015), and it may be necessary to investigate 
those before we gain a full understanding of the role of autoantibodies in 
diseases such as MS. 
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Chapter 7 
 
 
 
 
 
 
 
General Discussion 
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7.1 Principal findings of the thesis 
 
The primary aim of this thesis was to develop a simple in vitro cell culture model 
of the macroglia (oligodendrocytes and astrocytes) of the CNS that could be used 
to assess the presence and potential pathogenicity of antibodies from people with 
MS. The particular hypothesis to be tested was that antibodies from people with 
MS could recognize and target both oligodendrocytes and astrocytes. In the 
process of generating and testing this in vitro culture system, several novel 
observations relating to the expression of glutamate transporters were made, and 
the thesis diverged somewhat from its original aim in order to investigate those 
aspects more fully. The principal findings from this thesis are: 
 
1) the generation of a mixed glial culture consisting of both type 1 and type 2 
astrocytes and mature oligodendrocytes can be achieved without the 
requirement for a plethora of additional growth factors; 
2) that this in vitro culture model can be used successfully to investigate 
human antibody labelling and killing of oligodendrocytes and astrocytes; 
and 
3) that mature oligodendrocytes express many molecules involved in 
glutamate transport which were previously thought to be expressed only in 
astrocytes and neurons, and that oligodendrocytes and astrocytes 
therefore share more cell surface epitopes in common than was previously 
appreciated. These common antigens are potential targets of attack in 
demyelinating diseases such as MS. 
 
The potential significance of these findings is discussed in more detail below and 
some suggestions for how each of these findings could be developed further in 
the future are offered. 
 
7.2 Generation of mature mixed glial cell cultures can be achieved 
without the requirement for a plethora of additional growth factors. 
 
Many publications provide lists of numerous factors that inhibit the maturation of 
oligodendrocytes in vitro, including astrocytes, high serum concentrations, and 
the lack of added growth factors such as insulin, PDGF, biotin, transferrin, 3,5,3-
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triiodothyronine and FGF. However, in the mature mixed glial cell model 
described in this thesis, almost all of these negative regulatory conditions were 
present, and yet oligodendrocytes in the cultures matured and developed well. 
Similarly, the growth and survival of type 2 astrocytes in culture has been 
reported to have an absolute requirement for the growth factor HBEGF (Foo et 
al., 2011), and most reports in the literature state that type 2 astrocytes are 
almost never seen in cultures with type 1 astrocytes. The successful 
establishment of the mature mixed glial culture, which contains type 1 and type 2 
astrocytes and oligodendrocytes, shows that these cells are capable of producing 
the necessary trophic factors to support their growth and maturation.  
 
Astrocytes produce and release multiple growth factors and cytokines, which are 
used by oligodendrocyte precursors in proliferation (eg PDGF, FGF, IGF and 
CNTF) and maturation (eg neuregulin and neurotrophin 3). PDGF can work 
alone, or cooperatively with FGF, to encourage maturation of O2A cells from 
neuroepithelial stem cells, and proliferation of O2A cells in culture (Bogler et al., 
1990; Hu et al., 2008). Astrocytes are also largely responsible for thyroid 
hormone metabolism in the brain: they are the principal transporters of thyroxine 
from the blood and are responsible for converting it to 3,5,3-triiodothyronine, the 
biologically active form of the hormone, which is required for oligodendrocyte 
maturation (Richardson et al., 1988; Morte and Bernal, 2014). It is known, for 
example, that supplementation of thyroid hormone to mice with cuprizone-
induced demyelination improves the remyelination of the lesions (Zhang et al., 
2015). The use of newborn calf serum in our culture system, rather than foetal 
calf serum, would provide more thyroid hormone for the astrocytes to metabolise 
for the oligodendrocytes to use, as levels of thyroxine are substantially higher in 
newborn calf serum than in foetal calf serum (Trentin, 2006; Price and Gregory, 
1982).  
 
Most protocols for growing pure astrocyte cultures result in cultures that contain 
very few type 2 astrocytes. One recent paper identified HBEGF and wnt7a as 
crucial in the development of type 2 astrocytes (Foo et al., 2011). As discussed 
earlier in Chapter 2, these are both expressed by oligodendrocytes, and 
therefore, in our mixed culture model, the likely reason for the abundance of type 
156 
 
2 astrocytes is the presence of the oligodendrocytes in the culture. HBEGF 
interacts with both the EGF receptor and the neuregulin receptor, ErbB4, which is 
expressed on astrocytes and some neuronal populations in the brain (Kornblum 
et al., 1999). It has been reported that ErbB4 activation on oligodendrocyte halts 
their maturation (Sussman et al., 2005), so HBEGF produced by mature 
oligodendrocytes in our culture system could halt the development of O2A cells in 
the system along the oligodendrocyte development pathway, and encourage 
maturation of type 2 astrocytes instead. It is also possible that as yet unidentified 
factors produced by type 1 astrocytes also encourage the development of type 2 
astrocytes: one protocol reported that conditioned media from type 1 astrocytes 
was able to induce the development of type 2 astrocytes (Juurlink and Hertz, 
1991), however others have been unable to successfully replicate that protocol. 
One report also suggested that growing astrocytes together with microglia was 
another way to induce type 2 astrocytes (Brown, 1998), but again, this has not 
proven to be reproducible.  
 
In Figure 7.1, some additional growth factors that are likely to be being produced 
and potential interactions that are likely to be occurring between oligodendrocytes 
and astrocytes in the mature mixed glial cell cultures are added to the 
oligodendrocyte/astrocyte developmental pathway that was previously shown in 
Figure 1.14 in Chapter 1. 
 
It would be of interest in the future to investigate further the factors involved in 
autocrine/paracrine signalling in the mature mixed cultures. That could be done at 
the RNA level, using RNA extracted from individual cell types sorted from the 
mixed cultures at different time points in next generation sequencing (e.g. RNA-
Seq and/or Chip-Seq) experiments to identify differentially regulated molecules. 
Alternatively, sampling of cells and tissue culture media at defined time points, 
with the use of intracellular staining flow cytometry protocols (for cells) and 
identification of growth factors in the medium (e.g. by ELISA or mass-
spectroscopy) could be used to identify molecules produced at different time- 
points. Once some candidate growth factors were identified, confirmation of the 
specific cell types that they act on could be done through flow cytometric 
methods to investigate the expression of receptors for those molecules. 
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Figure 7.1. Proposed interactions between oligodendrocytes and astrocytes 
in the mixed glial cell cultures. Type 1 astrocytes convert thyroxine (supplied 
by new born calf serum in the media) to T3 for use by oligodendrocytes, which in 
turn produce HBEGF and Wnt 7a that impact on type 2 astrocyte growth and  
inhibit further differentiation of O2A cells. Factors in green promote progression, 
red inhibit progression, and purple induce proliferation and maintain cells. 
Abbreviations used in this figure: HBEGF, Heparin Binding Epidermal Growth 
Factor, T3, 3,5,3_-triiodothyronine, CNTF, cilliary neurotrophic factor; EGF, 
epidermal growth factor; FGF2, Fibroblast Growth Factor 2, PDGF, platelet-
derive growth factor. Derived from Holland, 2001. Used with permission: 
reference 3741730508487 
 
 
7.3 The mature mixed glial cell culture model can be used to study 
effects of MS patients’ sera on oligodendrocytes & astrocytes 
 
One of the benefits of a mature mixed glial cell culture method is that it allows the 
comparison, in the same tissue culture wells, of the effects of a human antibody 
on both oligodendrocytes and astrocytes. As discussed in the literature review, 
most studies in MS have focussed almost solely on antibody targets on 
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oligodendrocytes, with only a very small number of studies investigating neuronal 
targets (Acarin et al., 1996; Sadatipour et al., 1998; Silber et al., 2002; Reindl et 
al. , 2003; Mathey et al., 2007; Huizinga et al., 2008; Kawamura et al., 2013; 
Puentes et al., 2013), and even fewer have investigated targets on astrocytes 
(Lily et al., 2004; Srivastava et al., 2012). However, the recent findings relating to 
how antibodies against AQP4 can cause the demyelination characteristic of NMO 
suggest that antibodies targeting astrocytes could also potentially cause 
demyelination in other demyelinating diseases such as MS.  
 
In this thesis, it was shown that MS sera can specifically label both 
oligodendrocytes and astrocytes (especially type 2 astrocytes) in the mature 
mixed cultures, when used at an appropriate concentration. Furthermore, IgG 
purified from some of the sera could induce lysis of oligodendrocytes and 
astrocytes in the cultures. While these results will need to be replicated in 
additional studies, the findings within the cultures have been consistent, and, 
since the cultures were analysed in a blinded fashion, the results appear to be 
relatively robust. As discussed in Chapter 6, early studies that used very high 
concentrations of human serum on rat cerebellar slices concluded that almost 
any effects of human serum were a reflection of non-immunoglobulin cytotoxic 
components of serum, and did not reflect any antibody-mediated effects 
(Lumsden, 1971; Wolfgram and Duquette, 1976; Ulrich and Lardi, 1978; Bradbury 
et al., 1984; Suzumura et al., 1986; Silberberg et al., 1984; Ruijs et al., 1990). 
However, while we also found that high concentrations of serum could bind non-
specifically to the cells in the mature mixed cultures, at lower concentrations, 
there was a specific labelling of cells by sera from MS patients, but not controls. 
The concentrations of purified IgG samples used in the current study to 
investigate killing of oligodendrocytes and/or astrocytes were equivalent to 
approximately 1/40 and 1/200 dilutions of whole serum, i.e. 10 to 100 times more 
dilute than the concentrations of sera used in the early studies. This was still a 
higher concentration than was needed to immunolabel the cells in culture; 
however, because there is an amplification step in the immunolabeling (via the 
use of a labelled secondary antibody), it may not be necessary to have high 
occupancy of antigenic binding sites in order to detect a signal with the 
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immunolabeling, whereas, for killing, antibodies need to bind in close proximity to 
each other, in order to be able to induce activation of the complement cascade.  
 
It has been reported that rat oligodendrocytes express very low levels of CD59, 
an inhibitor of complement pathway activation (Piddlesden and Morgan, 1993): 
therefore, it could be argued that the ability of antibodies from patients to induce 
antibody-mediated killing of rat oligodendrocytes might be greater than their 
ability to induce such killing in humans. On the other hand, it has been reported 
that activation of kainite receptors by culturing oligodendrocytes with as little as 
10 μM glutamate sensitizes the oligodendrocytes to complement attack and lysis 
(Alberdi et al., 2006). Glutamate levels are increased in CNS lesions during MS 
(Pitt et al., 2003; Pampliega et al., 2011) and other CNS inflammatory situations 
(Erhardt et al., 2013; Degos et al., 2013). Therefore, it might be expected that 
oligodendrocytes in or near inflammatory loci could become more sensitized to 
antibody mediated attack than oligodendrocytes in other parts of the brain. 
 
It has been demonstrated in this thesis that mature oligodendrocytes and 
astrocytes do share proteins involved in the transport of glutamate (i.e. GLAST, 
C/GAP and glutamine synthetase (GS)), and that some patients have elevated 
levels of antibodies specific for these molecules in their serum, thus raising the 
possibility that antibodies targeting these molecules could have detrimental 
effects on both astrocytes and oligodendrocytes. For example, autoantibodies 
targeting C/GAP could therefore potentially block cystine entry into the cells, 
thereby stopping protein production and repair in response to the inflammatory 
attack and exacerbating the inflammatory response. As discussed in the 
introduction, another molecule present on both oligodendrocytes and astrocytes 
is Kir4.1. One point that has been noted with regards to Kir4.1, which could 
potentially be relevant to the glutamate transporter molecules, is that the 
configuration of Kir4.1 is slightly different in astrocytes and oligodendrocytes: in 
oligodendrocytes it occurs as a homotetramer, but in astrocytes it can occur in a 
heterotetramer with Kir5.1. (Schirmer et al., 2014). Therefore, antibodies 
recognizing a homotetrameric Kir4.1 structure on oligodendrocytes may not 
necessarily recognize the combination of Kir4.1 and Kir5.1 as the heterotetramer 
on astrocytes. Similarly, functional glutamate transporter proteins occur in a 
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trimeric configuration (Yernool et al., 2004, Slotboom et al., 1999, Jiang and 
Amara, 2011, Haugeto et al., 1996). The crystal structure of the eukaryotic 
glutamate transporter homologue GltPh from Pyrococcus horikoshii has been 
solved: it demonstrates the trimer formation, which forms a bowl-like dip in the 
middle of the structure that extends into the membrane bilayer. At the bottom of 
this there are helical hairpins (conserved amongst transporter homologues) 
holding 3 binding sites for Na+, which move upon ion binding to facilitate the 
transport of glutamate (Figure 7.2).   
 
 
 
Figure 7.2 Pictorial representation of the glutamate transporter in trimer 
formation. Crystal structure of the eukaryotic glutamate transporter homologue 
from Pyrococcus horikoshii, GltPh, as a trimer a) viewed from above, on the 
extracellular side of the membrane or b) viewed from the side, as the trimer 
would sit in the membrane. The middle of the trimer forms a ‘bowl’ in the middle 
extending through the bilayer. Yernool et al., 2004. Used with permission, 
reference 3763360612640 
 
Transfection experiments have demonstrated the splice variants GLAST 1b and 
GLT-1b can combine with their full length equivalents as trimers in HEK293 cells 
(Vallejo-Illarramendi et al., 2005; Gebhardt et al., 2010), i.e. multiple splice 
variants can group together to form one trimer. This could impact on the ability of 
autoantibodies to recognize the glutamate transporters, leading to protection of 
the hetero-trimer from pathogenic antibody binding and antibody-induced patho-
genic effects (Figure 7.3). However, even such a “protective” role could cause 
problems with glutamate transport, as it could result in an over-abundance of 
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splice variant trimers, which could impede transport of glutamate into the cell, 
thus contributing to further excitotoxicity. Therefore, depending on the exact 
specificity of antibodies (i.e. if they recognize a single subunit or an epitope 
formed across subunits), they could have direct or indirect pathogenic effects. 
 
Figure 7.3. Pictorial representation of antibody binding sites spanning two 
units of the trimer. The functional glutamate transporter forms a trimer, where 
an antibody recognition binding site could potentially span two units. The 
incorporation of a splice variant as one of the units could change the antibody 
recognition site and decrease the antibody affinity for the epitope.  
 
 
Several approaches could be taken to identify the specific targets of the 
autoantibodies on oligodendrocytes and astrocytes. In this thesis, this was not 
attempted, apart from several ELISA studies to show that at least some of the 
antibodies in the patient sera targeted PLP, molecules involved in glutamate 
transport, and/or gangliosides. However, in order to prove definitely that these 
molecules are targeted by pathogenic antibodies, it would be necessary to 
compete out the antibody by pre-absorption of antibodies with the putative 
autoantigen. It is likely, however, that some autoantibodies in MS patients target 
molecules that no one has yet considered as antigens. In the absence of knowing 
what the autoantigen might be, one approach could be to try to immunoaffinity 
purify the antigen, using patient antibodies to capture the antigen, which could 
then be eluted from the antibodies and sequenced. The only problem with that 
approach would be if patient sera contained antibodies of many specificities: - 
that could greatly complicate such an immunoaffinity approach. 
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The specific way in which antibodies exert their functional effects will depend on 
the fine specificity and the isotype of the antibodies. For example, in Chapter 6, 
one of the serum samples that was selected for testing in the killing assays on 
the basis of high levels of antibodies to PLP180-230 turned out to be of the IgG4 
isotype, which does not bind complement. Therefore, even though an antibody 
might be directed against an epitope that has the correct specificity, it will not be 
able to induce complement-mediated lysis if it is not of an isotype that can bind 
complement. However, such antibodies might be able to act in other ways, for 
example by opsonization of target proteins for attack by macrophages, cross-
linking of Fc receptors, blocking or destroying receptors involved in cellular 
homeostasis, and blocking of repair mechanisms such as remyelination (recently 
reviewed in Beasley and Greer, 2015).   
 
 
7.4 Oligodendrocytes express many molecules involved in 
glutamate transport 
 
A serendipitous finding in this thesis, which ended up being a major part of the 
investigations undertaken, was that oligodendrocytes express the glutamate 
transporter GLAST (although it appears to be a slightly different isoform to that 
which is expressed in astrocytes, in that it is not recognized by antibodies 
targeting the N-terminus of astrocytic GLAST) and other molecules involved in 
glutamate transport and metabolism. This finding raises many questions 
concerning the role that these glutamate transporters (and by extension, 
glutamate itself) play in oligodendrocytes, and whether they are potential targets 
of autoimmune attack in diseases such as MS.  
 
7.4.1 What role does glutamate play in oligodendrocytes and why would 
GLAST be required on oligodendrocytes?  
Glutamate is primarily investigated in its role as a neurotransmitter, and therefore 
the focus of most studies on glutamate are the presynaptic neurons that produce 
glutamate, the postsynaptic neurons expressing glutamate receptors that are 
activated by glutamate, and the astrocytes, whose end feet surround the synapse 
to mop up excess glutamate and convert it back to glutamine, thereby preventing 
accumulation of glutamate, which is toxic to many cell types (Figure 7.4).  
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Figure 7.4. Glutamate recycling in the CNS. Glutamine (Gln) is taken up by 
neurons and converted to glutamate (Glu) before being packaged into synaptic 
vesicles. Excess glutamate at the synapse is taken up into glial cells via EAATs, 
where it is converted to glutamine before it is released into the extracellular 
space. The blood–brain barrier has a very low permeability to glutamate, but is 
permeable to glutamine. The concentration of glutamate in the cerebrospinal fluid 
is about 1 M, but can increase to 20 M under pathological conditions that are 
characterized by defects in the blood–brain barrier and/or by cellular damage, 
such as stroke, trauma, meningitis, and MS. Adapted from Nedergaard et al., 
2002. Used with permission: Reference # 3764001321551. 
 
 
Since oligodendrocytes are not typically present at the synapse, they have been 
largely ignored in most studies of glutamate transporters. However, it has been 
known for over 20 years that at least 2 glutamate receptors, NMDA and AMPA, 
are expressed on pre-oligodendrocytes (Kastritsis and McCarthy, 1993, Gallo et 
al., 1994), where they are thought to play a role in the generation of new 
oligodendrocytes via signalling through the PKC pathway and the activation of 
the PI3/mTOR pathway (Gallo et al., 1996; Cavaliere et al., 2013; Yuan et al., 
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1998). More recently, signalling through the glutamate receptors has been 
proposed to play a role in migration of oligodendrocyte precursors to sites of 
injury (it has been shown, for example, that the AMPA receptor forms a protein 
complex with PLP and αv integrin, increasing the rate of cell movement and the 
frequency of Ca2+ influx to aid migration (Gudz et al., 2006)), and in the 
remyelination process itself (in combination with neuregulin) (Lundgaard et al., 
2013). NMDA receptors are also expressed in mature oligodendrocytes, and the 
myelinating processes of oligodendrocytes (Karadottir et al., 2005).  
 
Since oligodendrocytes have receptors that can respond to glutamate, it therefore 
seems logical that glutamate would be being released in the vicinity of the 
oligodendrocytes, and they would also need a way of taking up excess glutamate 
from their surroundings and converting it to the non-toxic glutamine. GLT-1 
(EAAT2) and EAAC1 (EAAT3) have been reported to be present on pre-
oligodendrocytes, and a small number of studies have also stated that GLAST is 
also present on pre-oligodendrocytes, but some of the main GLAST research 
groups worldwide have claimed that those results are just artefacts caused by 
poor antibody specificity (Zhou and Danbolt, 2013).  
 
One issue that should be investigated in the future is the functionality of the 
glutamate transporters expressed on the oligodendrocytes. One recent study 
(Martinez-Lozada et al., 2014) has reported that GLAST is present (together with 
GLT-1) on pre-oligodendrocytes, but that its role there is not to remove glutamate 
from the extracellular environment; instead, transport of glutamate via these 
transporters results in a transient increase in intracellular Ca2+ levels and a 
transient phosphorylation of a site within the actin binding/stabilizing domain of 
the calcium sensor calcium/ calmodulin-dependent kinase II (CaMKII), allowing 
detachment of CaMKII from actin, and a subsequent remodelling of the actin 
cytoskeleton of the oligodendrocyte. The authors therefore proposed that 
signalling through GLAST and GLT-1 is necessary for the major cytoskeletal 
changes required during the process of myelination.  
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It has been shown previously that glutamate transporters need to be present at a 
sufficient density, in order for them to be functionally active, as they need to be 
able to buffer synaptically released glutamate on a sub-millisecond time scale 
(Diamond and Jahr, 1997; Lehre and Danbolt, 1998; Jabaudon et al., 1999). It 
was therefore of interest in Chapters 3 and 4 to note that expression of GLAST 
and the GLAST splice variants often appeared to be much more densely 
localized on the oligodendrocytes than on astrocytes (as also shown in Figure 
7.5). Whether this correlates with greater functional capacity of GLAST on 
oligodendrocytes remains to be determined. 
 
 
 
Figure 7.5. GLAST expression is more concentrated on the cell bodies of 
oligodendrocytes than on astrocytes. The figure on the left shows mature 
mixed glial cells labelled with antibodies against RIP (green) and the C-terminus 
of full-length GLAST (red). The figure on the right shows the same image, but 
without the RIP staining, in order to better compare the density of staining for 
GLAST between the oligodendrocyte cell body, and the astrocytes. Scale bar = 
20µm. 
Oligodendrocyte 
cell body  
RIP 
C-GLAST 
DAPI 
 Astrocyte cell bodies 
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Another role for glutamate transporters on oligodendrocytes that hasn’t been 
reported, but which could potentially be considered, relates to a role in providing 
essential nutrients to the cells. All cells require glutamine and methionine in order 
to grow and divide. As outlined in this thesis, oligodendrocytes were found to 
express not only various isoforms of GLAST, but also glutamine synthetase, the 
enzyme that converts glutamate to glutamine, and C/GAP, which exchanges a 
molecule of glutamate for a molecule of cystine, the precursor of methionine.  
 
Therefore, glutamate signalling and/or transport, together with GLAST, could play 
several crucial roles in oligodendrocyte maturation. If these functions were 
disrupted due to antibody binding to one or more of the glutamate transporter 
molecules, there could be impacts on glutamate transport (thereby causing cell 
death by excitotoxicity), or there could be a disruption of the oligodendrocyte 
cytoskeleton (impacting on myelination and/or remyelination). There has recently 
been a single report of autoantibodies against glutamate receptors, particularly 
the GluN1 subunit of the NMDA receptor, occurring in patients with MS (Trippe et 
al., 2014). 
 
7.4.2 Altered glutamate transport in MS  
Although there are thus far only very limited reports of antibodies from MS 
patients that can bind to glutamate receptors (Trippe et al., 2014) or transporters 
(this thesis) on oligodendrocytes or astrocytes, such antibodies could have the 
potential to contribute to impaired glutamate homeostasis and signalling in MS. It 
has been reported that levels of some of the molecules involved in glutamate 
signalling and transport are altered in MS (Pitt et al., 2003; Newcombe et al., 
2008), resulting in elevated levels of extracellular glutamate (Srinivasan et al., 
2005; Sarchielli et al., 2003). There is a report of increased expression the AMPA 
receptor GluR1 (Ca2+ permeable), but not the GluR2 (Ca2+ impermeable), in 
perilesional oligodendrocytes in MS (Newcombe et al., 2008). That same group 
reported a significant upregulation of the glutamate transporters GLT-1/EAAT2 
and EAAC1/EAAT3 on astrocytes in active MS plaques (Newcombe et al., 2008). 
In contrast, another group has reported a marked reduction in levels of GLT-
1/EAAT2 and GLAST/EAAT1 on oligodendrocytes in the lesions, and has 
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suggested that this downregulation of transporters is driven by the 
proinflammatory cytokine TNF-, which is produced by reactive astrocytes and 
infiltrating immune cells (Pitt et al., 2003).  
 
As far as we are aware, no one has looked at expression of any of the GLAST 
splice variants in brain tissue of MS patients. However, it would be of interest to 
investigate this in future work. In particular, it would be interesting to investigate 
GLAST 1b expression: while we did not detect GLAST 1b staining of 
oligodendrocytes or astrocytes in culture or on normal rat brain sections, it has 
been reported to be upregulated in the brain only under hypoxic conditions or in 
pathological states such as Alzheimer’s disease (Macnab and Pow, 2007a; 
Macnab and Pow, 2007b). In MS, infiltration of immune cells, and their 
subsequent inflammatory responses, results in increased hypoxic conditions 
within the lesion: it would therefore be expected that GLAST 1b might be 
upregulated in the lesion area. Another potentially interesting aspect of GLAST 
1b is that it has been shown that functional GLAST trimers can form from a 
mixture of full length and GLAST 1b subunits: these are still able to transport 
glutamate, but at a lower efficiency than a trimer composed solely of full length 
GLAST (Vallejo-Illarramendi et al., 2005). It might be possible for GLAST 1a and 
GLAST 1c to also participate in these mixed trimers, but this has not yet been 
shown. 
  
Given that elevated levels of antibodies against the GLAST 1c isoform were 
observed in half of the MS samples tested in Chapter 6, it would be interesting to 
assess the expression levels of the GLAST splice variants in astrocytes and 
oligodendrocytes in brain tissue from MS patients, to determine if there is an 
increased proportional expression of one splice variant over wild type, and 
whether levels of expression of a particular splice variant correlated with 
increased levels of antibodies against that variant. Autoreactivity against the 
splice variants, particularly if they are only expressed under inflammatory and 
hypoxic conditions, might be more likely to occur than autoreactivity to the full-
length GLAST protein, as it has recently been demonstrated that central 
tolerogenic mechanisms in the thymus typically only result in the deletion of 
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selected exons of a gene, rather than the whole gene (Meredith et al., 2015), so 
some splice variants might be able to induce an immune response much more 
readily that the full-length protein.  
 
7.5 Final conclusions 
 
The data in this thesis has shown that oligodendrocytes and astrocytes (both type 
1 and 2) differentiate and grow well in the mixed glial cell cultures, with addition of 
minimal supplements to the media. It has also shown that autoantibodies in MS 
patients can act functionally in a variety of ways, including antibody-mediated 
killing of either astrocytes or oligodendrocytes, or opsonisation of myelin for 
subsequent attack by phagocytic cells. Importantly, this thesis has also shown 
that oligodendrocytes and astrocytes share proteins involved in glutamate 
transport, opening up new possible autoantibody targets for demyelinating 
diseases of the CNS and reinforcing the idea that the roles of oligodendrocytes 
and astrocytes in the brain are ever-evolving from their established definitions. 
The presence of glutamate transporters on oligodendrocytes raises questions on 
the role of glutamate for the health of oligodendrocytes at varying stages of their 
maturation and the subsequent effects that antibodies or expression of splice 
variants would have in interfering with glutamate transport in these cells. 
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